Sclerostin antibody crystals and formulations thereof

ABSTRACT

Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. ProvisionalApplication No. 61/467,868, filed Mar. 25, 2011, the disclosure of whichis incorporated herein by reference in its entirety.

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

This application contains, as a separate part of disclosure, a SequenceListing in computer-readable form (filename: 46053_SeqListing_ST25.txt;created: Mar. 25, 2011; 40,911 bytes), which is incorporated byreference in its entirety.

BACKGROUND

Monoclonal antibodies are extensively used as biotherapeutics with anincreasing demand to meet high concentrations of over a 100 mg/ml fordelivery. This presents a challenge for solubility limited proteins viaa subcutaneous route, since the preferred subcutaneous administrationlimit is 1.2 ml (Yang, M. X., Shenoy, B., Disttler, M., Patel, R.,McGrath, M., Pechenov, S., Margolin, A. L. (2003) Crystalline monoclonalantibodies for subcutaneous delivery, PNAS 100, 6934-6939). Developmentof a high concentration formulation poses a lot of challenges from aformulation, analytical, stability, manufacturing and drug deliverypoint of view (Shire, S. J., Zahra, S., Liu, J. (2004) Challenges in thedevelopment of high concentration formulations, J. Pharm. Sci. 93,1390-1402). So far, high concentration formulation demands have been metby addition of excipients like amino acids, sugars and salts thatincrease stability, reduce aggregation and viscosity (Shire, supra andJenkins, T. W. (1998) Three solutions of the protein solubility problem,Protein Science 7: 376-382).

Protein crystals are often viewed as only the intermediates to a proteinstructure but they also have an important role from a formulationperspective. Protein molecules in the crystalline form have the lowestentropy thus making them 3-6 kcal/mol more stable than in the liquidstate (Dreuth, J., Haas, C. (1992) Protein crystals and their stability,J. Crystal Growth 122, 107-109). The main advantages of crystallineformulation include high protein concentration, lower viscosity,stability, elimination of frequent dosage due to high concentration andcontrolled release properties (Yang, supra, and Basu, S. K., Govardhan,C. P., Jung, C. W., Margolin, A. L. (2004) Protein crystals for thedelivery of biopharmaceuticals, Expert Opin. Biol. Thera. 4, 301-317).

Crystallization conditions can be manipulated to achieve differentmorphologies for desired controlled release properties (Pechenov, S.,Shenoy, B., Yang, M. X., Basu, S., Margolin, A. L. (2004) Injectablecontrolled release formulations incorporating protein crystals, Journalof Controlled Release 96, 149-158). Insulin crystalline formulationswere first reported in 1920's and today, it is not only the firstrecombinant protein therapeutic approved by the FDA, it is also thefirst approved crystalline protein therapeutic (Hagedorn H. C.; Jensen,B. N.; Krarup, N. B.; Wodstrup, I. Protamine insulinate, (1936) J. Am.Med. Assn. 106, 177-180; Johnson, I. S. (2003) The trials andtribulations of producing the first genetically engineered drug. Nat.Rev. Drug. Discovery 2, 747-751; and Basu, S. K., Govardhan, C. P.,Jung, C. W., Margolin, A. L. (2004) Protein crystals for the delivery ofbiopharmaceuticals, Expert Opin. Biol. Thera. 4, 301-317).Macromolecules are challenging to crystallize due to their inherentflexibility, but, once crystallized, often pose challenges from aformulation and regulatory perspective (Basu, supra, and Jen, A.,Merkle, H. P. (2001) Diamonds in the rough: Protein crystals from aformulation perspective, Pharm. Res. 18, 1483-1488.).

SUMMARY OF THE INVENTION

The invention relates to crystals of anti-sclerostin immunoglobulin typeG (IgG) antibodies (more specifically, Ab-30 and Ab-31) that aresuitable for use in formulations for parenteral administration;solutions, salts and methods for producing such crystals; methods ofusing such crystals to prepare formulations for use as medicaments, andmethods of using such formulations for treating mammals, specificallyhumans.

In the crystals or formulations described herein, anti-sclerostin IgGantibody in the crystals or formulation can comprise the heavy and lightchain variable regions of any of Ab-30, Ab-30R, Ab-30Rm or Ab-31. Thus,in specific embodiments, the antibody is an IgG comprising the aminoacid sequences of: (a) SEQ ID NO: 5 (Ab-30 heavy chain variable region),and SEQ ID NO: 3 (Ab-30 light chain variable region), preferably eachfused to a suitable constant region, or (b) SEQ ID NO: 15 (Ab-30 matureheavy chain) and SEQ ID NO: 13 (Ab-30 mature light chain); (c) SEQ IDNO: 17 (Ab-30R heavy chain variable region), and SEQ ID NO: 16 (Ab-30Rlight chain variable region), preferably each fused to a suitableconstant region; (d) SEQ ID NO: 17 (Ab-30Rm heavy chain variableregion), and SEQ ID NO: 20 (Ab-30Rm light chain variable region); or (e)SEQ ID NO: 25 (Ab-31 heavy chain variable region), and SEQ ID NO: 23(Ab-31 light chain variable region), preferably each fused to a suitableconstant region. In some embodiments, the antibody comprises the matureheavy and light chains of Ab-30, Ab-30R, Ab-30Rm or Ab-31. In someembodiments, the antibody comprises amino acid sequences obtainable byexpressing in mammalian host cells the cDNA encoding the heavy and/orlight chain, or alternatively the heavy and/or light chain variableregions, preferably each fused to a suitable constant region, of any ofantibodies Ab-30, Ab-30R, Ab-30Rm, or Ab-31, as described herein.Preferably, the antibody binds to sclerostin of SEQ ID NO: 1 with a Kdbinding affinity of 10⁻⁷ M or less.

The antibody crystals described herein can be characterized, forexample, by size, shape, morphology, salt content and other properties.In some embodiments, the crystal length ranges from about 100 μM toabout 500 μM or from about 50 μM to about 100 μM, or from about 1 μM toabout 50 μM, optionally with a morphology that is needle shaped, rodshaped, plate-shaped, block-shaped, UFO shaped, football shaped, leafshaped, wheat shaped, singlet shaped, feather-shaped, ellipsoidal (orsurfboard shaped), straw-shaped, chrysanthemum-shaped, or spherical ormixtures thereof. In some embodiments, the crystal length ranges fromabout 1 μm to about 10 μm, or from about 1 μm to about 15 μm, or fromabout 1 μm to about 20 μm or from about 1 μm to about 25 μm or fromabout 1 μm to about 30 μm, or from about 1 μm to about 35 μm, or fromabout 1 μm to about 40 μm, or from about 1 μm to about 45 μm, or fromabout 5 μm to about 10 μm, or from about 5 μm to about 15 μm, or fromabout 5 μm to about 20 μm, or from about 5 μm to about 25 μm, or fromabout 5 μm to about 30 μm, or from about 5 μm to about 35 μm, or fromabout 5 μm to about 40 μm, or from about 5 μm to about 45 μm, or fromabout 50 μm to about 75 μm or from about 50 μm to about 80 μm, or fromabout 50 μm to about 85 μm, or from about 50 μm to about 90 μm, or fromabout 50 μm to about 95 μm, or from about 100 μm to about 150 μm, orfrom about 100 μm to about 200 μm, or from about 100 μm to about 250 μm,or from about 100 μm to about 300 μm, or from about 100 μm to about 350μm, or from about 100 μm to about 400 μm, or from about 100 μm to about450 μm.

Optionally, the crystals are in clusters. The crystals are alsocharacterized by x-ray diffraction. For example, Ab-30 crystals mayexhibit a needle shape, rod shape, block shape, or plate shape, or amixture thereof, or other shapes. Most of the Ab-30 crystals exhibitedrod, needle or ellipsoid shapes. For example, Ab-31 crystals may exhibita surfboard or ellipsoidal shape, or other shapes.

In some embodiments, the crystal length is about 5 μm, or about 10 μm,or about 15 μm, or about 20 μm, or about 25 μm, or about 30 μm, or about35 μm, or about 40 μm, or about 45 μm, or about 50 μm, or about 55 μm,or about 60 μm, or about 65 μm, or about 70 μm, or about 75 μm, or about80 μm, or about 85 μm, or about 90 μm, or about 95 μm, or about 100 μm,or about 125 μm, or about 150 μm, or about 175 μm, or about 200 μm, orabout 250 μm, or about 300 μm, or about 350 μm, or about 400 μm, orabout 450 μm, or about 500 μm. Regardless of the length of the crystalsproduced by the various crystallization conditions described herein, thelength can be altered subsequently to a desired length by methods knownin the art. For example, if the crystallization conditions produce anantibody crystal that is about 5 μm to about 100 μm or about 5 μm toabout 500 μm or about 100 μm to about 500 μm in length, the crystal canbe milled down to a shorter length such as a length in the range ofabout 5 μm to about 50 μm.

In some embodiments, the crystal growth conditions are modified toobtain a specific size, shape, length and/or morphology of the crystalin consideration. The crystal growth conditions are modified by anymeans known in the art including, but not limited to, change in pH,change in addition of precipitants, change in concentration ofprecipitant, change in temperature, and the inclusion of additivesincluding, but not limited to salts (including, but not limited to, zincacetate, zinc chloride, zinc sulfate, ammonium acetate, calcium acetate,lithium acetate dihydrate, magnesium acetate tetrahydrate, magnesiumchloride, magnesium formate, magnesium nitrate, magnesium sulfate andcombinations thereof), amino acids, sugars, carbohydrates, detergents(ionic non-ionic zwitter ion) and surfactants.

In some or any embodiments, the antibody crystals described herein arecharacterized by the type of salt in the crystallization reagent.

Suitable salts for the production of Ab-30 crystals include, but are notlimited to, sodium dihydrogen phosphate, di-potassium hydrogenphosphate, sodium chloride, ammonium sulfate, potassium sodium tartratetetrahydrate, tacsimate, sodium citrate dihydrate, sodium acetatetrihydrate, di-ammonium tartrate, sodium malonate, acetate, calciumacetate, cacodylate, CHES, lithium sulfate, magnesium chloride, zincacetate, cesium chloride, ammonium phosphate, sodium phosphase,potassium phosphate, sodium fluoride, potassium iodide, sodium idodide,ammonium iodide, sodium thiocyanate, potassium thiocyanate, sodiumformate, potassium formate and ammonium formate. For example, othersalts (including hydrates) for the production of Ab-30 crystals caninclude other dihydrogen phosphate salts, hydrogen phosphate salts,phosphate salts, fluoride salts, chloride salts, sulfate salts, tartratesalts, tacsimate salts, citrate salts, acetate salts, malonate salts,cacodylate salts, and iodide salts, thiocyanate salts, or formate salts;with, for example, monovalent (e.g. sodium, potassium, ammonium) ordivalent cations (e.g. zinc, magnesium).

Suitable salts for the production of Ab-31 crystals include, but are notlimited to, sodium chloride, potassium chloride, sodium acetate,potassium phosphate and histidine. For example, other salts for theproduction of Ab-31 crystals include chloride salts, acetate salts, orphosphate salts; with, for example, monovalent (e.g. sodium, potassium,ammonium) cations.

In some or any embodiments, the antibody crystals are characterized bycrystallization additives, which can influence the crystal growth and/orshape. Suitable crystallization additives include, but are not limitedto, precipitants such as PEG having a molecular weight of about 200 kDato about 20,000 kDa, or about 400 kDa to about 20,000 kDa, or about 1000kD to about 10,000 kD (e.g., PEG-3350 or PEG-8000) or2-methyl-2,4-pentanediol (MPD), surfactants such as polysorbate 20,polysorbate 80, detergents (ionic, non-ionic and zwitter ion); aminoacids, short peptides, small organic molecules, organic salts,nucleotides and carbohydrates. In some embodiments, the additives (e.g.,PEG, MPD, glycerol) are at a concentration of about 0.1% to about 75%(w/v or v/v), or about 0.1-50% (w/v or v/v), or about 0.1-10% (w/v orv/v), or about 10% to about 50% (w/v or v/v), or about 20%-50% (w/v orv/v), or at least 10%, or at least 20% (w/v or v/v). In some or anyembodiments, the crystals are also characterized by the process by whichthey are produced, including remaining impurities.

In some or any embodiments, the antibody crystals are produced undercrystallization conditions comprising a crystallization reagentcomprising succinic acid, HEPES and polyethylene glycol monomethyl ether2000. For example, in some embodiments, the crystallization conditionscomprise about 0.1M to about 5M, or about 0.1M to about 2M, or about0.1M to about 1 M, or about 1 M to about 5 M, or about 3 M to about 5 M,or about 2 M to about 4 M succinic acid (or about 0.1M, or about 0.5M,or about 1M, or about 1.5M, or about 2M, or about 2.5M, or about 3M, orabout 3.5M, or about 4M, or about 4.5M, or about 5M succinic acid);optionally further comprising about 0.1M to about 5M, or about 0.1M toabout 2M, or about 0.1M to about 1 M, or about 1 M to about 5 M, orabout 3 M to about 5 M, or about 2 M to about 4 M HEPES (or about 0.1M,or about 0.5M, or about 1M, or about 1.5M, or about 2M, or about 2.5M,or about 3M, or about 3.5M, or about 4M, or about 4.5M, or about 5MHEPES) at a pH of about 6 to about 9 or about 7 to about 8.5; andoptionally about 0.1% to about 60% (w/v), or about 0.1% to about 1%, orabout 1% to about 3%, or about 2% to about 4%, or about 3% to about 5%or about 20% to about 40%, or about 30% to about 60%, or about 10% toabout 20%, or about 25% to about 30%, or about 15% to about 25%polyethylene glycol monomethyl ether 2000 (or about 0.1%, or about 0.5%,or about 1%, or about 1.5%, or about 2%, or about 2.5%, or about 3%, orabout 3.5%, or about 4.5%, or about 5%, or about 10%, or about 15%, orabout 20%, or about 25%, or about 30%, or about 35%, or about 40%, orabout 45%, or about 50%, or about 55%, or about 60% polyethylene glycolmonomethyl ether 2000). In some embodiments, the crystallization reagentcomprises 1.0M succinic acid; 0.1M HEPES, pH 7; and 1% (w/v)polyethylene glycol monoethyl ether 2000.

In some or any embodiments, the antibody crystals are produced undercrystallization conditions comprising a crystallization reagentcomprising PEG-8000, imidazole, and calcium acetate. For example, insome embodiments, the crystallization reagent comprises about 1% toabout 50%, or about 1% to about 5%, or about 5% to about 10%, or about10% to about 15%, or about 20% to about 30%, or about 25% to about 50%,or about 30% to about 45% or about 40% to about 50% PEG-8000 (or about1%, or about 2%, or about 3%, or about 4%, or about 5%, or about 6%, orabout 7%, or about 8%, or about 9%, or about 10%, or about 11%, or about12% or about 13%, or about 14%, or about 15%, or about 20%, or about25%, or about 30%, or about 35%, or about 40%, or about 45% or about 50%PEG-8000); optionally further comprising about 0.05M to about 5M, orabout 0.05 to about 0.1M, or about 0.1M to about 2M, or about 0.1M toabout 1 M, or about 1 M to about 5 M, or about 3 M to about 5 M, orabout 2 M to about 4 M imidazole (or about 0.05, or about 0.1M, or about0.5M, or about 1M, or about 1.5M, or about 2M, or about 2.5M, or about3M, or about 3.5M, or about 4M, or about 4.5M, or about 5M imidazole);and optionally about 0.1M to about 5M or about 0.1M to about 2M, orabout 0.1M to about 1 M, or about 1 M to about 5 M, or about 3 M toabout 5 M, or about 2 M to about 4 M (or about 0.1M, or about 0.5M, orabout 1M, or about 1.5M, or about 2M, or about 2.5M, or about 3M, orabout 3.5M, or about 4M, or about 4.5M, or about 5M) calcium acetate. Insome embodiments, the crystallization reagent comprises 10% (w/v)PEG-8000, 0.1M imidazole, and 0.2M calcium acetate.

In some or any embodiments, the antibody crystals are produced undercrystallization conditions comprising a crystallization reagentcomprising PEG-8000, TRIS and magnesium chloride. For example, in someembodiments, the crystallization reagent comprises about 1% to about50%, or about 1% to about 5%, or about 5% to about 10%, or about 10% toabout 15%, or about 20% to about 30%, or about 25% to about 50%, orabout 30% to about 45% or about 40% to about 50% PEG-8000 (or about 1%,or about 2%, or about 3%, or about 4%, or about 5%, or about 6%, orabout 7%, or about 8%, or about 9%, or about 10%, or about 11%, or about12% or about 13%, or about 14%, or about 15%, or about 20%, or about25%, or about 30%, or about 35%, or about 40%, or about 45% or about 50%PEG-8000); optionally further comprising about 0.05M to about 5M, orabout 0.05M to about 1M, or about 0.1M to about 2M, or about 0.1M toabout 1M, or about 1M to about 5 M, or about 3 M to about 5 M, or about2 M to about 4 M TRIS (or about 0.05M, or about 0.1M, or about 0.5M, orabout 1M, or about 1.5M, or about 2M, or about 2.5M, or about 3M, orabout 3.5M, or about 4M, or about 4.5M, or about 5M TRIS); andoptionally about 0.05M to about 5M, or about 0.05 to about 1M, or about0.1M to about 2M, or about 0.1M to about 1 M, or about 1 M to about 5 M,or about 3 M to about 5 M, or about 2 M to about 4 M magnesium chloride(or about 0.1M, or about 0.5M, or about 1M, or about 1.5M, or about 2M,or about 2.5M, or about 3M, or about 3.5M, or about 4M, or about 4.5M,or about 5M magnesium chloride). In some embodiments, thecrystallization reagent comprises 10% (w/v) PEG-8000, 0.1M Tris, and0.2M magnesium chloride.

In some or any embodiments, the antibody crystals are produced undercrystallization conditions comprising a crystallization reagentcomprising PEG-1000, sodium/potassium phosphate and sodium chloride. Forexample, in some embodiments, the crystallization reagent comprisesabout 10% to about 80%, or about 10%-15%, or about 15% to about 20%, orabout 20% to about 25%, or about 25% to about 30% or about 20% to about30%, or about 40% to about 70%, or about 50% to about 80%, or about 30%to about 75% PEG-1000 (or about 10%, or about 15%, or about 20%, orabout 25%, or about 30%, or about 35%, or about 40%, or about 45%, orabout 50%, or about 55%, or about 60%, or about 65%, or about 70%, orabout 75%, or about 80% PEG-1000); optionally further comprising about0.05M to about 5M, or about 0.05M to about 1M, or about 0.1M to about2M, or about 0.1M to about 1 M, or about 1 M to about 5 M, or about 3 Mto about 5 M, or about 2 M to about 4 M sodium/potassium phosphate (orabout 0.05M, or about 0.1M, or about 0.5M, or about 1M, or about 1.5M,or about 2M, or about 2.5M, or about 3M, or about 3.5M, or about 4M, orabout 4.5M, or about 5M sodium/potassium phosphate); and optionallyabout 0.05M to about 5M, or about 0.05M to about 1M, or about 0.1M toabout 2M, or about 0.1M to about 1 M, or about 1 M to about 5 M, orabout 3 M to about 5 M, or about 2 M to about 4 M sodium chloride (orabout 0.1M, or about 0.5M, or about 1M, or about 1.5M, or about 2M, orabout 2.5M, or about 3M, or about 3.5M, or about 4M, or about 4.5M, orabout 5M sodium chloride). In some embodiments, the crystallizationreagent comprises 20% (w/v) PEG1000, 0.1M sodium/potassium phosphate,and 0.2M sodium chloride.

In some or any embodiments, the antibody crystals are produced undercrystallization conditions comprising a crystallization reagentcomprising PEG-8000, cacodylate, calcium acetate and glycerol. Forexample, in some embodiments, the crystallization reagent comprisesabout 1% to about 50% %, or about 1% to about 5%, or about 5% to about10%, or about 10% to about 15%, or about 20% to about 30%, or about 25%to about 50%, or about 30% to about 45% or about 40% to about 50%PEG-8000 (or about 1%, or about 2%, or about 3%, or about 4%, or about5%, or about 6%, or about 7%, or about 8%, or about 9%, or about 10%, orabout 11%, or about 12% or about 13%, or about 14%, or about 15%, orabout 20%, or about 25%, or about 30%, or about 35%, or about 40%, orabout 45% or about 50% PEG-8000); optionally further comprising about0.05M to about 5M or about 0.1M to about 2M, or about 0.1M to about 1 M,or about 1 M to about 5 M, or about 3 M to about 5 M, or about 2 M toabout 4 M cacodylate (or about 0.05M, or about 0.06M, or about 0.07M, orabout 0.8M, or about 0.9M, or about 1M, or about 1.5M or about 2M, orabout 2.5M, or about 3M, or about 3.5M, or about 4M, or about 4.5M, orabout 5M cacodylate) at a pH of about 5 to about 7, or about 6 to about7 or about 6.5; optionally about 0.05M to about 2M, or about 0.5M toabout 1M, or about 0.1M to about 1 M, or about 5 M to about 1 M, orabout 1 M to about 2 M calcium acetate (or about 0.05M, or about 0.1M,or about 0.12M, or about 0.14M, or about 0.16M, or about 0.18M, or about0.2M, or about 0.5M, or about 1M, or about 1.5M, or about 2M calciumacetate); and optionally about 1% to about 65% (w/v), or about 1% toabout 10%, or about 1% to about 5%, or about 5% to about 10%, or about10% to about 15%, or about 15% to about 20%, or about 20% to about 25%,or about 25% to about 30% or about 20% to about 30%, or about 35% toabout 50%, or about 50% to about 65% glycerol (or about 10%, or about15%, or about 20%, or about 25% or about 30% glycerol). In someembodiments, the crystallization reagent comprises about 14.4% (w/v)PEG-8000, 0.08M cacodylate, 0.16M calcium acetate and 20% (w/v)glycerol.

In some or any embodiments, the antibody crystals are produced undercrystallization conditions comprising a crystallization reagentcomprising isopropanol and sodium/potassium phosphate. For example, insome embodiments, the crystallization reagent comprises about 1% toabout 100%, or about 1% to about 5%, or about 5% to about 10%, or about10% to about 15%, or about 15% to about 20%, or about 20% to about 25%,or about 25% to about 30%, or about 20% to about 30%, or about 35% toabout 50%, or about 40%, to about 60%, or about 75% to about 90% orabout 80% to about 100% (v/v) isopropanol (or about 10%, or about 15%,or about 20%, or about 25% or about 30%, or about 35%, or about 40%, orabout 45%, or about 50%, or about 55%, or about 60%, or about 65%, orabout 70%, or about 75%, or about 80%, or about 85%, or about 90%, orabout 95%, or about 100% (v/v) isopropanol); and optionally about 0.05to about 4M, or about 0.05M to about 1M, or about 0.1M to about 1 M, orabout 5 M to about 1 M, or about 1 M to about 2 M, or about 2M to about4M, or about 3M to about 4M sodium/potassium phosphate (or about 0.1M,or about 0.2M, or about 0.3M, or about 0.4M, or about 0.5M, or about0.6M, or about 0.7M, or about 0.8M, or about 0.9M, or about 1M, or about1.5M, or about 2M, or about 2.5M, or about 3M, or about 3.5M, or about4M sodium/potassium phosphate). In some embodiments, the crystallizationreagent comprises about 19.9% isopropanol and about 0.2Msodium/potassium phosphate.

In some or any embodiments, the antibody crystals are produced undercrystallization conditions comprising a crystallization reagentcomprising a member selected from the group consisting of 2-propanol,ammonium phosphate dibasic, PEG-1000, ammonium sulfate, potassium/sodiumtartrate, PEG-3000, PEG-8000, 1,4-butanediol, sodium chloride, ethanol,PEG-400, 2-methyl-2,4-pentanediol (MPD), Jeffamine M-600, PEG-10,000.For example, in some embodiments, the crystallization reagent comprisesabout 1% to about 50%, or about 10% to about 20%, or about 1% to about10% or about 5% to about 10% or about 8% to about 12%, or about 15% toabout 20%, or about 20% to about 35%, or about 40% to about 50% (v/v)2-propanol (or about 1%, or about 5%, or about 10%, or about 15%, orabout 20%, or about 25%, or about 30%, or about 35%, or about 40%, orabout 45%, or about 50% (v/v) 2-propanol).

In some embodiments, the crystallization reagent comprises about 0.05 Mto about 10M, or about 0.5M to about 1M, or about 1 M to about 5M, orabout 5M to about 10M ammonium phosphate dibasic (or about 0.05M, orabout 0.1M, or about 0.5M, or about 1M, or about 1.5M, or about 2M, orabout 2.5M, or about 3M, or about 3.5M, or about 4M, or about 4.5M, orabout 5M, or about 6M, or about 6.5M, or about 7M, or about 7.5M, orabout 8M, or about 8.5M, or about 9M, or about 9.5M or about 10 Mammonium phosphate dibasic).

In some embodiments, the crystallization reagent comprises about 10% toabout 80% or about 10% to about 15%, or about 15% to about 20%, or about20% to about 25%, or about 25% to about 30% or about 20% to about 30%,or about 40% to about 70%, or about 50% to about 80%, or about 30% toabout 75% (w/v) PEG-1000 (or about 10%, or about 15%, or about 20%, orabout 25%, or about 30%, or about 35%, or about 40%, or about 45%, orabout 50%, or about 55%, or about 60%, or about 65%, or about 70%, orabout 75%, or about 80% (w/v) PEG-1000).

In some embodiments, the crystallization reagent comprises about 0.5M toabout 10M, or about 0.5M to about 1M, or about 1 M to about 5M, or about5M to about 10M ammonium sulfate (or about 0.05M, or about 0.1M, orabout 0.5M, or about 1M, or about 1.5M, or about 2M, or about 2.5M, orabout 3M, or about 3.5M, or about 4M, or about 4.5M, or about 5M, orabout 6M, or about 6.5M, or about 7M, or about 7.5M, or about 8M, orabout 8.5M, or about 9M, or about 9.5M or about 10 M ammonium sulfate).

In some embodiments, the crystallization reagent comprises about 0.5M toabout 10M, or about 0.5M to about 1M, or about 1 M to about 5M, or about5M to about 10M potassium/sodium tartrate (or about 0.05M, or about0.1M, or about 0.5M, or about 1M, or about 1.5M, or about 2M, or about2.5M, or about 3M, or about 3.5M, or about 4M, or about 4.5M, or about5M, or about 6M, or about 6.5M, or about 7M, or about 7.5M, or about 8M,or about 8.5M, or about 9M, or about 9.5M or about 10 M potassium sodiumtartrate).

In some embodiments, the crystallization reagent comprises about 1% toabout 50%, or about 1% to about 5%, or about 1% to about 10%, or about10% to about 20%, or about 15% to about 20%, or about 20% to about 25%,or about 25% to about 30%, or about 30% to about 50% (v/v)1,4-butanediol (or about 1%, or about 5%, or about 10%, or about 15%, orabout 20%, or about 25%, or about 30%, or about 35%, or about 40%, orabout 45%, or about 50% (v/v) 1,4-butanediol).

In some embodiments, the crystallization reagent comprises about 0.5M toabout 10M, or about 0.5M to about 1M, or about 1 M to about 5M, or about5M to about 10M sodium chloride (or about 0.05M, or about 0.1M, or about0.5M, or about 1M, or about 1.5M, or about 2M, or about 2.5M, or about3M, or about 3.5M, or about 4M, or about 4.5M, or about 5M, or about 6M,or about 6.5M, or about 7M, or about 7.5M, or about 8M, or about 8.5M,or about 9M, or about 9.5M or about 10 M sodium chloride).

In some embodiments, the crystallization reagent comprises about 10% toabout 50%, or about 10% to about 20%, or about 14% to about 18%, orabout 15% to about 20%, or about 20% to about 25%, or about 25% to about30%, or about 30% to about 50% (v/v) ethanol (or about 1%, or about 5%,or about 10%, or about 15%, or about 20%, or about 25%, or about 30%, orabout 35%, or about 40%, or about 45%, or about 50% (v/v) ethanol).

In some embodiments, the crystallization reagent comprises about 10% toabout 80% or about 10% to about 15%, or about 15% to about 20%, or about20% to about 25%, or about 25% to about 30% or about 20% to about 30%,or about 40% to about 70%, or about 50% to about 80%, or about 30% toabout 75% (w/v) PEG-400, PEG-1000, PEG-3,000, PEG-8,000 or PEG-10,000(or about 10%, or about 15%, or about 20%, or about 25%, or about 30%,or about 35%, or about 40%, or about 45%, or about 50%, or about 55%, orabout 60%, or about 65%, or about 70%, or about 75%, or about 80% (w/v)PEG-400, PEG-1000, PEG-3,000, PEG-8,000 or PEG-10,000.

In some embodiments, the crystallization reagent comprises about 10% toabout 50% (w/v) 2-methyl-2,4-pentanediol (MPD) (or about 10%, or about15%, or about 20%, or about 25%, or about 30%, or about 35%, or about40%, or about 45%, or about 50% (w/v) 2-methyl-2,4-pentanediol (MPD)).

In some embodiments, the crystallization reagent comprises about 1% toabout 50%, or about 1% to about 10%, or about 5% to about 15%, or about10% to about 20%, or about 20% to about 25%, or about 20% to about 30%,or about 15% to 25%, or about 30% to about 50% (v/v) Jeffamine M-600 (orabout 1%, or about 5%, or about 10%, or about 15%, or about 20%, orabout 25%, or about 30%, or about 35%, or about 40%, or about 45%, orabout 50% (v/v) Jeffamine M-600).

Another aspect described herein provides methods of making the crystalsdescribed herein. In some embodiments, the method comprises combining asolution of antibody Ab-30, Ab-30R, Ab-30Rm or Ab-31 with acrystallization reagent comprising an appropriate salt, including any ofthe previously described salts, such that a crystal is formed. In any ofthe embodiments described herein, the salt in the crystallizationreagent is present at a concentration of about 0.1M to about 30M,optionally about 0.1M to about 10M, or about 1M to about 10M or about 1Mto about 5M or about 5M to about 10M. In some embodiments, the methodcomprises combining a solution of antibody Ab-30, Ab-30R, Ab-30Rm orAb-31 with a crystallization reagent comprising succinic acid, PEG-1000,PEG-8000 or isopropanol such that a crystal is formed. For any of thecrystal production methods described herein, in some embodiments, atleast 80% (e.g., at least 85%, or at least 90%, or at least 95% or more)of the original amount of antibody in the solution is crystallizedfollowing the combining step. Determining the percent crystallizedantibody can be performed by methods described, for example, in Example5 or other methods known in the art.

Methods of making antibody crystals optionally further comprise removingat least a portion of the crystallization reagent (e.g., bycentrifugation) after the crystals are formed. In some embodiments, thecrystals are then placed into a solution comprising an organic additive(e.g., ethanol or isopropanol). In some embodiments, excipients (e.g.,sucrose, trehalose or sorbitol) are added to the solution.

The methods of making the antibody crystals optionally further comprisethe step of drying the crystals that have formed (e.g., by air dryingthe crystals or exposing the crystals to a vacuum or nitrogen gas).

Exemplary methods for producing the antibody crystals described hereininclude vapor diffusion and batch crystallization, which are known inthe art.

Another aspect described herein are formulations (e.g., powder andliquid formulations comprising ant-sclerostin antibodies describedherein) and methods of using antibody crystals described herein toprepare medicaments, such as formulations, for therapy of mammalsincluding humans. Therapy of any of the conditions described herein iscontemplated, optionally using any of the dosing and timing regimensdescribed herein. The formulations comprise antibody crystals, e.g.,Ab-30, Ab-30R, Ab-30Rm or Ab-31 crystals, having one or more of theproperties described herein (e.g., size, length, shape, salt content,additive content, or other properties). In some embodiments, the Ab-30,Ab-30R, Ab-30Rm or Ab-31 crystals in the formulation have a length ofabout 20 μm to about 1 mm and are shaped as ellipsoids, rods andneedles, or a mixture thereof. In some embodiments, the Ab-30, Ab-30R,Ab-30Rm or Ab-31 crystals in the formulation have a length of about 5 μmto about 500 μm and are shaped as ellipsoids, rods, and needles, or amixture thereof.

In some or any embodiments, the formulation is sterile and comprises acrystal of an anti-sclerostin IgG antibody, wherein at least 70% (or atleast 75%, or at least 80%, or at least 85% or at least 90%, or at least95% or more) of the antibody is in crystalline form. In someembodiments, the anti-sclerostin IgG antibody in the formulationcomprises light and heavy chain variable regions of SEQ ID NOS: 3 and 5,preferably having the amino acid sequences of SEQ ID NOS: 13 and 15.

The formulations are suitable for parenteral administration, e.g. aresterile; have endotoxin levels acceptable for parenteral administration,e.g. <0.25 EU/mL or 0.008 EU/mg; and comprise pharmaceuticallyacceptable excipients. The formulations are also preferably of highprotein concentrations, e.g., at least 100 mg of antibody per ml offormulation, or at least 120 mg/ml, or at least 140 mg/ml, or at least160 mg/ml, or at least 180 mg/ml, or at least 200 mg/ml, or at least 220mg/ml, or at least 240 mg/ml or higher. In some embodiments, theformulation comprises a concentration of at least 140 mg of antibodydispersed in 1.5 ml or less of liquid. In exemplary embodiments, suchformulations have a viscosity of about 10 cP or less, optionally 8 cP orless or 6 cP or less. The term “viscosity” as used herein refers to“absolute viscosity.” Absolute viscosity, sometimes called dynamic orsimple viscosity, is the product of kinematic viscosity and fluiddensity: Absolute Viscosity=Kinematic Viscosity×Density. The dimensionof kinematic viscosity is L²/T where L is a length and T is a time.Commonly, kinematic viscosity is expressed in centistokes (cSt). The SIunit of kinematic viscosity is mm²/s, which is 1 cSt. Absolute viscosityis expressed in units of centipoise (cP). The SI unit of absoluteviscosity is the millipascal-second (mPa^(−s)), where 1 cP=1 mPa^(−s).

In some or any embodiments, absolute viscosity of the resuspended liquidformulation at the storage and/or administration temperature is 15 cP orless, or 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, or 4 cP or less. In some orany embodiments, the formulation is injectable through a syringe that isa 20 Gauge needle or finer (e.g., a 25 Gauge needle, a 27 Gauge needleor finer) using a clinically acceptable amount of force.

In some or any embodiments, the formulation comprises excipientsincluding, but not limited to sucrose, trehalose and sorbitol, or othersugars or polyols.

In some or any embodiments, the formulations have a pH ranging fromabout 2 to about 12, or about 6 to about 9, or about 6 to 8.5, or about7 to about 7.5 and an osmolality ranging from about 180 to about 420mOsm/kg, or about 200 to about 400 mOsm/kg, or about 250 to about 350mOsm/kg. While isotonic (250-350 mOsm/kg) and physiologic pH (about7-7.5) is preferred, formulations may be prepared outside of theseranges.

The formulation is optionally resuspended in a suspension vehicle priorto parenteral administration. Exemplary suspension vehicles include, butare not limited to glutamate, sorbitol, HEPES, dextrose and water. Insome embodiments, the suspension vehicle is dextrose and the dextrose isprovided in an amount ranging from about 1% to about 10% dextrose orfrom about 5% to about 10% dextrose or from about 1% to about 5%dextrose, or from about 2% to about 4% dextrose (e.g., about 1%dextrose, about 2% dextrose, about 3% dextrose, about 4% dextrose, about5% dextrose, about 6% dextrose, about 7% dextrose, about 8% dextrose,about 9% dextrose or about 10% dextrose). In some embodiments, thesuspension vehicle is sorbitol and the sorbitol is provided in an amountranging from about 1% to about 10% sorbitol or from about 5% to about10% sorbitol or from about 1% to about 5% sorbitol, or from about 2% toabout 4% sorbitol (e.g., about 1% sorbitol, about 2% sorbitol, about 3%sorbitol, about 4% sorbitol, about 5% sorbitol, about 6% sorbitol, about7% sorbitol, about 8% sorbitol, about 9% sorbitol or about 10%sorbitol). In some embodiments, the suspension vehicle is glutamate andthe glutamate is provide in an amount ranging from 1 mM to about 20 mMglutamate or from about 10 mM to about 15 mM or from about 5 to about 10mM or from about 8 mM to about 12 mM (or about 1 mM glutamate, about 2mM glutamate, about 3 mM glutamate, about 4 mM glutamate, about 5 mMglutamate, about 6 mM glutamate, about 7 mM glutamate, about 8 mMglutamate, about 9 mM glutamate, about 10 mM glutamate, about 11 mMglutamate, about 12 mM glutamate, about 13 mM glutamate, about 14 mMglutamate, about 15 mM glutamate, about 16 mM glutamate, about 17 mMglutamate, about 18 mM glutamate, about 19 mM glutamate or about 20 mMglutamate). In some embodiments, the suspension vehicle comprises acombination of sorbitol and glutamate (e.g., about 1 mM to about 20 mMglutamate (including the intermediate ranges identified above) and about1% to about 10% sorbitol (including the intermediate ranges identifiedabove)). In some embodiments, the suspension vehicle comprises about 10mM glutamate and about 5% sorbitol.

In other embodiments, the suspension vehicle is selected from the groupconsisting of (1) HEPES and PEG-3350 (e.g., 0.5M HEPES and 20% PEG-3350,pH 7.5); (2) Tris and PEG-3350 (e.g., 0.5M Tris and 50% PEG-3350, pH8)and (3) Tris and PEG-3350 (e.g., 0.5M Tris and 50% PEG-3350, pH 8.5).

Optionally, the formulation suitable for parenteral administration(e.g., subcutaneous or intramuscular) is presented in a container, suchas a single dose vial, multidose vial, syringe, pre-filled syringe orinjection device. In some or any embodiments, the container comprises asingle dose of an anti-sclerostin antibody (e.g., about 70 to about 450mg of anti-sclerostin antibody). In some embodiments, the dose comprisesat least about 5 mg, 15 mg, 25 mg, 50 mg, about 60 mg, about 70 mg,about 80 mg, about 90 mg, about 100 mg, about 120 mg, about 150 mg,about 200 mg, about 240 mg, about 250 mg, about 280 mg, about 300 mg,about 350 mg, about 400 mg, about 420 mg, about 450 mg, about 500 mg,about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg,about 800 mg, about 850 mg, about 900 mg, about 950 mg or up to about1,000 mg of anti-sclerostin antibody. Ranges between any and all ofthese endpoints are also contemplated, e.g. about 50 mg to about 80 mg,about 70 mg to about 140 mg, about 70 mg about to about 350 mg, about 70mg to about 280, about 70 mg to about 210 mg, about 75 mg to about 100mg, about 100 mg to about 150 mg, about 140 mg to about 210 mg, or about150 mg to about 200 mg, or about 280 mg to about 410 mg ofanti-sclerostin antibody. The dose is administered at any interval, suchas multiple times a week (e.g., twice or three times per week), once aweek, once every two weeks, once every three weeks, or once every fourweeks. For example, in some or any embodiments, a dose ofanti-sclerostin antibody ranging from about 120 mg to about 210 mg isadministered twice a week. In some or any embodiments, a dose of about140 mg of the anti-sclerostin antibody is administered twice a week. Anyof the doses described herein may be administered as divided doses. Forexample, a dose of 140 mg of anti-sclerostin antibody may beadministered as two injections of 70 mg of anti-sclerostin antibody.Similarly, a dose of 210 mg of anti-sclerostin antibody may beadministered as two injections of 105 mg of anti-sclerostin antibody.

In some or any embodiments, a formulation comprising crystals of ananti-sclerostin antibody described herein retains at least 50% (or atleast 60%, or at least 65%, or at least 70%, or at least 75%, or atleast 80%, or at least 85%, or at least 90%, or at least 95%) or more ofthe in vivo activity of the same antibody that has not beencrystallized. For example, in some embodiments, a formulation comprisingcrystals of Ab30 retains at least about 50% to about 100%, or at leastabout 70% to about 100%, or at least 80% to at least 100% or at least90% to about 100% (e.g., about 50%, about 60%, about 70%, about 80%,about 90% or about 100%) of the level of activity, when given at thesame (or similar) dose and administered in the same (or similar) manner,as an Ab30 antibody that has not been crystallized. The formulation canbe administered in a single dose or in multiple doses as describedelsewhere herein. In some embodiments, the in vivo activity is anincrease in bone mineral density for the total body (e.g., head, trunk,arms, and legs) or at the hip (e.g., total hip and/or femoral neck),spine (e.g., lumbar spine), wrist, finger, shin bone and/or heelcompared to baseline.

In some or any embodiments, a formulation comprising Ab-30, Ab-30R,Ab-30Rm or Ab-31 crystals as described herein when administered to amammalian subject mediates an increase in bone mineral density (comparedto baseline or control) that is at least about 70% (or at least about80% or at least about 90% or at least about 100%) of the level of bonemineral density increase mediated by an Ab-30, Ab-30R, Ab-30Rm or Ab-31antibody, that has not been crystallized (when administered at the same(or similar) dose and via the same (or similar) route of administration;e.g., at a dose described herein, such as of about 100 mg/ml,administered by subcutaneous injection). The formulation can beadministered in a single dose or in multiple doses as describedelsewhere herein.

In one exemplary embodiment, a container may contain about 70 mg or 75mg of the formulation of anti-sclerostin antibody and would be suitablefor administering a single dose of about 1 mg/kg. In other embodiments,a container may contain about 50 mg, or about 60 mg, or about 70 mg, orabout 80 mg, or about 90 mg, or about 100 mg, or about 120 mg, or about130 mg, or about 140 mg or about 150 mg, or about 160 mg, or about 170mg, or about 180 mg, or about 190 mg, or about 200 mg, or about 210 mgor about 220 mg or about 230 mg; or about 240 mg, or at about 250 mg, orabout 250 mg to about 450 mg; or about 280 mg or 290 mg or 300 mg; orabout 350 mg or 360 mg; or about 420 mg or 430 mg or 440 mg or 450 mg ofthe formulation of anti-sclerostin antibody. In any of such embodiments,the container may be suitable for administering a single dose of about 2to about 6 mg/kg, or about 1 mg/kg to about 4 mg/kg, or about 3 mg/kg toabout 5 mg/kg, or about 1 mg/kg to about 3 mg/kg body weight (e.g.,about 2 mg/kg, or about 3 mg/kg, or about 4 mg/kg, or about 5 mg/kg orabout 6 mg/kg body weight). In any of these embodiments, the containermay comprise the antibody at a high protein concentration such as thosedescribed herein. In any of these embodiments, the container maycomprise a powdered or lyophilized formulation and be for suspension ina volume of about 0.5-2 mL.

Also disclosed are methods of resuspending any of the foregoing powderedformulations comprising adding a sterile diluent to achieve a highprotein concentration such as those described herein.

Also disclosed herein is a kit comprising such a container and a labelcomprising instructions to use the appropriate volume or amount of theformulation necessary to achieve a dose of from about 0.5-20 mg/kg, or0.5-10 mg/kg of patient body weight. In some embodiments, the dose offormulation comprises between about 0.1 to about 50 milligrams (e.g.,between about 5 and about 50 milligrams), or about 1 to about 100milligrams, of anti-sclerostin antibody per kilogram of body weight(mg/kg). For example, the dose of anti-sclerostin antibody may compriseat least about 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, about 2 mg/kg, about 3mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 20 mg/kg, about 25 mg/kg,about 26 mg/kg, about 27 mg/kg, about 28 mg/kg, about 29 mg/kg, about 30mg/kg, about 31 mg/kg, about 32 mg/kg, about 33 mg/kg, about 34 mg/kg,about 35 mg/kg, about 36 mg/kg, about 37 mg/kg, about 38 mg/kg, about 39mg/kg, about 40 mg/kg, about 41 mg/kg, about 42 mg/kg, about 43 mg/kg,about 44 mg/kg, about 45 mg/kg, about 46 mg/kg, about 47 mg/kg, about 48mg/kg, or about 49 mg/kg, or about 50 mg/kg, about 55 mg/kg, about 60mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg,about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or up to about 100mg/kg. Ranges between any and all of these endpoints are alsocontemplated, e.g., about 1 mg/kg to about 3 mg/kg, about 1 mg/kg toabout 5 mg/kg, about 1 mg/kg to about 10 mg/kg, about 1 mg/kg to about20 mg/kg, about 1 mg/kg to about 40 mg/kg, about 5 mg/kg to about 30mg/kg, about 5 mg/kg to about 20 mg/kg, about 2 mg/kg to about 6 mg/kg,about 1 mg/kg to about 4 mg/kg, or about 3 mg/kg to about 5 mg/kg.

Also disclosed herein are formulations (e.g., powder (i.e., lyophilized)and/or liquid formulations) that are stable at room temperature and/or4° C. for at least 6 months, 7 months, 8 months, 9 months, 10 months, 11months, 1 year, 18 months, 2 years, 3 years, 4 years, 5 years, 6 years,7 years, 8 years, 9 years, 10 years or longer. In some embodiments, theformulation comprises Ab-30 crystals and the formulation is stable atroom temperature and/or 4° C. for at least 6 months, 7 months, 8 months,9 months, 10 months, 11 months, 1 year, 18 months, 2 years, 3 years, 4years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years or more. Insome embodiments, the Ab-30 formulation is stable at 4° C. and/or roomtemperature for at least 9 months.

Also described herein are methods of using the formulations describedherein to treat any disorder associated with decreased bone density(bone-related disorders), including but not limited to, achondroplasia,cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, Gaucher'sDisease, hypophosphatemic rickets, Marfan's syndrome, multiplehereditary exotoses, neurofibromatosis, osteogenesis imperfecta,osteopetrosis, osteopoikilosis, sclerotic lesions, pseudoarthrosis,pyogenic osteomyelitis, periodontal disease, anti-epileptic drug inducedbone loss, primary or secondary hyperparathyroidism, familialhyperparathyroidism syndromes, weightlessness induced bone loss,osteoporosis in men, postmenopausal bone loss, osteoarthritis, renalosteodystrophy, infiltrative disorders of bone, oral bone loss,osteonecrosis of the jaw, juvenile Paget's disease, melorheostosis,metabolic bone diseases, mastocytosis, sickle cell anemia/disease, organtransplant related bone loss, kidney transplant related bone loss,systemic lupus erythematosus, ankylosing spondylitis, epilepsy, juvenilearthritides, thalassemia, mucopolysaccharidoses, Fabry Disease, TurnerSyndrome, Down Syndrome, Klinefelter Syndrome, leprosy, Perthe'sDisease, adolescent idiopathic scoliosis, infantile onset multi-systeminflammatory disease, Winchester Syndrome, Menkes Disease, Wilson'sDisease, ischemic bone disease (such as Legg-Calve-Perthes disease orregional migratory osteoporosis), anemic states, conditions caused bysteroids, glucocorticoid-induced bone loss, heparin-induced bone loss,bone marrow disorders, scurvy, malnutrition, calcium deficiency,osteoporosis, osteopenia, alcoholism, chronic liver disease,postmenopausal state, chronic inflammatory conditions, rheumatoidarthritis, inflammatory bowel disease, ulcerative colitis, inflammatorycolitis, Crohn's disease, oligomenorrhea, amenorrhea, pregnancy,diabetes mellitus, hyperthyroidism, thyroid disorders, parathyroiddisorders, Cushing's disease, acromegaly, hypogonadism, immobilizationor disuse, reflex sympathetic dystrophy syndrome, regional osteoporosis,osteomalacia, bone loss associated with joint replacement, HIVassociated bone loss, bone loss associated with loss of growth hormone,bone loss associated with cystic fibrosis, chemotherapy-associated boneloss, tumor-induced bone loss, cancer-related bone loss, hormoneablative bone loss, multiple myeloma, drug-induced bone loss, anorexianervosa, disease-associated facial bone loss, disease-associated cranialbone loss, disease-associated bone loss of the jaw, disease-associatedbone loss of the skull, bone loss associated with aging, facial boneloss associated with aging, cranial bone loss associated with aging, jawbone loss associated with aging, skull bone loss associated with aging,or bone loss associated with space travel.

The formulations described herein are useful for improving outcomes inorthopedic procedures, dental procedures, implant surgery, jointreplacement, bone grafting, bone cosmetic surgery and bone repair suchas fracture healing, nonunion healing, delayed union healing and facialreconstruction. One or more formulations may be administered before,during and/or after the procedure, replacement, graft, surgery orrepair.

Also contemplated are dental implants, matrices, gels and wounddressings comprising formulation described herein. In some embodiments,the dental implants, matrices, gels and wound dressings are coated withthe formulation. In other embodiments, the formulation is applied to atarget area (i.e., diseased gingival area or diseased periodontal pocketof the subject), optionally prior to (or after) application of a dentalimplant, matrices or wound dressing. In these embodiments, theformulation is applied by any means known in the art. In someembodiments, the formulation is administered to a target area bysubcutaneous injection prior to the application of the dental implant,matrix or wound dressing. In other embodiments, the formulation isadministered to the affected area by brushing or otherwise coating theaffected area prior to the application of the dental implant, matrix orwound dressing.

In another aspect, described herein are methods of increasing bonemineral density in a mammalian subject comprising administering aformulation described herein to the mammalian subject in an amounteffective to increase bone mineral density. In some embodiments, themethod optionally increases the level of a marker of bone formation. Insome embodiments the bone mineral density is increased for at leastabout 7 days, 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7weeks, 8 weeks, 2 months, 3 months or longer. In related aspects,described herein is a method of treating a bone-related disorder in amammalian subject comprising administering a formulation describedherein to the subject in an amount effective to treat the bone-relateddisorder.

In some embodiments, the formulation increases the level of a marker ofbone formation by at least about 10% compared to bone marker levelsabsent treatment. The formulation can be administered via a single doseor in multiple doses. For example, the formulation described herein canbe administered in a short-term therapy regimen to, e.g., increase boneformation, and/or can be administered long-term to prevent loss of bonemineral density in a maintenance therapeutic regimen.

In any of the preceding methods, the level of the marker of boneformation is increased by at least about 10%, about 20%, about 30%,about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about100% or more for at least about 2 weeks, 3 weeks, 30 days, 1 month, 6weeks, 2 months or longer, compared to pre-treatment levels or normallevels for that patient population. By way of non-limiting example, thelevel of the marker of bone formation by 3 weeks after treatment isincreased by, e.g., at least about 20% compared to pre-treatment levelsor normal levels for that patient population. In one exemplaryembodiment, the marker of bone resorption is serum level ofC-telopeptide of type I collagen (CTX). In other exemplary embodiments,the marker of bone formation is bone-specific alkaline phosphatase(BSAP), osteocalcin (OstCa), and/or N-terminal extension of procollagentype 1 (P1NP).

In another aspect, described herein is a method of treating abone-related disorder, wherein the method comprises administering to amammal a formulation described herein in an amount effective to increasebone mineral density for the total body (e.g., head, trunk, arms, andlegs) or at the hip (e.g., total hip and/or femoral neck), spine (e.g.,lumbar spine), wrist, finger, shin bone and/or heel by about 1%, about2%, about 3%, about 4%, about 5%, about 6%, about 8%, about 10%, about12%, about 15%, about 18%, about 20%, about 25%, or 30% or more. In someembodiments, the bone mineral density of the mammalian subject beforetreatment is characteristic of osteoporosis or osteopenia, and one ormore doses of the formulation are administered in an amount and for atime effective to improve bone mineral density such that the bonemineral density is no longer characteristic of osteoporosis and/orosteopenia. For example, one or more doses may be administered for aninitial time period to increase bone mineral density to within 2.5, orone, standard deviations of the density normal for a young adult (i.e.,a T-score≧−2.5 or a T-score≧−1). In exemplary embodiments, the initialtime period is about 3 months or less, 6 months or less, 9 months orless, 1 year or less, 18 months or less, or longer. The method mayfurther comprise subsequently administering one or more amounts of aformulation described herein effective to maintain bone mineral density,optionally for a maintenance time period of at least about 6 months, 1year, 2 years or longer (e.g., over the life-time of the subject).

In another aspect, described herein is a method of treating abone-related disorder in a mammalian subject by administering aformulation described herein, wherein the formulation comprises ananti-sclerostin antibody described herein at a dose of 0.1 mg/kg, 0.5mg/kg, 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about10 mg/kg, about 20 mg/kg, about 25 mg/kg, about 26 mg/kg, about 27mg/kg, about 28 mg/kg, about 29 mg/kg, about 30 mg/kg, about 31 mg/kg,about 32 mg/kg, about 33 mg/kg, about 34 mg/kg, about 35 mg/kg, about 36mg/kg, about 37 mg/kg, about 38 mg/kg, about 39 mg/kg, about 40 mg/kg,about 41 mg/kg, about 42 mg/kg, about 43 mg/kg, about 44 mg/kg, about 45mg/kg, about 46 mg/kg, about 47 mg/kg, about 48 mg/kg, or about 49mg/kg, or about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg,about 90 mg/kg, about 95 mg/kg, or up to about 100 mg/kg. Ranges betweenany and all of these endpoints are also contemplated, e.g., about 1mg/kg to about 3 mg/kg, about 1 mg/kg to about 5 mg/kg, about 1 mg/kg toabout 10 mg/kg, about 1 mg/kg to about 20 mg/kg, about 1 mg/kg to about40 mg/kg, about 5 mg/kg to about 30 mg/kg, about 5 mg/kg to about 20mg/kg, about 2 mg/kg to about 6 mg/kg, about 1 mg/kg to about 4 mg/kg,or about 3 mg/kg to about 5 mg/kg.

In some embodiments, a dose from about 50 milligrams to about 1,000milligrams is administered a subject (e.g., a human subject). Forexample, in some embodiments, the formulation comprises ananti-sclerostin antibody described herein at a dose of about 5 mg, 15mg, 25 mg, 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg,about 100 mg, about 120 mg, about 150 mg, about 200 mg, about 240 mg,about 250 mg, about 280 mg, about 300 mg, about 350 mg, about 400 mg,about 420 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg,about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg,about 900 mg, about 950 mg or up to about 1,000 mg of anti-sclerostinantibody. Ranges between any and all of these endpoints are alsocontemplated, e.g. about 50 mg to about 80 mg, about 70 mg to about 140mg, about 70 mg to about 350 mg, about 70 mg to about 280 mg, about 70mg to about 210, about 75 mg to about 100 mg, about 100 mg to about 150mg, about 140 mg to about 210 mg, or about 150 mg to about 200 mg, orabout 280 to about 410 mg.

In any of the methods described herein. the dose is administered at anyinterval, such as multiple times a week (e.g., twice or three times perweek), once a week, once every two weeks, once every three weeks, oronce every four weeks. In some or any embodiments, a formulationcomprising an anti-sclerostin antibody described herein at a doseranging from about 120 mg to about 210 mg is administered twice a week.In some or any embodiments, a formulation comprising an anti-sclerostinantibody described herein at a dose of about 140 mg of the formulationis administered twice a week. Any of the doses described herein may beadministered as divided doses. For example, a formulation comprising ananti-sclerostin antibody described herein as a dose of 140 mg ofanti-sclerostin antibody may be administered as two injections of 70 mgof anti-sclerostin antibody. Similarly, a dose of 210 mg ofanti-sclerostin antibody may be administered as two injections of 105 mgof anti-sclerostin antibody.

Additionally, described herein is method of treating a bone-relateddisorder in a mammalian subject suffering from or at risk ofhypocalcemia or hypercalcemia, a mammalian subject in which treatmentwith a parathyroid hormone or analog thereof is contraindicated, or amammalian subject in which treatment with a bisphosphonate iscontraindicated. The method comprises administering to the mammaliansubject a formulation described herein in amount effective to increasethe level of a marker of bone formation, without resulting inhypocalcemia or hypercalcemia (e.g., clinically-significant hypocalcemiaor hypercalcemia).

In yet another aspect, described herein is the use of anti-sclerostinantibody crystals described herein in the preparation of a medicamentfor treating a bone-related disorder in a first amount for a firstperiod of time, wherein the amount is effective to increase bone mineraldensity at the hip, spine, wrist, finger, shin bone and/or heel by atleast about 3%, followed by a second amount of for a second period oftime effective to maintain bone mineral density.

Also provided is the use of anti-sclerostin antibody crystals describedherein to treat a bone-related disorder first amount for a first periodof time, wherein the amount is effective to increase bone mineraldensity at the hip, spine, wrist, finger, shin bone and/or heel by atleast about 3%, followed by a second amount of for a second period oftime effective to maintain bone mineral density. Exemplary doses rangefrom. about 0.1 to about 20 mg/kg, or about 0.1 to about 12 mg/kg, orabout 0.5 to about 12 mg/kg, or about 1 to about 10 mg/kg, or about 1 toabout 8 mg/kg, or about 2 to about 8 mg/kg, or about 3 to about 8 mg/kg.In some embodiments, a dose from about 50 milligrams to about 1,000milligrams is administered a subject (e.g., a human subject). Forexample, in some embodiments, the formulation comprising ananti-sclerostin antibody described herein at a dose of about 5 mg, 15mg, 25 mg, 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg,about 100 mg, about 120 mg, about 150 mg, about 200 mg, about 240 mg,about 250 mg, about 280 mg, about 300 mg, about 350 mg, about 400 mg,about 420 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg,about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg,about 900 mg, about 950 mg or up to about 1,000 mg of anti-sclerostinantibody. Ranges between any and all of these endpoints are alsocontemplated, e.g. about 50 mg to about 80 mg, about 70 mg to about 140mg, about 70 mg to about 350 mg, about 70 mg to about 280 mg, about 70mg to about 210, about 75 mg to about 100 mg, about 100 mg to about 150mg, about 140 mg to about 210 mg, or about 150 mg to about 200 mg, orabout 280 to about 410 mg.

In some or any embodiments, a method or use described herein furthercomprises administering a second bone-enhancing therapeutic for thetreatment of bone-related disorder described herein. Many therapeuticsof this type are known in the art. In some embodiments, thebone-enhancing therapeutic is selected from the group consisting of ananti-resorptive drug, a bone-forming agent, an estrogen receptormodulator (including, but not limited to, raloxifene, bazedoxifene andlasofoxifene) and a drug that has an inhibitory effect on osteoclasts.In some embodiments, the second bone-enhancing agent is selected fromthe group consisting of, a bisphosphonate (including, but not limitedto, alendronate sodium (FOSAMAX®), risedronate, ibandronate sodium(BONIVA®) and zoledronic acid (RECLAST®)), an estrogen or estrogenanalogue, a calcium source, Tibolone, calcitonin, a calcitriol andhormone replacement therapy. In some embodiments, the secondbone-enhancing agent includes, but is not limited to parathyroid hormone(PTH) or a peptide fragment thereof, PTH-related protein (PTHrp), bonemorphogenetic protein, osteogenin, NaF, a PGE₂ agonist, a statin, ananti-DKK1 antibody or inhibitor, an anti-RANK ligand (RANKL) antibody(e.g., PROLIA®) or RANKL inhibitor, strontium ranelate, vitamin D, or avitamin D derivative or mimic thereof. In some embodiments, the secondbone-enhancing agent is Forteo® (Teriparatide, or recombinant humanparathyroid hormone analog (1-34)) or Preotact® (parathyroid hormone).In some or any embodiments, the bone-enhancing agent is Protelos®.

In some embodiments, the second bone-enhancing agent is administeredconcurrently with the formulation (e.g., for a length of time within thetreatment period). In other embodiments, the second bone-enhancing agentis administered for a length of time once the treatment period with theanti-sclerostin antibody has ended (i.e., for a maintenance period). Insuch embodiments, the second bone-enhancing agent is administered for amaintenance period of about 1 week to about 5 years.

The method may further comprise subsequently administering one or moreamounts of the formulation effective to maintain bone mineral density,optionally for a maintenance period of at least about 12 weeks, 6months, 1 year, 2 years, 3 years, 4 years, 5 years or longer (e.g., overthe lifetime of the subject) after the treatment period has ended.

Additional aspects of the invention are defined or summarized in thefollowing numbered paragraphs:

1. A crystal of an anti-sclerostin IgG antibody comprising light andheavy chain variable regions of SEQ ID NOS: 3 and 5, preferably havingthe amino acid sequences of SEQ ID NOS: 13 and 15.

2. A sterile formulation comprising a crystal of an anti-sclerostin IgGantibody, wherein at least 70% of the antibody is in a crystalline form.

3. A sterile formulation comprising a crystal of an anti-sclerostin IgGantibody, wherein at least 90% of the antibody is in a crystalline form.

4. The formulation of paragraph 2 or paragraph 3, wherein the IgGantibody comprises light and heavy chain variable regions of SEQ ID NOS:3 and 5, preferably having the amino acid sequences of SEQ ID NOS: 13and 15.

5. The crystal or formulation of any of the preceding paragraphs,wherein the crystal has a length of up to 500 μm.

6. The crystal or formulation of any of the preceding paragraphs,wherein the crystal has a shape selected from the group consisting ofellipsoids, rods and needles.

7. The formulation of any of the preceding claims, comprising crystalshaving a length of up to about 500 μm and a shape selected from thegroup consisting of ellipsoids, rods and needles or mixtures thereof.

8. The crystal or formulation of any of the preceding paragraphs,wherein the crystal comprises a salt selected from the group consistingof sodium dihydrogen phosphate, di-potassium hydrogen phosphate, sodiumchloride, ammonium sulfate, potassium sodium tartrate tetrahydrate,tacsimate, sodium citrate dihydrate, sodium acetate trihydrate,di-ammonium tartrate, sodium malonate, acetate, calcium acetate,cacodylate, CHES, lithium sulfate, magnesium chloride, zinc acetate,cesium chloride, ammonium phosphate, sodium phosphase, potassiumphosphate, sodium fluoride, potassium iodide, sodium idodide, ammoniumiodide, sodium thiocyanate, potassium thiocyanate, sodium formate,potassium formate and ammonium formate.

9. The formulation of any of the preceding paragraphs, that is alyophilized formulation.

10. The formulation of any of the preceding paragraphs, that is a liquidformulation.

11. The formulation of paragraph 10, comprising a concentration of atleast about 100 mg of said antibody per ml of formulation.

12. The formulation of paragraph 10, comprising at least about 140 mg ofantibody dispersed in 1.5 ml or less of liquid.

13. The formulation of paragraph 11 or paragraph 12, that is injectablethrough a syringe having a 20 Gauge needle or finer using a clinicallyacceptable amount of force.

14. The formulation of any of the preceding paragraphs, that retains atleast 50% the in vivo activity, when given at the same dose and in thesame manner, of a liquid formulation of said antibody that has not beencrystallized.

15. The formulation of paragraph 11 or paragraph 12, that, whenadministered to a mammalian subject, mediates an increase in bonemineral density that is at least about 70% or of the level of bonemineral density increase mediated by a liquid formation of the antibodythat has not been crystallized, when the formulation and liquidformulation of the antibody that has not been crystallized isadministered to the subject at the same dose and in the same manner.

16. The formulation of paragraph 14 or paragraph 15, that isadministered as a single dose.

17. The formulation of paragraph 14 or paragraph 15, that isadministered in multiple doses.

18. The formulation of any of the preceding paragraphs comprising atleast 20% PEG-3350.

19. The formulation of any of the preceding paragraphs comprising atleast 10% PEG-8000.

20. The formulation of any of the preceding paragraphs, wherein theosmolality of the formulation ranges from about 180 to about 420mOsm/kg.

21. A container comprising at least 50 mg of the antibody crystal ofparagraph 1 for suspension in a volume of 0.5-2 mL.

22. A container comprising the formulation of paragraph 2 or paragraph3.

23. The container of paragraph 21 or 22, wherein the container is avial, syringe or injection device.

24. The container of paragraph 23, wherein the syringe needle is 20Gauge or finer.

25. A method of resuspending the formulation of paragraph 9, comprisingcontacting the formulation with about 0.5-2 mL of a sterile suspensionvehicle.

26. The method of paragraph 25, wherein the suspension vehicle isselected from the group consisting of glutamate, sorbitol, HEPES,dextrose and water or combinations thereof.

27. A method of making a crystal of an anti-sclerostin IgG antibodycomprising light and heavy chain variable regions of SEQ ID NOS: 3 and5, preferably having the amino acid sequences of SEQ ID NOS: 13 and 15,the method comprising combining a solution of the antibody with acrystallization reagent comprising a salt selected from the groupconsisting of sodium dihydrogen phosphate, di-potassium hydrogenphosphate, sodium chloride, ammonium sulfate, ammonium acetate,potassium sodium tartrate tetrahydrate, tacsimate, sodium citratedihydrate, sodium acetate trihydrate, di-ammonium tartrate, sodiummalonate, acetate, calcium acetate, cacodylate, CHES, lithium sulfate,lithium acetate dihydrate, magnesium chloride, magnesium acetatetetrahydrate, magnesium formate, magnesium nitrate, magnesium sulfate,zinc acetate, zinc chloride, zinc sulfate, cesium chloride, ammoniumphosphate, sodium phosphase, potassium phosphate, sodium fluoride,potassium iodide, sodium idodide, ammonium iodide, sodium thiocyanate,potassium thiocyanate, sodium formate, potassium formate and ammoniumformate, optionally at pH of about 6 to about 8, such that a crystal isformed.

28. The method of paragraph 27, wherein the concentration of the salt isfrom about 0.1M to about 10M.

29. The method of paragraph 27, wherein the reagent further comprises2-methyl-2,4-pentanediol (MPD) or polyethylene glycol (PEG).

30. The method of paragraph 27, wherein the MPD is present at aconcentration of about 0.1% to about 50%.

31. The method of paragraph 27, wherein the PEG has a molecular weightof about 400 kDa to about 20,000 kDa.

32. The method of paragraph 31, wherein the PEG is present at aconcentration of 0.1% to about 50%.

33. A method of making a crystal of an anti-sclerostin IgG antibodycomprising light and heavy chain variable regions of SEQ ID NOS: 3 and5, preferably having the amino acid sequences of SEQ ID NOS: 13 and 15,the method comprising combining a solution of the antibody with acrystallization reagent comprising a member selected from the groupconsisting of succinic acid, PEG-1000, PEG-8000 and isopropanol, suchthat a crystal is formed.

34. The method of paragraph 33, wherein the crystallization reagentcomprises

(a) from about 0.1 M to about 5 M succinic acid, from about 0.1 M toabout 5 M HEPES and from about 0.1% (w/v) to about 60% (w/v)polyethylene glycol monomethyl ether 2000;(b) from about 1% (w/v) to about 50% (w/v) PEG-8000, from about 0.05 Mto about 5 M imidazole and from about 0.1 to about 5 M calcium acetate;(c) from about 1% (w/v) to about 50% (w/v) PEG-8000, from about 0.05M toabout 5M TRIS and from about 0.05M to about 5M magnesium chloride(d) from about 10% to about 80% (w/v) PEG-1000, from about 0.05M toabout 5M sodium/potassium phosphate and from about 0.05M to about 5Msodium chloride;(e) from about 1% (w/v) to about 20% (w/v) PEG-8000, from about 0.05 Mto about 5M cacodylate, from about 0.1 M to about 2 M calcium acetate,and from about 10% to about 30% (w/v) glycerol; or(f) from about 10% to about 30% isopropanol and from about 0.1 M toabout 2 M sodium/potassium phosphate.

35 The method of any one of paragraphs 27-34, further comprisingremoving at least a portion of the crystallization reagent aftercrystals have formed.

36. The method of paragraph 35, wherein the portion of crystallizationreagent is removed by centrifugation.

37. The method of paragraph 35, wherein the crystals are placed in asolution containing an organic additive.

38. The method of paragraph 37, further comprising the addition of anexcipient to the solution.

39. The method of paragraph 38, wherein the excipient is selected fromthe group consisting of sucrose, trehalose, and sorbitol.

40. The method of paragraph 37, wherein the organic additive is ethanolor isopropanol.

41. The method of paragraph 27 or paragraph 33, further comprisingdrying crystals that have formed.

42. The method of paragraph 41, wherein the crystals are dried byexposure to air, or by exposure to a vacuum, or by exposure to nitrogengas.

43. The method of paragraph 27 or 33, wherein at least 80% of theantibody is crystallized.

44. The method of any of paragraphs 27-43, that is a batchcrystallization method,

45. An antibody crystal produced by the method of paragraph 27 orparagraph 33.

46. A method of increasing bone mineral density, treating a disorderassociated with decreased bone density, treating a bone-relateddisorder, or improving outcomes in a procedure, replacement, graft,surgery or repair in a mammalian subject comprising administering theformulation of any of the preceding paragraphs in an amount effective toincrease bone mineral density in the subject.

47. A crystal of an anti-sclerostin IgG antibody comprising light andheavy chain variable regions of SEQ ID NOS: 23 and 25, preferably havingthe amino acid sequences of SEQ ID NOS: 33 and 35.

48. The crystal of paragraph 47, wherein the crystal has a length ofabout 100 μM to about 500 μM or about 5 μM to about 50 μM.

49. The crystal of paragraph 47 or 48, wherein the crystal has anellipsoidal shape.

50. The crystal of any one of paragraphs 47-49, wherein the crystalcomprises a salt selected from the group consisting of sodium chloride,potassium chloride, sodium acetate, potassium phosphate and histidine.

51. A sterile formulation comprising the antibody crystal of paragraph47, wherein at least 70% of the antibody is in crystalline form.

52. The crystal or formulation of any one of paragraphs 47-51, whereinthe crystal has a length of up to about 500 μm.

53. The crystal or formulation of any one of the paragraphs 47-51wherein the crystal has a shape selected from the group consisting ofellipsoids, rods and needles.

54. The formulation of any one of the paragraphs 51-53, comprisingcrystals having a length of up to about 500 μm and a shape selected fromthe group consisting of ellipsoids, rods and needles or mixturesthereof.

55. A method of making a crystal of an anti-sclerostin IgG antibodycomprising light and heavy chain variable regions of SEQ ID NOS: 23 and25, preferably having the amino acid sequences of SEQ ID NOS: 33 and 35,the method comprising combining a solution of the antibody with acrystallization reagent comprising a salt selected from the groupconsisting of potassium phosphate and histidine, optionally at pH ofabout 6 to about 8, such that a crystal is formed.

56. The method of paragraph 55, wherein the concentration of the salt isfrom about 1-30 mM, optionally about 10 mM.

57. The method of paragraph 55 or 56, wherein the crystallizationreagent further comprises polyethylene glycol (PEG).

58. The method of paragraph 55, further comprising removing at least aportion of the crystallization reagent after crystals have formed.

59. The method of paragraph 58, wherein the portion of crystallizationreagent is removed by centrifugation.

60. The method of paragraph 55, wherein the crystals are placed in asolution containing an organic additive.

61. The method of paragraph 55, further comprising the addition of anexcipient to the solution.

62. The method of paragraph 61, wherein the excipient is selected fromthe group consisting of sucrose, trehalose, or sorbitol.

63. The method of paragraph 60, wherein the organic additive is ethanolor isopropanol.

64. The method of paragraph 55, further comprising drying crystals thathave formed.

65. The method of paragraph 64, wherein the crystals are dried byexposure to air, or by exposure to a vacuum, or by exposure to nitrogengas.

66. An antibody crystal produced by the method of any of paragraphs55-65.

67. The formulation of any one of paragraphs 51-54 that is a lyophilizedformulation.

68. The formulation of any one of paragraphs 51-54 that is a liquidformulation.

69. The formulation of paragraph 68, comprising a concentration of atleast about 100 mg of said antibody per ml of formulation.

70. The formulation of any one of paragraphs 51-54, wherein the crystalcomprises a salt selected from the group consisting of sodium chloride,potassium chloride, sodium acetate, potassium phosphate and histidine.

71. The formulation of any one of paragraphs 51-54, comprisingsucrolose, trehalose and/or sorbitol.

72. The formulation of paragraph 68, wherein the osmolality of theformulation ranges from about 180 to about 420 mOsm/kg.

73. The formulation of paragraph 68, comprising at least about 140 mg orantibody dispersed in 1.5 ml or less of liquid.

74 The formulation of paragraph 69 or 73, that is injectable through asyringe having 20 Gauge needle or finer using a clinically acceptableamount of force.

75. The formulation of any of paragraphs 51-54 and 66-75, that retainsat least 50% of the in vivo activity, when given at the same dose and inthe same manner, of a liquid formulation of said antibody that has notbeen crystallized.

76. A container comprising at least 50 mg or more of an antibody crystalof paragraph 66 for suspension in a volume of 0.5-2 mL.

77. A container comprising a formulation of paragraph 51.

78. The container of paragraph 77, wherein the container is a vial,syringe or injection device.

79. The container of paragraph 78, wherein the syringe has a needlehaving a 20 Gauge or finer.

80. A method of resuspending the formulation of paragraph 67, comprisingcontacting the crystal with about 0.5-2 mL of sterile suspensionvehicle.

81. The formulation of any one of paragraphs 51-54 and 66-75 thatretains at least 50% of the in vivo activity, when given at the samedose and in the same manner, of a liquid formulation of said antibodythat has not been crystallized.

82. The formulation of any one of paragraphs 51-54 and 66-75, that, whenadministered to a mammalian subject, mediates an increase in bonemineral density that is at least about 70% of the level of bone mineraldensity increase mediated by a liquid formulation of said antibody thathas not been crystallized, wherein the formulation and the liquidformulation of the antibody that has not been crystallized isadministered to the subject at the same dose and in the same manner.

83. The formulation of claim 81 or 82, that is administered as a singledose.

84. The formulation of claim 81 or 82, that is administered in multipledoses.

85. A method of increasing bone mineral density, treating a disorderassociated with decreased bone density, treating a bone-relateddisorder, or improving outcomes in a procedure, replacement, graft,surgery or repair in a mammalian subject comprising administering theformulation of any one of paragraphs 51-54 and 66-75 in an amounteffective to increase bone mineral density in the subject.

It should be understood that while various embodiments in thespecification are presented using “comprising” language, under variouscircumstances, a related embodiment may also be described using“consisting of” or “consisting essentially of” language. It is to benoted that the term “a” or “an”, refers to one or more, for example, “animmunoglobulin molecule,” is understood to represent one or moreimmunoglobulin molecules. As such, the terms “a” (or “an”), “one ormore,” and “at least one” can be used interchangeably herein.

It should also be understood that when describing a range of values, thecharacteristic being described could be an individual value found withinthe range. For example, “a pH from about pH 4 to about pH 6,” could be,but is not limited to, pH 4, 4.2, 4.6, 5.1, 5.5 etc. and any value inbetween such values. Additionally, “a pH from about pH 4 to about pH 6,”should not be construed to mean that the pH of a formulation in questionvaries 2 pH units in the range from pH 4 to pH 6 during storage, butrather a value may be picked in that range for the pH of the solution,and the pH remains buffered at about that pH. In some embodiments, whenthe term “about” is used, it means the recited number plus or minus 5%,10%, 15% or more of that recited number. The actual variation intendedis determinable from the context.

In any of the ranges described herein, the endpoints of the range areincluded in the range. However, the description also contemplates thesame ranges in which the lower and/or the higher endpoint is excluded.Additional features and variations of the invention will be apparent tothose skilled in the art from the entirety of this application,including the drawing and detailed description, and all such featuresare intended as aspects of the invention Likewise, features of theinvention described herein can be re-combined into additionalembodiments that also are intended as aspects of the invention,irrespective of whether the combination of features is specificallymentioned above as an aspect or embodiment of the invention. Also, onlysuch limitations which are described herein as critical to the inventionshould be viewed as such; variations of the invention lackinglimitations which have not been described herein as critical areintended as aspects of the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A provides the osmolality data for the various Ab-30Rmcrystallization screens. FIG. 1B is a graph showing the osmolality dataof compositions Ab-30Rm, LISS Buffers and X % PEG-3350.

FIG. 2 shows Ab-30Rm crystal morphology in #12 0.05M Tris pH 8.0 and atdifferent percentages of PEG-3350, as observed and recorded using a CarlZeiss Axiocam MRc Microscope.

FIGS. 3A and 3B are graphs showing the dissolution rate of Ab-30crystals in various suspension vehicles.

FIG. 4 is a graph showing the dissolution rate of Ab-30 crystals basedon crystal morphology.

FIGS. 5A-5F are graphs showing the dissolution rate of Ab-30 crystalsbased on crystal packing.

FIGS. 6A and 6B are graphs showing the dissolution rate of Ab-30crystals based on temperature and crystal morphology.

FIG. 7 shows bone mineral density (BMD) in rats as absolute BMD (A) andas percent change from baseline (B) measured at lumbar vertebrae overtime after administration of a single injection of buffer/vehicle or asingle injection of “liquid” Ab-30Rm (50 mg/kg of a 100 mg/ml solution)or a single injection of “crystal/crystalline” Ab-30Rm (50 mg/kg of a100 mg/ml solution). BL=baseline. Data are shown as mean+/− standarderror of the mean (SEM). Statistically significant differences versusbuffer/vehicle control group are indicated by asterisks. *p<0.05 vs.Vehicle by ANOVA Dunnett's Test. N=9 for buffer/vehicle group. N=10 forthe “liquid” Ab-30Rm group. N=10 for the “crystal/crystalline” Ab-30Rmgroup.

FIG. 8 shows bone mineral density (BMD) in rats as absolute BMD (A) andas percent change from baseline (B) measured at leg (femur-tibia) overtime after administration of a single injection of buffer/vehicle or asingle injection of “liquid” Ab-30Rm (50 mg/kg of a 100 mg/ml solution)or a single injection of “crystal/crystalline” Ab-30Rm (50 mg/kg of a100 mg/ml solution). BL=baseline. Data are shown as mean+/− standarderror of the mean (SEM). Statistically significant differences versusbuffer/vehicle control group are indicated by asterisks. For FIG. 8B*p<0.05, **p<0.01, ***p<0.001 vs. Vehicle by ANOVA Dunnett's Test. N=8for each group N=9 for buffer/vehicle group. N=10 for the “liquid”Ab-30Rm group. N=10 for the “crystal/crystalline” Ab-30Rm group.

FIG. 9 shows bone mineral density (BMD) in rats as absolute BMD (A) andas percent change from baseline (B) measured at lumbar vertebrae overtime after administration of a single injection of buffer/vehicle or asingle injection of “liquid” Ab-30 (100 mg/kg of a 100 mg/ml solution)or a single injection of “crystal/crystalline” Ab-30 (100 mg/kg of a 100mg/ml solution) of crystal formulation W35, I34, I36 or W46.BL=baseline. Data are shown as mean+/− standard error of the mean (SEM).Statistically significant differences versus buffer/vehicle controlgroup are indicated by asterisks. For FIG. 9A **p<0.01 vs. Vehicle byANOVA Dunnett's Test. For FIG. 9B *p<0.05, **p<0.01, ***p<0.001 vs.Vehicle by ANOVA Dunnett's Test.

FIG. 10 shows bone mineral density (BMD) in rats as absolute BMD (A) andas percent change from baseline (B) measured at leg (femur-tibia) overtime after administration of a single injection of buffer/vehicle or asingle injection of “liquid” Ab-30 (100 mg/kg of a 100 mg/ml solution)or a single injection of “crystal/crystalline” Ab-30 (100 mg/kg of a 100mg/ml solution) of crystal formulation W35, I34, I36 or W46.BL=baseline. Data are shown as mean+/− standard error of the mean (SEM).Statistically significant differences versus buffer/vehicle controlgroup are indicated by asterisks. For FIG. 10B *p<0.05, **p<0.01,***p<0.001 vs. Vehicle by ANOVA Dunnett's Test. N=8 for each group.

DETAILED DESCRIPTION

Described herein are crystals of anti-sclerostin immunoglobulin type G(IgG) antibodies, suitable for use in formulations for parenteraladministration; methods of using such crystals of Ab-30 or Ab-31 toprepare formulations for use as medicaments; formulations comprisinghigh concentrations of a crystalline anti-sclerostin antibody, methodsof using these formulations for treatment, methods of administeringthese formulations, e.g., subcutaneously or intramuscularly, andcontainers or kits comprising these formulations.

I. Antibodies in the Formulation

In some embodiments, the anti-sclerostin antibody in the formulation ispresent at a concentration (a “high protein concentration”) of at leastabout 100 mg/ml, about 101 mg/ml, about 102 mg/ml, about 103 mg/ml,about 104 mg/ml, about 105 mg/ml, about 106 mg/ml, about 107 mg/ml,about 108 mg/ml, about 109 mg/ml, about 110 mg/ml, about 111 mg/ml,about 112 mg/ml, about 113 mg/ml, about 114 mg/ml, about 115 mg/ml,about 116 mg/ml, about 117 mg/ml, about 118 mg/ml, about 119 mg/ml,about 120 mg/ml, about 121 mg/ml, about 122 mg/ml, about 123 mg/ml,about 124 mg/ml, about 125 mg/ml, about 126 mg/ml, about 127 mg/ml,about 128 mg/ml, about 129 mg/ml, about 130 mg/ml, about 131 mg/ml,about 132 mg/ml, about 132 mg/ml, about 133 mg/ml, about 134 mg/ml,about 135 mg/ml, about 136 mg/ml, about 137 mg/ml, about 138 mg/ml,about 139 mg/ml, about 140 mg/ml, about 141 mg/ml, about 142 mg/ml,about 143 mg/ml, about 144 mg/ml, about 145 mg/ml, about 146 mg/ml,about 147 mg/ml, about 148 mg/ml, about 149 mg/ml, about 150 mg/ml,about 151 mg/ml, about 152 mg/ml, about 153 mg/ml, about 154 mg/ml,about 155 mg/ml, about 156 mg/ml, about 157 mg/ml, about 158 mg/ml,about 159 mg/ml, about 160 mg/ml, about 161 mg/ml, about 162 mg/ml,about 163 mg/ml, about 164 mg/ml, about 165 mg/ml, about 166 mg/ml,about 167 mg/ml, about 168 mg/ml, about 169 mg/ml, about 170 mg/ml,about 171 mg/ml, about 172 mg/ml, about 173 mg/ml, about 174 mg/ml,about 175 mg/ml, about 176 mg/ml, about 177 mg/ml, about 178 mg/ml,about 179 mg/ml, about 180 mg/ml, about 181 mg/ml, about 182 mg/ml,about 183 mg/ml, about 184 mg/ml, about 185 mg/ml, about 186 mg/ml,about 187 mg/ml, about 188 mg/ml, about 189 mg/ml, about 190 mg/ml,about 191 mg/ml, about 192 mg/ml, about 193 mg/ml, about 194 mg/ml,about 195 mg/ml, about 196 mg/ml, about 197 mg/ml, about 198 mg/ml,about 199 mg/ml, about 200 mg/ml, and may range up to, e.g., about 400mg/ml, about 390 mg/ml, about 380 mg/ml, about 370 mg/ml, about 360mg/ml, about 350 mg/ml, about 340 mg/ml, about 330 mg/ml, about 320mg/ml, about 310 mg/ml, about 300 mg/ml, about 290 mg/ml, about 280mg/ml, about 270 mg/ml, about 260 mg/ml, about 250 mg/ml, or about 240mg/ml. Any range featuring a combination of the foregoing endpoints iscontemplated, including but not limited to: about 70 mg/ml to about 250mg/ml, about 70 mg/ml to about 140 mg/ml, about 70 mg/ml to about 350mg/ml, about 50 mg/ml to about 80 mg/ml, about 70 mg/ml to about 210mg/ml, about 100 mg/ml to about 150 mg/ml, about 280 mg/ml to about 410mg/ml, about 100 mg/ml to about 200 mg/ml, about 100 mg/ml to about 250mg/ml, about 100 mg/ml to about 300 mg/ml, about 100 mg/ml to about 320mg/ml or about 100 mg/ml to about 350 mg/ml.

The anti-sclerostin antibody is optionally formulated as a single dose(e.g., about 70 to about 450 mg of anti-sclerostin antibody). In someembodiments, the dose comprises at least about 5 mg, 15 mg, 25 mg, 50mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg,about 120 mg, about 150 mg, about 200 mg, about 240 mg, about 250 mg,about 280 mg, about 300 mg, about 350 mg, about 400 mg, about 420 mg,about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg,about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg,about 950 mg or up to about 1,000 mg of anti-sclerostin antibody. Rangesbetween any and all of these endpoints are also contemplated, e.g. about50 mg to about 80 mg, about 70 mg to about 140 mg, about 70 mg to about350 mg, about 70 mg to about 280, about 70 mg to about 210 mg, about 75mg to about 100 mg, about 100 mg to about 150 mg, about 140 mg to about210 mg, or about 150 mg to about 200 mg, or about 280 mg to about 410 mgof anti-sclerostin antibody. The dose is administered at any interval,such as multiple times a week (e.g., twice or three times per week),once a week, once every two weeks, once every three weeks, or once everyfour weeks. For example, in some or any embodiments, a dose ofanti-sclerostin antibody ranging from about 120 mg to about 210 mg isadministered twice a week. In some or any embodiments, a dose of about140 mg of the anti-sclerostin antibody is administered twice a week. Anyof the doses described herein may be administered as divided doses. Forexample, a dose of 140 mg of anti-sclerostin antibody may beadministered as two injections of 70 mg of anti-sclerostin antibody.Similarly, a dose of 210 mg of anti-sclerostin antibody may beadministered as two injections of 105 mg of anti-sclerostin antibody anda dose of 140 mg of anti-sclerostin antibody may be administered asseven injections of 20 mg of anti-sclerostin antibody.

In some embodiments, the formulation comprises about 70 mg or 75 mg ofanti-sclerostin antibody, which is suitable for administering a singledose of about 1 mg/kg. In other embodiments, the formulation comprisesabout 50 mg, or about 60 mg, or about 70 mg, or about 80 mg, or about 90mg, or about 100 mg, or about 120 mg, or about 130 mg, or about 140 mgor about 150 mg, or about 160 mg, or about 170 mg, or about 180 mg, orabout 190 mg, or about 200 mg, or about 210 mg or about 220 mg or about230 mg; or about 240 mg, or about 250 mg, or about 250 mg to about 450mg; or about 280 mg or 290 mg or 300 mg; or about 350 mg or 360 mg; orabout 420 mg or 430 mg or 440 mg or 450 mg of the anti-sclerostinantibody. In any of such embodiments, the formulation comprises anamount of anti-sclerostin antibody suitable for administering a singledose of about 2 to about 6 mg/kg, or about 1 mg/kg to about 4 mg/kg, orabout 3 mg/kg to about 5 mg/kg, or about 1 mg/kg to about 3 mg/kg bodyweight (e.g., about 2 mg/kg, or about 3 mg/kg, or about 4 mg/kg, orabout 5 mg/kg or about 6 mg/kg body weight).

In some embodiments, the anti-sclerostin antibody is Ab-30. In someembodiments, the anti-sclerostin antibody is Ab-31. Antibodies Ab-30 andAb-31 were previously described in U.S. Patent Application PublicationNo. 2007/0110747, the disclosure of which, including sequence listing,is incorporated herein by reference in its entirety. In otherembodiments, the anti-sclerostin antibody is Ab-30R (SEQ ID NOs: 16-19)or Ab-30Rm (SEQ ID NOs: 17 and 19-21).

The anti-sclerostin antibody described herein binds to sclerostin of SEQID NO: 1 with a Kd of 10⁻⁶ M or less, or 10⁻⁷ M or less, or 10⁻⁸M orless, or 10⁻⁹ M or less. Affinity can be determined by any means knownin the art, including via Biacore technology and ELISA as described in,e.g., US Patent Application Publication Bo. 2007/0110747.

In some embodiments, the antibody comprises the heavy and/or light chainof antibody Ab-30, Ab-30R, Ab-30Rm, or Ab-31. The amino acid sequencesof the mature full length light and heavy chains of antibodies Ab-30,Ab-30R, Ab-30Rm, or Ab-31, including the constant region, are set forthin SEQ ID NOs: 13 and 15; SEQ ID NOs: 16 and 19; SEQ ID NOs: 20 and 19;and SEQ ID NOs: 33 and 35, respectively. The corresponding cDNA sequenceencoding the full length light and heavy chains of antibodies Ab-30 andAb-31, including the constant region, are set forth in SEQ ID NOs: 12and 14; SEQ ID NOs: 32 and 34 respectively.

The term “Ab-30 antibody” as used herein refers to an IgG immunoglobulincomposed of two heavy chains and two light chains, wherein the heavychain comprises SEQ ID NO: 5 (Ab-30 heavy chain variable region) fusedto an IgG constant region, and the light chain comprises SEQ ID NO: 3(Ab-30 light chain variable region) fused to a light chain constantregion. Preferably Ab-30 comprises the mature heavy and light chainamino acid sequences set forth in SEQ ID NOs: 15 and 13, respectively.In some embodiments, the antibody comprises the heavy and/or light chainvariable region of antibody Ab-30 SEQ ID NO: 5 (Ab-30 heavy chainvariable region) fused to a human heavy chain constant region of isotypeIgG1, 2, 3 or 4 (e.g., native, consensus or modified, and a number ofmodifications that are known not to affect binding are known in theart), and/or SEQ ID NO: 3 (Ab-30 light chain variable region) fused to ahuman light chain constant region (e.g., native, consensus or modifiedto have a number of modifications that are known not to affect bindingSEQ ID NO: 17 (Ab-30R heavy chain variable region) fused to a humanheavy chain constant region of isotype IgG1, 2, 3 or 4, and/or SEQ IDNO: 16 (Ab-30R light chain variable region) fused to a human light chainconstant region; SEQ ID NO: 17 (Ab-30Rm heavy chain variable region)fused to a human heavy chain constant region of isotype IgG1, 2, 3 or 4,and/or SEQ ID NO: (Ab-30Rm light chain variable region) fused to a humanlight chain constant region.

The term “Ab-31 antibody” as used herein refers to an IgG immunoglobulincomposed of two heavy chains and two light chains, wherein the heavychain comprises SEQ ID NO: 25 (Ab-31 heavy chain variable region) fusedto an IgG constant region, and the light chain comprises SEQ ID NO: 23(Ab-31 light chain variable region) fused to a light chain constantregion. Preferably Ab-31 comprises the mature heavy and light chainamino acid sequences set forth in SEQ ID NOs: 35 and 33, respectively.Thus, in some embodiments, the antibody comprises the heavy and/or lightchain variable region of antibody Ab-31 SEQ ID NO: 25 (Ab-30 heavy chainvariable region) fused to a human heavy chain constant region of isotypeIgG1, 2, 3 or 4 (e.g., (e.g., native, consensus or modified to have anumber of modifications that are known not to affect binding) and/or SEQID NO: 23 (Ab-31 light chain variable region) fused to a human lightchain constant region (e.g., (e.g., native, consensus or modified tohave a number of modifications that are known not to affect binding).

In some embodiments, the antibody comprises amino acid sequencesobtainable by expressing in mammalian host cells the cDNA encoding theheavy and/or light chain, or alternatively the heavy and/or light chainvariable region, of antibody Ab-30, Ab-30R, Ab-30Rm, or Ab-31. The term“antibody” refers to an intact immunoglobulin, e.g. in the case of IgG,a tetrameric immunoglobulin composed of two heavy chains and two lightchains (e.g., chimeric, humanized, or human versions preferably havingfull length heavy and/or light chains, optionally with mutations withinthe framework or constant regions that retain the anti-sclerostinbinding properties).

An “isolated” antibody refers to an antibody, as that term is definedherein, that has been separated from a component of its naturalenvironment. Contaminant components of its natural environment arematerials that would interfere with diagnostic or therapeutic uses forthe antibody, and may include enzymes, hormones, and other proteinaceousor nonproteinaceous solutes. In certain embodiments, the antibody willbe purified (1) to greater than 95% by weight of antibody, and mostpreferably more than 99% by weight, (2) to a degree sufficient to obtainat least 15 residues of N-terminal or internal amino acid sequence, or(3) to homogeneity by SDS-PAGE under reducing or nonreducing conditionsusing Coomassie blue or, preferably, silver stain. Isolated naturallyoccurring antibody includes the antibody in situ within recombinantcells since at least one component of the antibody's natural environmentwill not be present. Ordinarily, however, isolated antibody will beprepared by at least one purification step.

A “monoclonal” antibody refers to an antibody obtained from a populationof substantially homogeneous antibodies, i.e., the individual antibodiescomprising the population are identical except for possible naturallyoccurring mutations that may be present in minor amounts, compared to a“polyclonal” antibody which refers to a mixed population of antibodiesof diverse sequence that bind diverse epitopes. The phrase “humanizedantibody” refers to an antibody derived from a sequence of a non-humanantibody, typically a rodent monoclonal antibody, which comprisesmodifications that render the sequence more human-like. Alternatively, ahumanized antibody may be derived from a chimeric antibody. The phrase“human” antibody refers to an antibody derived from human sequences,e.g., through screening libraries of human antibody genes through knowntechniques such as phage display, or produced using transgenic animalsthat have no endogenous immunoglobulin production and are engineered tocontain human immunoglobulin loci.

An “immunoglobulin G” or “native IgG antibody” is a tetramericglycoprotein. In a naturally-occurring immunoglobulin, each tetramer iscomposed of two identical pairs of polypeptide chains, each pair havingone “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa). Theamino-terminal portion of each chain includes a “variable” (“V”) regionof about 100 to 110 or more amino acids primarily responsible forantigen recognition. The carboxy-terminal portion of each chain definesa constant region primarily responsible for effector function.Immunoglobulins can be assigned to different classes depending on theamino acid sequence of the constant domain of their heavy chains. Heavychains are classified as mu (μ), delta (Δ), gamma (γ), alpha (α), andepsilon (ε), and define the antibody's isotype as IgM, IgD, IgG, IgA,and IgE, respectively. Several of these may be further divided intosubclasses or isotypes, e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.Different isotypes have different effector functions; for example, IgG1and IgG3 isotypes have antibody-dependent cellular cytotoxicity (ADCC)activity. Human light chains are classified as kappa (κ) and lambda (λ)light chains. Within light and heavy chains, the variable and constantregions are joined by a “J” region of about 12 or more amino acids, withthe heavy chain also including a “D” region of about 10 more aminoacids. See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nded. Raven Press, N.Y. (1989)).

The term “hypervariable” region refers to amino acid residues from acomplementarity determining region or CDR (i.e., residues 24-34 (L1),50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35(H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain asdescribed by Kabat et al., Sequences of Proteins of ImmunologicalInterest, 5th Ed. Public Health Service, National Institutes of Health,Bethesda, Md. (1991)). “Framework” or FR residues are those variableregion residues other than the hypervariable region residues.

The term “variant” when used in connection with antibodies refers to apolypeptide sequence of an antibody that contains at least one aminoacid substitution, deletion, or insertion in the variable region or theportion equivalent to the variable region, provided that the variantretains the desired binding affinity or biological activity. Inaddition, the antibodies as described herein may have amino acidmodifications in the constant region to modify effector function of theantibody, including half-life or clearance, ADCC and/or CDC activity.Such modifications can enhance pharmacokinetics or enhance thetherapeutic effectiveness of the antibody, for example. See Shields etal., J. Biol. Chem., 276(9):6591-6604 (2001), incorporated by referenceherein in its entirety. In the case of IgG1, modifications to theconstant region, particularly the hinge or CH2 region, may increase ordecrease effector function, including ADCC and/or CDC activity. In otherembodiments, an IgG2 constant region is modified to decreaseantibody-antigen aggregate formation. In the case of IgG4, modificationsto the constant region, particularly the hinge region, may reduce theformation of half-antibodies.

The term “modification” when used in connection with antibodies orpolypeptides described herein, includes but is not limited to, one ormore amino acid change(s) (including substitutions, insertions ordeletions); chemical modifications that do not interfere withsclerostin-binding activity; covalent modification by conjugation totherapeutic or diagnostic agents; labeling (e.g., with radionuclides orvarious enzymes); covalent polymer attachment such as pegylation(derivatization with polyethylene glycol) and insertion or substitutionby chemical synthesis of non-natural amino acids. In some embodiments,modified polypeptides (including antibodies) of the invention willretain the binding properties of unmodified molecules of the invention.

The term “derivative” when used in connection with antibodies orpolypeptides of the invention refers to antibodies or polypeptides thatare covalently modified by conjugation to therapeutic or diagnosticagents, labeling (e.g., with radionuclides or various enzymes), covalentpolymer attachment such as pegylation (derivatization with polyethyleneglycol) and insertion or substitution by chemical synthesis ofnon-natural amino acids. In some embodiments, derivatives of theinvention will retain the binding properties of underivatized moleculesof the invention.

Proteins and non-protein agents may be conjugated to the antibodies bymethods that are known in the art. Conjugation methods include directlinkage, linkage via covalently attached linkers, and specific bindingpair members (e.g., avidin-biotin). Such methods include, for example,that described by Greenfield et al., Cancer Research 50, 6600-6607(1990) for the conjugation of doxorubicin and those described by Arnonet al., Adv. Exp. Med. Biol. 303, 79-90 (1991) and by Kiseleva et al.,Mol. Biol. (USSR) 25, 508-514 (1991) for the conjugation of platinumcompounds.

II. Production of Crystals, Crystal Formulations and Compositions

Polypeptide crystals are grown by controlled crystallization ofpolypeptides from aqueous solutions or from aqueous solutions containingorganic solvents or additives. Solution conditions that may becontrolled include, for example, the rate of evaporation of solvent,organic solvents or additives, the presence of appropriate co-solutesand buffers, pH, and temperature. A comprehensive review of the variousfactors affecting the crystallization of proteins has been published byMcPherson (1985, Methods Enzymol 114: 112-120). In addition, McPhersonand Gilliland (1988, J Crystal Growth, 90: 51-59) have compiledcomprehensive lists of polypeptides that have been crystallized, as wellas the conditions under which they were crystallized. A compendium ofcrystals and crystallization recipes, as well as a repository ofcoordinates of solved protein structures, is maintained by the ProteinData Bank at the Brookhaven National Laboratory (www.rcsb.org/pdb/;Bernstein et al., 1977, J Mol Biol 112: 535-542). It should be noted,however, that the conditions reported in most of the above-citedreferences have been optimized to yield, in most instances, a few large,diffraction quality crystals. Accordingly, it will be appreciated bythose of skill in the art that these conditions vary from protein toprotein, and do not provide a high yielding process for the large scaleproduction of crystals of any given polypeptide.

In general, crystals are produced by combining the polypeptide (i.e.,antibody) to be crystallized with an appropriate aqueous solvent oraqueous solvent containing appropriate crystallization agents, such assalts or organic solvents or additives (collectively the“crystallization reagent”). The solvent is combined with the polypeptideand may be subjected to agitation at a temperature determinedexperimentally to be appropriate for the induction of crystallizationand acceptable for the maintenance of polypeptide activity andstability. Laboratory-scale methods for crystallization include hangingdrop vapor diffusion, sitting drop vapor diffusion, microdialysis,microbatch, under oil, in gel and sandwich drop methods. The solvent canoptionally include co-crystallization additives, such as precipitants,fatty acids, reducing agents, glycerol, sulfobetaine, surfactants,polyols, divalent cations, co-factors, or chaotropes, as well as bufferspecies to control pH.

“Co-crystallization additives” include compounds that facilitatecrystallization of a polypeptide and/or compounds that stabilize theprotein and protect against denaturation. Examples of co-solutes includeammonium acetate, ammonium chloride, ammonium fluoride, ammoniumformate, ammonium nitrate, ammonium phosphate, ammonium sulfate, cadmiumchloride, cadmium sulfate, calcium acetate, calcium chloride, cesiumchloride, cobaltous chloride, CH₃(CH₂)₁₅N(CH₃)₃ ⁺Br⁻. (CTAB),di-ammonium citrate, di-ammonium hydrogen phosphate, di-ammoniumphosphate, di-ammonium tartrate, di-potassium phosphate, di-sodiumphosphate, di-sodium tartrate, DL-malic acid, ferric chloride,L-proline, lithium acetate, lithium chloride, lithium nitrate, lithiumsulfate, magnesium acetate, magnesium chloride, magnesium formate,magnesium nitrate, magnesium sulfate, nickel chloride, potassiumacetate, potassium bromide, potassium chloride, potassium citrate,potassium fluoride, potassium formate, potassium nitrate, potassiumphosphate, potassium sodium tartrate, potassium sulfate, potassiumthiocyanate, sodium acetate, sodium bromide, sodium chloride, sodiumcitrate, sodium fluoride, sodium formate, sodium malonate, sodiumnitrate, sodium phosphate, sodium sulfate, sodium thiocyanate, succinicacid, tacsimate, tri-ammonium citrate, tri-lithium citrate,trimethylamine N-oxide, tri-potassium citrate, tri-sodium citrate, zincacetate, zinc sulfate, and other compounds that function to supplyco-solutes. “Crystallization buffers” include compounds that maintainthe pH of a solution in a desired range to facilitate crystallization ofa polypeptide. Examples include ACES(N-(2-acetamido)-2-aminoethanesulfonic acid), BES(N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), Bicine(N,N-Bis(2-hydroxyethyl)glycine), BIS-TRIS(2,2-bis-(hydroxymethyl)-2,2′,2″-nitrilotriethanol), boric acid, CAPS(3-[cyclohexylamino]-1-propanesulfonic acid), EPPS (HEPPS,4-(2-Hydroxyethyl)piperazine-1-propanesulfonic acid), Gly-Gly(NH₂CH₂CONHCH₂COOH, glycyl-glycine), HEPES(4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), imidazole, MES(2-morpholinoethanesulfonic acid), MOPS(3-(N-morpholino)-propanesulfonic acid), PIPES(piperazine-1,4-bis(2-ethanesulfonic acid)), sodium acetate, sodiumbicarbonate, sodium phosphate monobasic (sodium dihydrogen phosphate),TAPS(N-[tris-(hydroxymethyl)methyl]-3-aminopropanesulfonic acid),TAPSO(N-[tris(hydroxymethyl)methyl]-3-amino-2-hydroxypropanesulfon-icacid), TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid),Tricine (N-[tris(hydroxymethyl)methyl]glycine), Tris-HCl, TRIZMA(2-amino-2-(hydroxymethyl)-1,3-propanediol), and other compounds thatfunction to maintain a solution at or near a specified pH.

The selection of precipitants are one factor affecting crystallization.For example, PEG products, e.g., of molecular weight 600 to 20,000 kD,can be used. PEG-3350 is a long polymer precipitant or dehydrant whichworks by volume exclusion effect. Lyotropic salts, such as ammoniumsulfate, promote precipitation processes, as do short-chain fatty acids,such as caprylic acid. Polyionic species also are useful precipitants.

Antibodies for use in formulations for subcutaneous injection, forexample, preferably are precipitated at a physiologic pH range and in acrystallization reagent that provides isotonic osmolality.

The need for additives, co-solutes, buffers, etc. and theirconcentrations are determined experimentally to facilitatecrystallization. Some examples of suitable crystallization conditionsfor a polypeptide are described in Example 1 below.

Ab-30, in particular, is easily crystallized under a variety ofconditions. Various morphologies of Ab-30 crystals can be grown underscale-up conditions whereby the antibody in a liquid formulation isadded to a volume of known crystallization reagent and stored in asealed container. Ab-30 crystals can be grown under these conditions inless than 24 hours, at room temperature or refrigerated temperatures (4°C.) and have been shown to produce slow release and high yield.

In an industrial-scale process, the controlled precipitation leading tocrystallization can best be carried out by the simple combination ofpolypeptide, precipitant, co-solutes and, optionally, buffers in a batchprocess. As another option, polypeptides may be crystallized by usingpolypeptide precipitates as the starting material (“seeding”). In thiscase, polypeptide precipitates are added to a crystallization solutionand incubated until crystals form. Alternative laboratorycrystallization methods, such as dialysis or vapor diffusion, can alsobe adopted. McPherson, supra and Gilliland, supra, include acomprehensive list of suitable conditions in their reviews of thecrystallization literature. Occasionally, in cases in which thecrystallized polypeptide is to be crosslinked, incompatibility betweenan intended crosslinking agent and the crystallization medium mightrequire exchanging the crystals into a more suitable solvent system.

According to some embodiments, polypeptide crystals, crystalformulations and compositions are prepared by the following process:first, the polypeptide is crystallized. Next, excipients or ingredientsas described herein are added directly to the mother liquor.Alternatively, the crystals are suspended in a solution of excipient orother formulary ingredients, after the mother liquor is removed, for aminimum of 1 hour to a maximum of 24 hours. The excipient concentrationis typically between about 0.01% to 30% w/w, which corresponds to apolypeptide crystal concentration of 99.99% to 70% w/w, respectively. Inone embodiment, the excipient concentration is between about 0.1% to10%, which corresponds to a crystal concentration of 99.9 to 90% w/w,respectively. The mother liquor can be removed from the crystal slurryeither by filtration, buffer exchange, or by centrifugation.Subsequently, the crystals are washed optionally with solutions of 50%to 100% one or more organic solvents or additives such as, for example,ethanol, methanol, isopropanol or ethyl acetate, either at roomtemperature or at temperatures between −20° C. to 25° C. The crystalsare dried by passing a stream of nitrogen, air, or inert gas over thecrystals. Alternatively, the crystals are dried by air drying or bylyophilization or by vacuum drying. The drying is carried out for aminimum 1 hour to a maximum of 72 hours after washing, until themoisture content of the final product is below 10% by weight, mostpreferably below 5%. Finally, micronizing of the crystals can beperformed if necessary. The drying of polypeptide crystals is theremoval of water, organic solvent or additive, or liquid polymer bymeans including drying with N₂, air, or inert gases; vacuum oven drying;lyophilization; washing with a volatile organic solvent or additivefollowed by evaporation of the solvent; or evaporation in a fume hood.Typically, drying is achieved when the crystals become a free-flowingpowder. Drying may be carried out by passing a stream of gas over wetcrystals. The gas may be selected from the group consisting of:nitrogen, argon, helium, carbon dioxide, air or combinations thereof.The polypeptide crystals of the invention can be further processed toachieve a desired particle size distribution by micronizing in asuitable mill, such as a jet mill, and the components of the particle orpowder formulation may be mixed before or after micronizing. Thediameter of the particles achieved can be in the range of 0.1 to 100micrometers, or in the range of 0.2 to 10 micrometers, or in the rangeof 10 to 50 micrometers, or in the range of 0.5 to 2 micrometers. In oneembodiment, the particles formed from the polypeptide crystals are inthe range of 0.5 to 1 micrometers, which is a suitable range for e.g.,inhalation.

According to some embodiments, when preparing protein crystals, proteincrystal formulations or compositions, enhancers (such as surfactants)are not added during crystallization. Excipients or ingredients areadded to the mother liquor after crystallization, at a concentration ofbetween about 1%-10% w/w, alternatively at a concentration of betweenabout 0.1%-25% w/w, alternatively at a concentration of between about0.1%-50% w/w. These concentrations correspond to crystal concentrationsof 99%-90% w/w, 99.9%-75% w/w and 99.9%-50% w/w, respectively. Theexcipient or ingredient is incubated with the crystals in the motherliquor for about 0.1-3 hrs, alternatively the incubation is carried outfor 0.1-12 hrs, alternatively the incubation is carried out for 0.1-24hrs.

In some or any embodiments, the ingredient or excipient is dissolved ina solution other than the mother liquor, and the protein crystals areremoved from the mother liquor and suspended in the excipient oringredient solution. The ingredient or excipient concentrations and theincubation times are the same as those described above.

Polypeptide Crystals

As used herein, “crystal” or “crystalline” refers to one form of thesolid state of matter, which is distinct from a second form—theamorphous solid state. Crystals display characteristic featuresincluding a lattice structure, characteristic shapes, and opticalproperties such as refractive index and birefringence. A crystalconsists of atoms arranged in a pattern that repeats periodically inthree dimensions (C. S. Barrett, Structure of Metals, 2nd ed.,McGraw-Hill, New York, 1952, p. 1). In contrast, amorphous material is anon-crystalline solid form of matter, sometimes referred to as anamorphous precipitate. Such precipitates have no molecular latticestructure characteristic of the crystalline solid state and do notdisplay birefringence or other spectroscopic characteristics typical ofthe crystalline forms of matter.

Polypeptide crystals are polypeptide molecules arranged in a crystallattice. Polypeptide crystals contain a pattern of specificpolypeptide-polypeptide interactions that are repeated periodically inthree dimensions. The polypeptide crystals of this invention are to bedistinguished from amorphous solid forms or precipitates ofpolypeptides, such as those obtained by lyophilizing a polypeptidesolution.

In polypeptide crystals, the polypeptide molecules form asymmetric unitswhich are arranged together to form symmetric units. The geometricstructure of the symmetric units of polypeptide crystals can be, forexample, cubic, hexagonal, monoclinic, orthorhombic, tetragonal,triclinic, or trigonal. The overall structure of the crystals in theirentirely can be, for example, in the form of bipyramids, cubes, needles,plates, prisms, rhomboids, rods, or spheres, or combinations thereof.Other observed forms include block-shaped, UFO shaped, football shaped,leaf shaped, wheat shaped, singlet shaped, feather-shaped, straw-shaped,chrysanthemum-shaped, spherical or mixtures thereof. In someembodiments, the crystals are observed in clusters. Crystals that are ofthe “cubic” structural class can more specifically have octadecahedralor dodecahedral crystal forms. The diameter of the crystals is definedas the Martin's diameter. It is measured as the length of the line,parallel to the ocular scale, that divides the randomly orientedcrystals into two equal projected areas. Crystals in forms such asneedles or rods will also have a maximal dimension that is referred toherein as the length of the crystal. The crystals are also characterizedby x-ray diffraction.

Testing Properties of Crystalline Polypeptides

After polypeptide crystals are formed, they can be subjected to variousanalyses to confirm their polypeptide content and to further examinetheir physical structure. For example, if necessary, individual crystalscan be removed from the crystallization solution and washed with aqueousor organic solvents or additives, then dried (for example, by airdrying, by passing a stream of inert gas over the crystal, bylyophilization, or by vacuum). Crystals can be isolated, removed fromthe crystal growth drop, and then mounted for X-ray diffraction.

Crystals can also be characterized by a variety of means described inthe art. See, e.g., Basu et al., Expert Opin. Biol. Thera. 4, 301-317(2004), incorporated herein by reference in its entirety for itsdisclosure of protein crystal production and formulation procedures, andanalytical tools for characterizing crystals and their componentprotein. While powder X-ray diffraction is commonly used to identifycrystalline material, it requires very large and perfect proteincrystals and is not commonly applied to the protein microcrystalstypically used in crystalline formulations. Electron diffraction andsolid state nuclear magnetic resonance (ssNMR) can be applied tocharacterize crystals. Crystal size, shape and morphology (e.g., surfacemorphology) can be inspected, for example, by light microscopy,transmission electron microscopy, scanning electron microscopy, atomicforce microscopy, and/or light scattering (e.g., photon correlationspectroscopy or DLS, low angle laser light scattering or LAALS). Totalsurface area and porosity of crystals can also be characterized. Massspectrometry, micro-attenuated total reflectance Fourier transforminfrared spectroscopy (FTIR) and/or differential scanning calorimetry(DSC) can provide information about protein primary and secondarystructure.

As another example, polypeptide crystals can be removed fromcrystallization solution and washed or rinsed, or the majority ofcrystallization solution can be removed from the crystals and replacedwith a different solution. In this way, the particular salt that wasused in the crystallization procedure can be replaced in the crystallattice with a different salt. In one embodiment of the invention,crystallized Ab-30, Ab-30R, Ab-30Rm, or Ab-31 antibodies are separatedfrom the crystallization buffer and placed in a solution containing asalt of sodium, potassium, or magnesium (for example, sodium acetate,sodium chloride, sodium citrate, sodium phosphate, sodium sulfate,potassium chloride, potassium citrate, or magnesium sulfate). For X-raydiffraction, the replacement solution can contain heavy atoms useful indetermining the atomic coordinates of the crystallized polypeptide. As afurther embodiment, antibody Ab-30, Ab-30R, Ab-30Rm, or Ab-31 can beco-crystallized with sclerostin for determination of the detailedstructure of the Ab-30, Ab-30R, Ab-30Rm, or Ab-31-sclerostininteraction.

In a further example, polypeptide crystals can be removed fromcrystallization solution and solubilized in an appropriate buffer forfurther testing, such as an SDS-containing buffer for analysis of thepolypeptide that had been crystallized by gel electrophoresis. Methodsfor analysis of proteins by gel electrophoresis are well known andinclude staining a gel with silver or Coomassie blue dye, and comparingthe electrophoretic migration of the polypeptide that had beencrystallized with the migration of polypeptide markers of knownmolecular weight. In another method, the polypeptide is visualized inthe gel by use of a labeled antibody that specifically binds to thepolypeptide. Polypeptides that have been crystallized can also besolubilized in buffers appropriate for amino acid sequencing by Edmandegradation, for mass spectrometry, for other spectrographic scattering,refraction, diffraction, or absorption studies, or for labeling of thepolypeptide by attachment of a label molecule to the polypeptide.

III. Formulations for Therapeutic Administration

As used herein, the term “composition” as used herein means a mixturecomprising at least two components. In particular, described herein arecompositions comprising a crystalline anti-sclerostin antibody, andcompositions prepared using a crystalline anti-sclerostin antibody. Insome embodiments, the composition or formulation comprising or preparedusing a crystalline anti-sclerostin antibody is suitable for injectionand/or administration to a patient in need thereof. Compositions to beadministered for pharmaceutical purposes to patients are substantiallysterile and do not contain agents that are unduly toxic or infectious tothe recipient.

In some embodiments, crystalline anti-sclerostin antibodies such ascrystalline antibody Ab-30, Ab-30R, Ab-30Rm, or Ab-31 are administeredin the form of a physiologically acceptable composition (also referredto herein as a pharmaceutical composition or as a pharmaceuticalformulation) comprising a crystalline anti-sclerostin antibody that isformulated with one or more of the following: physiologically acceptablecarriers, excipients, or diluents. Such carriers, excipients, ordiluents are nontoxic to recipients at the dosages and concentrationsemployed. Ordinarily, the preparation of such compositions entailscombining the crystalline anti-sclerostin antibody with one or more ofthe following: buffers, antioxidants such as ascorbic acid, lowmolecular weight polypeptides (such as those having fewer than 10 aminoacids), proteins, amino acids, carbohydrates such as glucose, sucrose ordextrins, chelating agents such as EDTA, glutathione and otherstabilizers and excipients. In liquid formulations, neutral bufferedsaline or saline mixed with nonspecific serum albumin are exemplaryappropriate diluents. In accordance with appropriate industry standards,preservatives may also be added, such as benzyl alcohol. Furtherexamples of components that may be employed in pharmaceuticalformulations are presented in Remington's Pharmaceutical Sciences,16^(th) Ed., Mack Publishing Company, Easton, Pa., 1980, and in theHandbook of Pharmaceutical Excipients, published jointly by the AmericanPharmaceutical Association and the Pharmaceutical Society of GreatBritain.

In one embodiment, it is contemplated that the formulation describedherein is prepared in a bulk formulation and as such, the components ofthe pharmaceutical composition are adjusted so that they are higher thanwould be required for administration, and are diluted appropriatelyprior to administration.

The antibody crystals described herein can be formulated as a solidcrystalline or powder formulation in forms suitable for storage andhandling, and in forms suitable for inhalation or pulmonaryadministration, for example in the form of powders for the preparationof aerosol formulations. In an further embodiment, the antibody crystalscan be formulated in a liquid solution of such crystals, or in a slurryof such crystals. In another embodiment, the antibody crystals are usedto prepare a liquid formulation, such as an aqueous formulation, fortherapeutic administration.

A. Solid Formulations of Antibody Crystals

Solid formulations of antibody crystals include crystals that have beensubstantially isolated from liquid solution or dried, and are present asfree crystals or as particles in, for example, powder form. In thepresent context, the term “powder” refers to a collection of essentiallydry particles, i.e. the moisture content being below about 10% byweight, or below 6% by weight, or below 4% by weight. Polypeptidecrystals or powders can be optionally combined with carriers orsurfactants. Suitable carrier agents include, but are not limited to, 1)carbohydrates, e.g., monosaccharides such as fructose, galactose,glucose and sorbose; 2) disaccharides, such as lactose and trehalose; 3)polysaccharides, such as raffmose, maltodextrins and dextrans; 4)alditols, such as mannitol and xylitol; 5) inorganic salts, such assodium chloride; and 6) organic salts, such as sodium citrate and sodiumascorbate. In certain embodiments, the carrier is selected from thegroup consisting of trehalose, raffinose, mannitol, sorbitol, xylitol,inositol, sucrose, sodium chloride, and sodium citrate. Surfactants canbe selected from the group consisting of salts of fatty acids, bilesalts or phospholipids. Fatty acids salts include salts of C₁₀₋₁₄ fattyacids, such as sodium caprate, sodium laurate, and sodium myristate.Bile salts include salts of ursodeoxycholate, taurocholate,glycocholate, and taurodihydrofusidate. In one embodiment, thesurfactant is a salt of taurocholate such as sodium taurocholate.Phospholipids that can be used as surfactants includelysophosphatidylcholine. The molar ratio of crystalline polypeptide tosurfactant in a powder formulation of the present invention is forexample 9:1 to 1:9, or between 5:1 to 1:5, or between 3:1 to 1:3.

B. Crystals in Solution or Slurries

Also described herein is a method for rendering polypeptide crystalssuitable for storage in suspensions comprising replacing thecrystallization buffer (the mother liquor) with a non-aqueous solvent.In yet another embodiment, the crystalline slurry can be rendered solidby spinning out the first solvent and washing the remaining crystallinesolid using a second organic solvent or additive to remove water,followed by evaporation of the non-aqueous solvent. Non-aqueous slurriesof crystalline therapeutic proteins are especially useful forsubcutaneous delivery.

In one such embodiment, the polypeptide crystals described herein arecombined with liquid organic additives with the object of stabilizingthe polypeptide crystals. Such a mixture can be characterized as anaqueous-organic mixture that comprises n % organic additive, where n isbetween 1 and 99, and m % aqueous solution, where m is 100-n. Examplesof organic additives include phenolic compounds, such as m-cresol orphenol or a mixture thereof, and acetone, methyl alcohol, methylisobutyl ketone, chloroform, 1-propanol, isopropanol, 2-propanol,acetonitrile, 1-butanol, 2-butanol, ethyl alcohol, cyclohexane, dioxane,ethyl acetate, dimethylformamide, dichloroethane, hexane, isooctane,methylene chloride, tert-butyl alcohol, toluene, carbon tetrachloride,or combinations thereof.

C. Liquid Formulations

Another embodiment provided herein is an aqueous formulation that allowsfor stable long-term storage of a pharmaceutical composition wherein acrystalline anti-sclerostin antibody is the active ingredient used inthe preparation of the pharmaceutical composition. This formulation isuseful, in part, because it is more convenient to use for the patient,as this formulation does not require any extra steps such asrehydrating. As used herein, a “solution” or “liquid formulation” is aliquid preparation that contains one or more chemical substancesdissolved in a suitable solvent or mixture of mutually misciblesolvents.

Reconstitution is the dissolution of polypeptide crystals or crystalformulations or compositions in an appropriate buffer or pharmaceuticalformulation.

Resuspension refers to the suspension of polypeptide crystals in anappropriate buffer or pharmaceutical formulation. In some em

D. Components of Pharmaceutical Formulations

The present pharmaceutical composition is prepared by combining, inaddition to a crystalline anti-sclerostin antibody as described above,one or more of the following types of ingredients or excipients listedin the paragraphs below, many or all of which are available fromcommercial suppliers. It will be understood by one of ordinary skill inthe art that the combining of the various components to be included inthe composition can be done in any appropriate order, namely, the buffercan be added first, middle or last and the tonicity modifier can also beadded first, middle or last. It is also to be understood by one ofordinary skill in the art that some of these chemicals can beincompatible in certain combinations, and accordingly, are easilysubstituted with different chemicals that have similar properties butare compatible in the relevant mixture. There is knowledge in the artregarding the suitability of various combinations of excipients andother ingredients or materials present in, for example, the containersused for storage of the pharmaceutical composition and/or the devicesused for therapeutic administration (see, for example, Akers, 2002, JPharm Sci 91: 2283-2300).

Non-limiting examples of additional agents that can be included in theformulations described herein include acidifying agents (including, butnot limited to, acetic acid, glacial acetic acid, citric acid, fumaricacid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitricacid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaricacid, and other suitable acids); active ingredients (including, but notlimited to, additional active ingredients to reduce injection sitediscomfort, and non-steroidal anti-inflammatory drugs such as, forexample, tromethamine, in an appropriate dosage); aerosol propellants(including, but not limited to, butane, dichlorodifluoromethane,dichlorotetrafluoroethane, isobutane, propane andtrichloromonofluoromethane); alcohol denaturants (including, but notlimited to, denatonium benzoate, methyl isobutyl ketone, sucroseoctacetate); alkalizing agents (including, but not limited to, strongammonia solution, ammonium carbonate, diethanolamine,diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodiumborate, sodium carbonate, sodium hydroxide, trolamine); anticakingagents (including, but not limited to, calcium silicate, magnesiumsilicate, colloidal silicon dioxide and talc); antifoaming agents(including, but not limited to, dimethicone and simethicone); chelatingagents (also called sequestering agents) (including, but not limited to,edetate disodium, ethylenediaminetetraacetic acid and salts and edeticacid); coating agents (including, but not limited to, sodiumcarboxymethylcellulose, cellulose acetate, cellulose acetate phthalate,ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose,hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate,methacrylic acid copolymer, methylcellulose, polyethylene glycol,polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide,carnauba wax, microcrystalline wax and zein); colors (including, but notlimited to, caramel, erythrosine (FD&C Red No. 3); FD&C Red No. 40; FD&CYellow No. 5; FD&C Yellow No. 6; FD&C Blue No. 1; red, yellow, black,blue or blends and ferric oxide); complexing agents (including, but notlimited to, ethylenediaminetetraacetic acid (EDTA) and salts thereof,edetic acid, gentisic acid ethanolmaide and oxyquinoline sulfate);desiccants (including, but not limited to. calcium chloride, calciumsulfate and silicon dioxide); filtering aids (including, but not limitedto, powdered cellulose and purified siliceous earth); flavors andperfumes (including, but not limited to, anethole, anise oil,benzaldehyde, cinnamon oil, cocoa, ethyl vanillin, menthol, methylsalicylate, monosodium glutamate, orange flower oil, orange oil,peppermint, peppermint oil, peppermint spirit, rose oil, stronger rosewater, thymol, tolu balsam tincture, vanilla, vanilla tincture andvanillin); humectants (including, but not limited to, glycerin, hexyleneglycol, propylene glycol and sorbitol); ointment bases (including, butnot limited to, lanolin, anhydrous lanolin, hydrophilic ointment, whiteointment, yellow ointment, polyethylene glycol ointment, petrolatum,hydrophilic petrolatum, white petrolatum, rose water ointment andsqualane); plasticizers (including, but not limited to, castor oil,diacetylated monoglycerides, diethyl phthalate, glycerin, mono- anddi-acetylated monoglycerides, polyethylene glycol, propylene glycol,triacetin and triethyl citrate); polymer membranes (including, but notlimited to, cellulose acetate); solvents (including, but not limited to,acetone, alcohol, diluted alcohol, amylene hydrate, benzyl benzoate,butyl alcohol, carbon tetrachloride, chloroform, corn oil, cottonseedoil, ethyl acetate, glycerin, hexylene glycol, isopropyl alcohol, methylalcohol, methylene chloride, methyl isobutyl ketone, mineral oil, peanutoil, polyethylene glycol, propylene carbonate, propylene glycol, sesameoil, water for injection, sterile water for injection, sterile water forirrigation and purified water); sorbents (including, but not limited topowdered cellulose, charcoal, purified siliceous earth; and carbondioxide sorbents: barium hydroxide lime and soda lime); stiffeningagents (including, but not limited to, hydrogenated castor oil,cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat,paraffin, polyethylene excipient, stearyl alcohol, emulsifying wax,white wax and yellow wax); suppository bases (including, but not limitedto, cocoa butter, hard fat and polyethylene glycol); Suspending and/orviscosity-increasing agents (including, but not limited to, acacia,agar, alginic acid, aluminum monostearate, bentonite, purifiedbentonite, magma bentonite, carbomer 934p, carboxymethylcellulosecalcium, carboxymethylcellulose sodium, carboxymethylcellulose sodium12, carrageenan, microcrystalline and carboxymethylcellulose sodiumcellulose, dextrin, gelatin, guar gum, hydroxyethyl cellulose,hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesiumaluminum silicate, methylcellulose, pectin, polyethylene oxide,polyvinyl alcohol, povidone, propylene glycol alginate, silicon dioxide,colloidal silicon dioxide, sodium alginate, tragacanth and xanthan gum);sweetening agents (including, but not limited to, aspartame, dextrates,dextrose, excipient dextrose, fructose, mannitol, saccharin, calciumsaccharin, sodium saccharin, sorbitol, solution sorbitol, sucrose,compressible sugar, confectioner's sugar and syrup); tablet binders(including, but not limited to, acacia, alginic acid, sodiumcarboxymethylcellulose, microcrystalline cellulose, dextrin,ethylcellulose, gelatin, liquid glucose, guar gum, hydroxypropylmethylcellulose, methylcellulose, polyethylene oxide, povidone,pregelatinized starch and syrup); tablet and/or capsule diluents(including, but not limited to, calcium carbonate, dibasic calciumphosphate, tribasic calcium phosphate, calcium sulfate, microcrystallinecellulose, powdered cellulose, dextrates, dextrin, dextrose excipient,fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinizedstarch, sucrose, compressible sugar and confectioner's sugar); tabletdisintegrants (including, but not limited to, alginic acid,microcrystalline cellulose, croscarmellose sodium, corspovidone,polacrilin potassium, sodium starch glycolate, starch and pregelatinizedstarch); tablet and/or capsule lubricants (including, but not limitedto, calcium stearate, glyceryl behenate, magnesium stearate, lightmineral oil, polyethylene glycol, sodium stearyl fumarate, stearic acid,purified stearic acid, talc, hydrogenated vegetable oil and zincstearate); ehicles (include, but are not limited to flavored and/orsweetened (aromatic elixir, compound benzaldehyde elixir, iso-alcoholicelixir, peppermint water, sorbitol solution, syrup, tolu balsam syrup);oleaginous (almond oil, corn oil, cottonseed oil, ethyl oleate,isopropyl myristate, isopropyl palmitate, mineral oil, light mineraloil, myristyl alcohol, octyldodecanol, olive oil, peanut oil, persicoil, sesame oil, soybean oil, squalane); solid carriers such as sugarspheres; and sterile vehicles (bacteriostatic water for injection,bacteriostatic sodium chloride injection); and water-repelling agents(including, but not limited to, cyclomethicone, dimethicone andsimethicone).

Aggregation inhibitors, which reduce a polypeptide's tendency toassociate in inappropriate or unwanted ternary or quaternary complexes,can also be included in the formulations described herein. Suitableaggregation inhibitors include the amino acids L-arginine and/or,L-cysteine, which can act to reduce aggregation of polypeptidescontaining an Fc domain over long periods, e.g., two years or more. Theconcentration of the aggregation inhibitor in the formulation can bebetween about 1 mM to 1M, or about 10 mM to about 200 mM, or about 10 mMto about 100 mM, or about 15 mM to about 75 mM, or about 5 mM to about10 mM, or about 5 mM to about 15 mM, or about 10 mM to about 20 mM, orabout 150 mM to about 250 mM, or about 25 mM.

Antioxidants may also be included in the formulations described herein.Antioxidants contemplated for use in the preparation of the formulationsinclude amino acids such as glycine and lysine, chelating agents such asEDTA and DTPA, and free-radical scavengers such as sorbitol andmannitol. Additional antioxidants include ascorbic acid, ascorbylpalmitate, butylated hydroxyanisole, butylated hydroxytoluene,hypophosphorous acid, monothioglycerol, propyl gallate, sodiumbisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodiumthiosulfate, sulfur dioxide, tocopherol, and tocopherols excipient. Alsocontemplated for use in inhibiting oxidation is nitrogen or carbondioxide overlay. Nitrogen or carbon dioxide overlay can be introduced tothe headspace of a vial or prefilled syringe during the filling process.

Buffering agents, which maintain the pH of the pharmaceuticalformulation in a desired range, can also be included in the formulationsdescribed herein. When the pH of the pharmaceutical composition is setat or near physiological levels, comfort of the patient uponadministration is maximized. In particular, in certain embodiments thepH of a pharmaceutical composition is within a pH range of about 4.0 to8.4, or a pH range of about 5.0 to 8.0, or a pH range of about 5.8 to7.4, or about 6.2 to 7.0. It is to be understood that the pH can beadjusted as necessary to maximize stability and solubility of thepolypeptide in a particular formulation and as such, a pH outside ofphysiological ranges, yet tolerable to the patient, is within the scopeof the invention. Various buffers suitable for use in the pharmaceuticalcomposition of the invention include histidine, alkali salts (sodium orpotassium phosphate or their hydrogen or dihydrogen salts), sodiumcitrate/citric acid, sodium acetate/acetic acid, potassium citrate,maleic acid, ammonium acetate, tris-(hydroxymethyl)-aminomethane (tris),various forms of acetate and diethanolamine, ammonium carbonate,ammonium phosphate, boric acid, lactic acid, phosphoric acid, potassiummetaphosphate, potassium phosphate monobasic, sodium lactate solution,and any other pharmaceutically acceptable pH buffering agent known inthe art. pH-adjusting agents such as hydrochloric acid, sodiumhydroxide, or a salt thereof, may also be included in order to obtainthe desired pH. One suitable buffer is sodium phosphate for maintainingpharmaceutical compositions at or near pH 6.2. In another example,acetate is a more efficient buffer at pH 5 than pH 6 so less acetate maybe used in a solution at pH 5 than at pH 6. The concentration of thebuffer in the formulation can be between about 1 mM to about 1 M, orabout 0.1 mM to about 1 mM or about 0.1 mM to about 0.5 mM or about 10mM to about 300 mM.

Polymeric carriers can also be included in the formulations describedherein. Polymeric carriers are polymers used for encapsulation ofpolypeptide crystals for delivery of polypeptide, including biologicaldelivery. Such polymers include biocompatible and biodegradablepolymers. The polymeric carrier may be a single polymer type or it maybe composed of a mixture of polymer types. Polymers useful as thepolymeric carrier, include for example, poly(acrylic acid),poly(cyanoacrylates), poly(amino acids), poly(anhydrides),poly(depsipeptide), poly(esters) such as poly(lactic acid) or PLA,poly(lactic-co-glycolic acid) or PLGA, poly(B-hydroxybutryate),poly(caprolactone) and poly(dioxanone); poly(ethylene glycol),poly((hydroxypropyl)methacrylamide, poly [(organo)phosphazene],poly(ortho esters), poly(vinyl alcohol), poly(vinylpyrrolidone), maleicanhydride-alkyl vinyl ether copolymers, pluronic polyols, albumin,natural and synthetic polypeptides, alginate, cellulose and cellulosederivatives, collagen, fibrin, gelatin, hyaluronic acid,oligosaccharides, glycaminoglycans, sulfated polysaccharides, or anyconventional material that will encapsulate polypeptide crystals.

Preservatives, such as antimicrobial preservatives, are alsocontemplated for use in the formulations described herein. Suitablepreservatives include, but are not limited to, benzalkonium chloride,benzalkonium chloride solution, benzelthonium chloride, benzoic acid,benzyl alcohol, butylparaben, cetylpyridinium chloride, chlorobutanol,chlorocresol, cresol, dehydroacetic acid, ethylparaben, methylparaben,methylparaben sodium, phenol, phenylethyl alcohol, phenylmercuricacetate, phenylmercuric nitrate, potassium benzoate, potassium sorbate,propylparaben, propylparaben sodium, sodium benzoate, sodiumdehydroacetate, sodium propionate, sorbic acid, thimerosal, and thymol.The amount of preservative included will be in the range of 0% to 2%(w/v) or about 1% (w/v).

Solubilizing agents and stabilizers (also referred to as emulsifyingagents, co-solutes, or co-solvents) that increase the solubility of thepolypeptide and/or stabilize the polypeptide while in solution (or indried or frozen forms) can also be added to a pharmaceuticalcomposition. Examples of solubilizing and stabilizing agents include butare not limited to sugars/polyols such as: sucrose, lactose, glycerol,xylitol, sorbitol, mannitol, maltose, inositol, trehalose, glucose;polymers such as: serum albumin (bovine serum albumin (BSA), human SA(HSA), or recombinant HA), dextran, PVA, hydroxypropyl methylcellulose(HPMC), polyethyleneimine, gelatin, polyvinylpyrrolidone (PVP),hydroxyethylcellulose (HEC); non-aqueous solvents such as: polyhydricalcohols (e.g., PEG, ethylene glycol and glycerol), dimethylsulfoxide(DMSO), and dimethylformamide (DMF); amino acids such as: proline,L-methionine, L-serine, sodium glutamic acid, alanine, glycine, lysinehydrochloride, sarcosine, and gamma-aminobutyric acid; surfactants suchas: Tween-80, Tween-20, SDS, polysorbate, polyoxyethylene copolymer; andmiscellaneous stabilizing excipients such as: potassium phosphate,sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate,trimethylamine N-oxide, betaine, metal ions (e.g., zinc, copper,calcium, manganese, and magnesium), CHAPS, monolaurate,2-O-beta-mannoglycerate; or any of the following: acacia, cholesterol,diethanolamine (adjunct), glyceryl monostearate, lanolin alcohols,lecithin, mono- and di-glycerides, monoethanolamine (adjunct), oleicacid (adjunct), oleyl alcohol (stabilizer), poloxamer, polyoxyethylene50 stearate, polyoxyl 35 caster oil, polyoxyl 40 hydrogenated castoroil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate80, propylene glycol diacetate, propylene glycol monostearate, sodiumlauryl sulfate, sodium stearate, sorbitan monolaurate, sorbitanmonooleate, sorbitan monopalmitate, sorbitan monostearate, stearic acid,trolamine, emulsifying wax; wetting and/or solubilizing agents such asbenzalkonium chloride, benzethonium chloride, cetylpyridinium chloride,docusate sodium, nonoxynol 9, nonoxynol 10, octoxynol 9, polyoxyl 50stearate, tyloxapol; or any combination of the above. The concentrationof solubilizers/stabilizers in the formulation can be between about0.001% to 5% weight, or about 0.1% to 2% weight. In one embodiment, thestabilizer is selected from sorbitan mono-9-octadecenoatepoly(oxy-1,2-ethanediyl) derivatives, including but not limited to,polysorbate 80 or polysorbate 20. The amount of polysorbate 20 or 80 tobe used in this embodiment is in the range of 0.001% to 1.0% (w/v), suchas 0.005% (w/v), in single use or in multi-dose formulations. In anotherembodiment, free L-methionine in the range of 0.05 mM to 50 mM isincluded in the formulation: the amount of free L-methionine is 0.05 mMto 5 mM for single use formulations, and 1 mM to 10 mM for multi-doseformulations.

Tonicity modifiers can also be included in the formulations describedherein. Tonicity modifiers are understood to be molecules thatcontribute to the osmolality of a solution. The osmolality of apharmaceutical composition is preferably regulated in order to maximizethe active ingredient's stability and also to minimize discomfort to thepatient upon administration. Serum is approximately 300+/−50milliosmolals per kilogram. It is generally preferred that apharmaceutical composition be isotonic with serum, i.e., having the sameor similar osmolality, which is achieved by addition of a tonicitymodifier, thus it is contemplated that the osmolality will be from about180 to about 420 milliosmolals, however, it is to be understood that theosmolality can be either higher or lower as specific conditions require.Examples of tonicity modifiers suitable for modifying osmolalityinclude, but are not limited to amino acids (e.g., arginine, cysteine,histidine and glycine), salts (e.g., sodium chloride, potassium chlorideand sodium citrate) and/or saccharides (e.g., sucrose, glucose,dextrose, glycerin, and mannitol). The concentration of the tonicitymodifier in the formulation can be between about 1 mM to 1M, or about 10mM to about 200 mM. In one embodiment, the tonicity modifier is sodiumchloride within a concentration range of 0 mM to 200 mM. In anotherembodiment, the tonicity modifier is sorbitol or trehalose and no sodiumchloride is present.

In certain embodiments, the formulation comprises a compound selectedfrom the following, or any combination thereof: salts of 1) amino acidssuch as glycine, arginine, aspartic acid, glutamic acid, lysine,asparagine, glutamine, proline; 2) carbohydrates, e.g. monosaccharidessuch as glucose, fructose, galactose, mannose, arabinose, xylose,ribose; 3) disaccharides, such as lactose, trehalose, maltose, sucrose;4) polysaccharides, such as maltodextrins, dextrans, starch, glycogen;5) alditols, such as mannitol, xylitol, lactitol, sorbitol; 6)glucuronic acid, galacturonic acid; 7) cyclodextrins, such as methylcyclodextrin, hydroxypropyl-β-cyclodextrin; 8) inorganic salts, such assodium chloride, potassium chloride, magnesium chloride, phosphates ofsodium and potassium, boric acid ammonium carbonate and ammoniumphosphate; 9) organic salts, such as acetates, citrate, ascorbate,lactate; 10) emulsifying or solubilizing agents such as acacia,diethanolamine, glyceryl monostearate, lecithin, monoethanolamine, oleicacid, oleyl alcohol, poloxamer, polysorbates, sodium lauryl sulfate,stearic acid, sorbitan monolaurate, sorbitan monostearate, and othersorbitan derivatives, polyoxyl derivatives, wax, polyoxyethylenederivatives, sorbitan derivatives; 11) viscosity increasing reagentssuch as agar, alginic acid and its salts, guar gum, pectin, polyvinylalcohol, polyethylene oxide, cellulose and its derivatives propylenecarbonate, polyethylene glycol, hexylene glycol, tyloxapol; and 12)particular ingredients such as sucrose, trehalose, lactose, sorbitol,lactitol, inositol, salts of sodium and potassium such as acetate,phosphates, citrates, borate, glycine, arginine, polyethylene oxide,polyvinyl alcohol, polyethylene glycol, hexylene glycol, methoxypolyethylene glycol, gelatin, and hydroxypropyl-β-cyclodextrin.

E. Sustained-Release Forms

In some embodiments, sustained-release forms (also called“controlled-release” forms) of crystalline anti-sclerostin antibodiesare used, including sustained-release forms of crystalline antibodyAb-30, Ab-30R, Ab-30Rm, or Ab-31; sustained- or controlled-release formscomprising crystalline antibody Ab-30, Ab-30R, Ab-30Rm, or Ab-31 and asubstance for extending the physical release or biological availabilityof the crystalline antibody Ab-30, Ab-30R, Ab-30Rm, or Ab-31 over adesired period of time.

Sustained-release forms suitable for use in the disclosed methodsinclude, but are not limited to, crystalline antibody Ab-30, Ab-30R,Ab-30Rm, or Ab-31 that is encapsulated in a sustained-release materialsuch as a slowly-dissolving biocompatible polymer (for example, thepolymeric carriers described herein, the alginate microparticlesdescribed in U.S. Pat. No. 6,036,978, or the polyethylene-vinyl acetateand poly(lactic-glucolic acid) compositions described in U.S. Pat. No.6,083,534), admixed with such a polymer (including topically appliedhydrogels), and or encased in a biocompatible semi-permeable implant.Further embodiments of the invention include additionalsustained-release forms such as polymeric microparticles, wherein amixture of the active ingredient and sustained-release means such aspolymers (for example, PLGA) are dispersed within a continuous phase,and the resulting dispersion is directly lyophilized to remove water andorganic solvents or additives and form said microparticles (U.S. Pat.No. 6,020,004, incorporated herein by reference in its entirety);injectable gel compositions comprising a biodegradable anionicpolysaccharide such as an alginate ester, a polypeptide, and at leastone bound polyvalent metal ion (U.S. Pat. No. 6,432,449, incorporatedherein by reference in its entirety); injectable biodegradable polymericmatrices having reverse thermal gelation properties and optionallypH-responsive gelation/de-gelation properties (U.S. Pat. Nos. 6,541,033and 6,451,346, incorporated herein by reference in their entireties);biocompatible polyol:oil suspensions, such as those wherein thesuspension comprises polyol in the range of from about 15% to about 30%by weight (U.S. Pat. No. 6,245,740, incorporated by reference in itsentirety). Such sustained release forms are suitable for continuousdelivery of polypeptides through administration in the form of a depot,wherein the depot can be an implant, or can be in the form of injectablemicrospheres, nanospheres, or gels. The above listed U.S. patents (U.S.Pat. Nos. 6,036,978; 6,083,534; 6,020,004; 6,432,449; 6,541,033;6,451,346, and 6,245,740) are incorporated in their entirety byreference herein. In addition, sustained- or controlled-release forms ofcrystalline polypeptides of the invention comprise types of sustainedrelease materials such as those described in Kim, C., 2000, “ControlledRelease Dosage Form Design”, Techonomic Publishing Co., Lancaster Pa.,which include the following: natural polymers (gelatin, sodium alginicacid, xanthan gum, arabic gum, or chitosan), semi-synthetic polymers orcellulose derivatives (e.g., methylcellulose, ethylcellulose,hydroxyethylcellulose, hydroxypropylcellulose,hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, sodiumcarboxymethylcellulose, cellulose acetate, cellulose acetate butyrate,cellulose acetate proprionate, cellulose acetatephthalate, orhydroxypropylmethylcellulose phthalate), and synthetic polymers (e.g.,ion exchange resins (methacrylic acid, sulfonatedpolystyrene/divinylbenzene), polyacrylic acid (Carbopol), poly(MMA/MAA),poly(MMA/DEAMA), poly(MMA/EA), poly(vinylacetate phthalate), poly(vinylalcohol), poly(vinyl pyrrolidone), poly(lactic acid), poly(glycolicacid), poly(lactic/glycolic acid), polyethylene glycol, polyethyleneoxide, poly(dimethyl silicone), poly(hydroxyethyl methacrylate),poly(ethylene/vinyl acetate), poly(ethylene/vinyl alcohol),polybutadiene, poly(anhydride), poly(orthoester), and poly(glutamicacid)).

Further embodiments disclosed herein include Ab-30, Ab-30R, Ab-30Rm, orAb-31 crystals encapsulated in at least one polymeric carrier to formmicrospheres by virtue of encapsulation within the matrix of thepolymeric carrier to preserve their native and biologically activetertiary structure, as described in U.S. Pat. No. 6,541,606, which isincorporated in its entirety by reference herein. Ab-30, Ab-30R,Ab-30Rm, or Ab-31 crystals or formulations thereof are suspended in apolymeric carrier, such as PLGA, which is dissolved in an organicsolvent or additive. Such encapsulated Ab-30, Ab-30R, Ab-30Rm, or Ab-31crystals maintain the biological activity of antibody Ab-30, Ab-30R,Ab-30Rm, or Ab-31 for a longer period of time than antibody Ab-30,Ab-30R, Ab-30Rm, or Ab-31 in solution when stored under comparableconditions.

IV. Kits

As an additional aspect, described herein are kits which comprise one ormore formulations described herein packaged in a manner whichfacilitates their use for administration to subjects. In one embodiment,such a kit includes a formulation described herein (e.g., a compositioncomprising any of the antibodies described therein), packaged in acontainer such as a sealed bottle, vessel, single-use or multi-use vial,prefilled syringe, or prefilled injection device, optionally with alabel affixed to the container or included in the package that describesuse of the compound or composition in practicing the method. In oneaspect, the compound or composition is packaged in a unit dosage form.The kit may further include a device suitable for administering thecomposition according to a specific route of administration. Preferably,the kit contains a label that describes use of an antibody describedherein or formulation described herein.

V. Dosages

The dosage regimen involved in a method for treating a conditiondescribed herein will be determined by the attending physician,considering various factors which modify the action of drugs, e.g., theage, condition, body weight, sex and diet of the patient, the severityof any infection, time of administration and other clinical factors. Invarious aspects, the daily regimen is in the range of 0.1-50 mg of apreparation of antibody per kilogram of body weight (calculating themass of the protein alone, without chemical modification). In someembodiments, the dosage is about 0.5 mg/kg to 20 mg/kg, or about 0.5-10mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 4mg/kg, or about 1 mg/kg to about 5 mg/kg, or about 2 mg/kg to about 4mg/kg, or about 2 mg/kg to about 5 mg/kg. about 1 mg/kg to about 3mg/kg, about 1 mg/kg to about 5 mg/kg, about 2 mg/kg to about 6 mg/kg,or about 3 mg/kg to about 5 mg/kg, about 1 mg/kg to about 10 mg/kg,about 1 mg/kg to about 20 mg/kg, about 1 mg/kg to about 40 mg/kg, about5 mg/kg to about 30 mg/kg or about 5 mg/kg to about 20 mg/kg.

The formulations are generally administered parenterally, e.g.,intravenously, subcutaneously, intramuscularly, via aerosol(intrapulmonary or inhalational administration), or via depot forlong-term release. In some embodiments, the formulation is administeredintravenously by an initial bolus followed by a continuous infusion tomaintain therapeutic circulating levels of drug product. In otherembodiments, the formulation is administered as a one-time dose. Thoseof ordinary skill in the art will readily optimize effective dosages andadministration regimens as determined by good medical practice and theclinical condition of the individual patient. The frequency of dosingwill depend on the pharmacokinetic parameters of the agents and theroute of administration. The optimal pharmaceutical formulation will bedetermined by one skilled in the art depending upon the route ofadministration and desired dosage. See for example, Remington'sPharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton,Pa. 18042) pages 1435-1712, the disclosure of which is herebyincorporated by reference. Such formulations may influence the physicalstate, stability, rate of in vivo release, and rate of in vivo clearanceof the administered agents. Depending on the route of administration, asuitable dose may be calculated according to body weight, body surfacearea or organ size. Further refinement of the calculations necessary todetermine the appropriate dosage for treatment involving each of theabove mentioned formulations is routinely made by those of ordinaryskill in the art without undue experimentation, especially in light ofthe dosage information and assays disclosed herein, as well as thepharmacokinetic data observed in the human clinical trials discussedabove. Appropriate dosages may be ascertained through use of establishedassays for determining blood level dosages in conjunction withappropriate dose-response data.

As studies are conducted, further information will emerge regarding theappropriate dosage levels and duration of treatment for various diseasesand conditions.

VI. Therapeutic Uses of the Formulation

The formulations described herein are useful for treating or preventingbone-related disorders, such as bone-related disorders associated withabnormal osteoblast or osteoclast activity. In some embodiments, theformulation is administered to a subject suffering from a bone relateddisorder selected from the group consisting of achondroplasia,cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, Gaucher'sDisease, hypophosphatemic rickets, Marfan's syndrome, multiplehereditary exotoses, neurofibromatosis, osteogenesis imperfecta,osteopetrosis, osteopoikilosis, sclerotic lesions, pseudoarthrosis,pyogenic osteomyelitis, periodontal disease, anti-epileptic drug inducedbone loss, primary and secondary hyperparathyroidism, familialhyperparathyroidism syndromes, weightlessness induced bone loss,osteoporosis in men, postmenopausal bone loss, osteoarthritis, renalosteodystrophy, infiltrative disorders of bone, oral bone loss,osteonecrosis of the jaw, juvenile Paget's disease, melorheostosis,metabolic bone diseases, mastocytosis, sickle cell anemia/disease, organtransplant related bone loss, kidney transplant related bone loss,systemic lupus erythematosus, ankylosing spondylitis, epilepsy, juvenilearthritides, thalassemia, mucopolysaccharidoses, Fabry Disease, TurnerSyndrome, Down Syndrome, Klinefelter Syndrome, leprosy, Perthe'sDisease, adolescent idiopathic scoliosis, infantile onset multi-systeminflammatory disease, Winchester Syndrome, Menkes Disease, Wilson'sDisease, ischemic bone disease (such as Legg-Calve-Perthes disease andregional migratory osteoporosis), anemic states, conditions caused bysteroids, glucocorticoid-induced bone loss, heparin-induced bone loss,bone marrow disorders, scurvy, malnutrition, calcium deficiency,osteoporosis, osteopenia, alcoholism, chronic liver disease,postmenopausal state, chronic inflammatory conditions, rheumatoidarthritis, inflammatory bowel disease, ulcerative colitis, inflammatorycolitis, Crohn's disease, oligomenorrhea, amenorrhea, pregnancy,diabetes mellitus, hyperthyroidism, thyroid disorders, parathyroiddisorders, Cushing's disease, acromegaly, hypogonadism, immobilizationor disuse, reflex sympathetic dystrophy syndrome, regional osteoporosis,osteomalacia, bone loss associated with joint replacement, HIVassociated bone loss, bone loss associated with loss of growth hormone,bone loss associated with cystic fibrosis, chemotherapy-associated boneloss, tumor-induced bone loss, cancer-related bone loss, hormoneablative bone loss, multiple myeloma, drug-induced bone loss, anorexianervosa, disease-associated facial bone loss, disease-associated cranialbone loss, disease-associated bone loss of the jaw, disease-associatedbone loss of the skull, bone loss associated with aging, facial boneloss associated with aging, cranial bone loss associated with aging, jawbone loss associated with aging, skull bone loss associated with aging,and bone loss associated with space travel.

In some embodiments, the formulations described herein are useful forimproving outcomes in orthopedic procedures, dental procedures, implantsurgery, joint replacement, bone grafting, bone cosmetic surgery andbone repair such as fracture healing, nonunion healing, delayed unionhealing and facial reconstruction. One or more compositions may beadministered before, during and/or after the procedure, replacement,graft, surgery or repair.

The formulation need not cure the subject of the disorder or completelyprotect against the onset of a bone-related disorder to achieve abeneficial biological response. The formulation may be usedprophylactically, meaning to protect, in whole or in part, against abone-related disorder or symptom thereof. The formulation also may beused therapeutically to ameliorate, in whole or in part, a bone-relateddisorder or symptom thereof, or to protect, in whole or in part, againstfurther progression of a bone-related disorder or symptom thereof.Indeed, the materials and methods of the invention are particularlyuseful for increasing bone mineral density and maintaining the increasedbone mineral density over a period of time.

One or more administrations of a formulation described herein may becarried out over a therapeutic period of, for example, about 1 week toabout 18 months (e.g., about 1 month to about 12 months, about 1 monthto about 9 months or about 1 month to about 6 months or about 1 month toabout 3 months). In some embodiments, a subject is administered one ormore doses of a formulation described herein over a therapeutic periodof, for example about 1 month to about 12 months (e.g., about 2 months,about 3 months, about 4 months, about 5 months, about 6 months, about 7months, about 8 months, about 9 months, about 10 months, or about 11months). In some embodiments, a subject is administered one or moredoses of the formulation to maintain bone mineral density. The term“maintain bone mineral density” as used herein means that the increasedbone mineral density resulting from the initial dose of the formulationdoes not fall more than about 1% to about 5% over the course of about 6months, about 9 months about 1 year, about 18 months, about 2 years, orover the course of the patient's life). It will be appreciated that apatient can require alternate treatment phases for increasing bonedensity and maintaining bone density.

In addition, it may be advantageous to administer multiple doses of theformulation or space out the administration of doses, depending on thetherapeutic regimen selected for a particular subject. The formulationcan be administered periodically over a time period of one year or less(e.g., 9 months or less, 6 months or less, or 3 months or less). In thisregard, the formulation can be administered to the human once everyabout 3 days, or about 7 days, or 2 weeks, or 3 weeks, or 4 weeks, or 5weeks, or 6 weeks, or 7 weeks, or 8 weeks, or 9 weeks, or 10 weeks, or11 weeks, or 12 weeks, or 13 weeks, or 14 weeks, or 15 weeks, or 16weeks, or 17 weeks, or 18 weeks, or 19 weeks, or 20 weeks, or 21 weeks,or 22 weeks, or 23 weeks, or 6 months, or 12 months.

VII. Monitoring Therapy

Anti-sclerostin antibody-mediated increases in bone mineral content orbone density may be measured using single- and dual-energy X-rayabsorptometry, ultrasound, computed tomography, radiography, andmagnetic resonance imaging. The amount of bone mass may also becalculated from body weights or by using other methods (seeGuinness-Hey, Metab. Bone Dis. Relat. Res., 5:177-181 (1984)). Animalmodels are used in the art for testing the effect of the pharmaceuticalcompositions and methods on, for example, parameters of bone loss, boneresorption, bone formation, bone strength, or bone mineralization thatmimic conditions of human disease such as osteoporosis and osteopenia.Examples of such models include the ovariectomized rat model (Kalu, Boneand Mineral, 15:175-192 (1991); Frost and Jee, Bone and Mineral,18:227-236 (1992); and Jee and Yao, J. Musculoskel. Neuron. Interact.,1:193-207 (2001)). The methods for measuring anti-sclerostin antibodyactivity described herein also may be used to determine the efficacy ofother sclerostin inhibitors.

In humans, bone mineral density can be determined clinically using dualx-ray absorptiometry (DXA) of, for example, the hip and spine. Othertechniques include quantitative computed tomography (QCT),ultrasonography, single-energy x-ray absorptiometry (SXA), andradiographic absorptiometry. Common central skeletal sites formeasurement include the spine and hip; peripheral sites include theforearm, finger, wrist and heel. Except for ultrasonography, theAmerican Medical Association notes that BMD techniques typically involvethe use of x-rays and are based on the principle that attenuation of theradiation depends on thickness and composition of the tissues in theradiation path. All techniques involve the comparison of results to anormative database.

Alternatively, a physiological response to one or more sclerostinbinding agents can be gauged by monitoring bone marker levels. Bonemarkers are products created during the bone remodeling process and arereleased by bone, osteoblasts, and/or osteoclasts. Fluctuations in boneresorption and/or bone formation “marker” levels imply changes in boneremodeling/modeling. The International Osteoporosis Foundation (IOF)recommends using bone markers to monitor bone density therapies (see,e.g., Delmas et al., Osteoporos Int., Suppl. 6:S2-17 (2000),incorporated herein by reference). Markers indicative of bone resorption(or osteoclast activity) include, for example, C-telopeptide (e.g.,C-terminal telopeptide of type 1 collagen (CTX) or serum cross-linkedC-telopeptide), N-telopeptide (N-terminal telopeptide of type 1 collagen(NTX)), deoxypyridinoline (DPD), pyridinoline, urinary hydroxyproline,galactosyl hydroxylysine, and tartrate-resistant acid phosphatase (e.g.,serum tartrate-resistant acid phosphatase isoform 5b). Boneformation/mineralization markers include, but are not limited to,bone-specific alkaline phosphatase (BSAP), peptides released from N- andC-terminal extension of type I procollagen (P1NP, PICP), and osteocalcin(OstCa). Several kits are commercially-available to detect and quantifymarkers in clinical samples, such as urine and blood.

VIII. Combination Therapy

Treatment of a pathology by combining two or more agents that target thesame pathogen or biochemical pathway sometimes results in greaterefficacy and diminished side effects relative to the use of thetherapeutically relevant dose of each agent alone. In some cases, theefficacy of the drug combination is additive (the efficacy of thecombination is approximately equal to the sum of the effects of eachdrug alone), but in other cases the effect can be synergistic (theefficacy of the combination is greater than the sum of the effects ofeach drug given alone). As used herein, the term “combination therapy”means the two compounds can be delivered in a simultaneous manner, e.g.,concurrently, or wherein one of the compounds is administered first,followed by the second agent, e.g., sequentially. The desired result canbe either a subjective relief of one or more symptoms or an objectivelyidentifiable improvement in the recipient of the dosage.

In some embodiments, the formulation is administered along with astandard of care therapeutic for the treatment of decreased bone mineraldensity. As used herein, the term “standard of care” refers to atreatment that is generally accepted by clinicians for a certain type ofpatient diagnosed with a type of illness. In some embodiments, thestandard of care therapeutic is selected from the group consisting of ananti-resorptive drug, a bone-forming agent, an estrogen receptorantagonist (including, but not limited to, raloxifene, bazedoxifene andlasofoxifene) and a drug that has a stimulatory effect on osteoclasts.In some embodiments, the anti-resorptive drug includes, but is notlimited to, a bisphosphonate (including, but not limited to,alendronate, risedronate, ibandronate and zoledronate), an estrogen orestrogen analogue, a selective estrogen receptor modulator (SERM) and acalcium source, Tibolone, calcitonin, a calcitriol and hormonereplacement therapy. In some embodiments, the bone-forming agentincludes, but is not limited to parathyroid hormone (PTH) or a peptidefragment thereof, PTH-related protein (PTHrp), bone morphogeneticprotein, osteogenin, NaF, a PGE₂ agonist, a statin, an anti-DKKantibody, and a RANK ligand (RANKL). In some embodiments, the drughaving a stimulatory effect on osteoclasts includes, but it not limitedto, vitamin D, or a vitamin D derivative or mimic thereof.

In some embodiments, the formulation is administered to a subject whentreatment of a standard of care therapeutic described herein iscontraindicated.

EXAMPLES Example 1 Crystallization of Ab-30

Antibody Ab-30, consisting of two mature heavy chains (SEQ ID NO: 15)and two mature light chains (SEQ ID NO: 13) recombinantly produced byDNA encoding each of these chains, was crystallized under a variety ofconditions.

Crystallization of Ab-30 was achieved using a crystallization screen(Index Screen; Hampton Research, Aliso Viejo, Calif.), which employs amethod for crystallization of macromolecules known as “hanging drop”vapor diffusion. A drop composed of a mixture of the polypeptide sampleand the crystallization reagent (the “crystallization buffer” or the“mother liquor”) is deposited on the underside of a sialanizedcoverslip, and then the drop on the coverslip is sealed with grease andplaced over typically a 24 well VDX tray causing a vapor equilibriumwith a liquid reservoir of reagent. To achieve equilibrium, water vaporexchanges between the drop and a 1 ml reservoir solution in the well ofthe tray. As water leaves the drop, the polypeptide sample undergoes anincrease in relative concentration which may eventually lead tosupersaturation. It is the increased concentration of the polypeptidesample that is required for crystallization to take place. Typically thedrop contains a lower concentration of reagent than the reservoir, andtypically, the drop contained half the concentration of reagent in thereservoir, because equal volumes of sample and reagent were mixed toform the drop.

In these experiments, the initial polypeptide concentration in the dropwas usually 0.1-300 mg/mL or between 3-100 mg/mL.

The crystallization screen was set up in 24-well VDX polypropylenetissue culture trays. Each position in the VDX tray contained 1 mL ofreagent reservoir, with the reagent reservoir in each well differing incomposition from that in the other wells, to establish an array ofdiffering crystallization buffer conditions. 1-10 μL of polypeptidesolution at each polypeptide concentration was added to 1-10 μl ofreservoir solution to form the drops. Trays were incubated either at 4°C. or at ambient room temperature.

Crystallization Conditions:

Ab-30 crystallization was observed at both 4° C. and room temperatureusing a plurality of reagents (see Tables 1-8 below).

TABLE 1 Crystallization conditions producing Ab-30 crystals after oneday at room temperature. Crystallization Crystal screen Crystallizationconditions Morphology INDX #18 0.49M Sodium dihydrogen Phosphate, rods0.91M di-Potassium hydrogen Phosphate, pH 6.9 INDX #22 0.8M SuccinicAcid pH 7 rod clusters INDX #30 0.1M Sodium Chloride, 0.1M Bis-Tris pHrods 6.5, 1.5M Ammonium Sulfate INDX #31 0.8M Potassium Sodium Tartraterod clusters tetrahydrate, 0.1M Tris pH 8.5; 0.50% w/v PolyethyleneGlycol Monomethyl ether 5000 INDX #34 1M Succinic Acid pH 7.0, 0.1MHEPES rod clusters pH 7.0, 1% w/v Polyethylene INDX #35 1M AmmoniumSulfate, 0.1M HEPES pH rod clusters 7.0, 0.50% w/v Polyethylene Glycol8000 INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES rods, rod pH 7.0, 2%w/v Polyethylene Glycol 3350 clusters

TABLE 2 Crystallization conditions producing Ab-30 crystals after oneday at 4° C. Crystallization Crystal screen Crystallization conditionsMorphology INDX #12 0.1M Tris pH 8.5, 3M Sodium Chloride not recordedINDX #18 0.49M Sodium dihydrogen Phosphate, rods 0.91M di-Potassiumhydrogen Phosphate, pH 6.9 INDX #22 0.8M Succinic Acid pH 7 rod clustersINDX #31 0.8M Potassium Sodium Tartrate rod clusters tetrahydrate, 0.1MTris pH 8.5; 0.50% w/v Polyethylene Glycol Monomethyl ether 5000 INDX#35 1M Ammonium Sulfate, 0.1M HEPES pH rod clusters 7.0, 0.50% w/vPolyethylene Glycol 8000 INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESrods, rod pH 7.0, 2% w/v Polyethylene Glycol clusters 3350

TABLE 3 Crystallization conditions producing Ab-30 crystals after twodays at room temperature. Crystallization Crystal Screen Crystallizationconditions morphology SALT-RX#1 1.8M Sodium Acetate pH 7.0, 0.1M Seedsor Bis-Tris Propane, pH 7 small rods SALT-RX#19 0.7M tri-Sodium Citratedehydrate, 0.1M rod clusters Bis-Tris Propane pH 7 SALT-RX#20 0.7Mtri-Sodium Citrate dihydrate, 0.1M rods Tris pH 8.5 INDX#17 1.26M Sodiumdihydrogen Phosphate, rods 0.14M di-Potassium hydrogen Phosphate

TABLE 4 Crystallization conditions producing Ab-30 crystals after twodays at 4° c. Crystallization Crystal Screen Crystallization conditionsmorphology SALT-RX#1 1.8M Sodium Acetate pH 7.0, 0.1M rods Bis-TrisPropane, pH 7 SALT-RX#19 0.7M tri-Sodium Citrate dehydrate, 0.1M seedsBis-Tris Propane pH 7 SALT-RX#20 0.7M tri-Sodium Citrate dihydrate, 0.1Mrod clusters Tris pH 8.5

TABLE 5 Additional commercially available screen conditions producingAb-30 crystals at room temperature. Crystallization Crystal ScreenCrystallization conditions morphology SALT-RX#2 2.8M Sodium Acetate pH7.0, 0.1M Bis-Tris Propane not recorded pH 7.0 INDX #24 2.8M SodiumAcetate trihydrate pH 7.0 needles INDX #26 1.1M di-Ammonium Tartrate pH7.0 rod clusters INDX #28 35% v/v Tacsimate pH 7.0 chrysanthemums INDX#33 1.1M Sodium Malonate pH 7.0, 0.1M HEPES pH not recorded 7.0, 0.50%v/v Jeffamine ED-2001 Reagent pH 7.0 WIZ I #9 0.1M Acetate, pH 4.5, 1M(NH₄)₂HPO₄ Rods WIZ I #12 0.2M Ca(OAc)₂, 0.1M Imidazole pH 8, 20% w/vPEG- not recorded 1000 WIZ I #13 0.1M Cacodylate, pH 6.5, 1.26M(NH₄)₂SO₄ not recorded WIZ I #22 0.1M Tris pH 8.5, 10% v/v 2-propanolRods WIZ I #26 0.1M CHES pH 9.5, 10% w/v PEG-3000 Rods WIZ I #29 0.2MNaCl, 0.1M CHES pH 9.5, 10% w/v PEG-8000 not recorded WIZ I #30 0.2MNaCl, 0.1M Acetate pH 4.5, 1.26M (NH₄)₂SO₄ small crystals WIZ I #35 0.1MAcetate pH 4.5, 20% v/v 1,4-butanediol not recorded WIZ I #37 0.1MImidazole pH 8, 2.5M NaCl not recorded WIZ I #39 0.2M Li₂SO₄, 0.1MPhosphate-citrate pH 4.2, 20% not recorded w/v PEG-1000 WIZ I #42 0.1MTris pH 7.0, 15% v/v Ethanol needles WIZ I #46 0.2M Ca(OAc)₂, 0.1MImidazole pH 7.0, 10% w/v small crystals PEG-8000 WIZ II #10 0.1M TrispH 8.5, 1M (NH₄)₂HPO₄ Rods WIZ II #12 0.2M Li₂SO₄, 0.1M Cacodylate, pH6.5, 30% v/v PEG- small crystals 400 WIZ II #15 0.1M HEPES pH 7.5, 1.26M(NH₄)₂HPO₄ Rods WIZ II #21 0.1M Acetate pH 4.5, 35% v/v 2-methyl-2,4-small crystals pentanediol WIZ II #22 0.1M Imidazole pH 8.0, 10% v/v2-propanol Rods WIZ II #25 0.2M NaCl, 0.1M HEPES pH 7.5, 35% v/v2-methyl- small crystals 2,4-pentanediol WIZ II #26 0.1M CHES pH 9.5,30% v/v PEG-400 small crystals WIZ II #27 0.2M MgCl₂, 0.1M Cacodylate pH6.5, 10% w/v Rods PEG-3000 WIZ II #30 0.2M Zn(OAc)₂, 0.1M Imidazole pH8.0, 20% v/v small crystals 1,4-butanediol WIZ II #32 0.1M Tris pH 8.5,20% w/v PEG-1000 small crystals WIZ II #38 0.2M Li₂SO₄, 0.1M Acetate pH4.5, 2.5M NaCl small crystals WIZ II #42 0.2M NaCl, 0.1M HEPES pH 7.5,30% v/v PEG-400 rods WIZ III #22 0.1M Tris pH 8.5, 20% v/v Ethanolneedles WIZ III #25 10% w/v PEG 8000, 10% w/v PEG 1000 small crystalsWIZ III #28 0.1M HEPES, pH 7.5, 70% v/v MPD small crystals WIZ III #290.1M Tris pH 8.0, 40% v/v MPD small crystals WIZ III #35 0.16M CalciumAcetate, 0.08M Cacodylate pH 6.5, Rods 4.4% w/v PEG 8000, 20% v/vGlycerol WIZ III #38 2% v/v Dioxane, 0.1M Citrate pH 5.5, 15% w/v PEGsmall crystals 10,000 WIZ III #39 0.1M HEPES pH 7.5, 20% v/v JeffamineM-600 Rods WIZ III #40 0.1M Bicine, pH 9.0, 10% v/v MPD Rods WIZ III #410.2M Calcium Chloride, 0.1M HEPES pH 7.5, 28% small crystals v/v PEG 400WIZ III #42 0.2M Lithium Sulfate, 0.1M Tris pH 8.5, 30% w/v smallcrystals PEG 4000 WIZ III #46 0.2M Ammonium Phosphate (monobasic), 0.1MTris small crystals pH 8.5, 50% v/v MPD WIZ III #58 0.1M HEPES pH 7.5,20% w/v PEG 10,000 small crystals WIZ IV #13 0.8M Succinic Acid pH 7.0Rods WIZ IV #14 40% (v/v) PEG 400, 0.1M Tris base/Hydrochloric Rods acidpH 8.5, 0.2M Lithium sulfate WIZ IV #26 10% (w/v) PEG2000MME, 0.1MSodium Rods acetate/Acetic acid pH5.5, 0.2M Ammonium Sulfate WIZ IV #3120% (w/v) Polyacrylic acid 5100, 0.1M Rods HEPES/Sodium hydroxide pH7.0, 0.02M Magnesium Chloride WIZ IV #33 0.8M Potassium phosphate(dibasic), 0.1M Rods HEPES/Sodium hydroxide pH 7.5, 0.8M Sodiumphosphate CS-CRYO # 36 0.065 Tris Hydrochloride pH 8.5, 5.2% w/v RodsPolyethylene Glycol 8,000, 35% Glycerol CS-CRYO #46 0.16M CalciumAcetate Hydrate, 0.08M Sodium needles Cacodylate Trihydrate pH 6.5,14.4% w/v Polyethylene Glycol 8,000, 20% Glycerol PPT 33% #3 0.66MAmmonium Sulfate, 0.33% v/v MPD, 0.1M Rods HEPES pH 7.5 PPT 33% #4 0.66MAmmonium Sulfate, 1.65% v/v PEG 400, needles 0.05M Magnesium Sulfate,0.1M Tris base pH 8.5 PPT 33% #10 6.6% v/v Glycerol, 0.825M PotassiumPhosphate Rods Monobasic/Sodium Phosphate Dibasic pH 7.5 PPT 33% #131.65% v/v Isopropanol, 0.66M Ammonium Rods Citrate/Citric Acid pH 6.5PPT 33% #14 1.65% v/v PEG 400, 0.66M Ammonium Citrate/Citric Rods AcidpH 7.5 PPT 33% #17 0.561 Lithium Sulfate, 2.24% v/v MPD, 0.085M needlesImidazole pH 6.5 PPT 33% #18 0.66M Lithium Sulfate, 0.66% v/v PEG 400,0.1M small needles Tris base pH 8.5 PPT 33% #24 6.6% v/v PEG 400, 0.165Potassium Phosphate Rods Monobasic/Sodium Phosphate Dibasic pH 7.5 PPT33% #34 13.2% v/v Isopropanol, 4.65% w/v PEG 8000, 0.1M needlesImidazole pH 6.5 PPT 33% #35 6.6% v/v Isopropanol, 4.95% w/v PEG 3350,0.2M rods Ammonium Citrate/Citric Acid pH 7.5 PPT 33% #39 6.6% v/v PEG400, 4.95% w/v PEG 1000, 0.15M Rods Potassium Phosphate Monobasic/SodiumPhosphate Dibasic pH 6.5 PPT 33% #41 8.25% v/v PEG 400, 6/6% w/v PEG3350, 0.1M Rods Magnesium Chloride, 0.1M Tris base pH 8.5 PPT 33% #439.9% w/v PEG 1500, 3.3% v/v Isopropanol, 0.1M Rods Calcium Chloride,0.1M Imidazole pH 6.5 PPT 33% #45 9.9% w/v PEG 1500, 2.64% v/v MPD, 0.1MTris base Small pH 8.5 PPT 33% #46 8.25% w/v PEG 3350, 4.95% v/vIsopropanol, 0.2M Rods Ammonium Citrate/Citric Acid pH 4.5 PPT 33% #488.25% w/v PEG 3350, 4.95% v/v MPD, 0.2M Rods Lithium Sulfate, 0.1MImidazole pH 6.5 PPT 67% #4 1.34M Ammonium Sulfate, 3.35% v/v PEG 400,Rods 0.05M Magnesium Sulfate, 0.1M Tris base pH 8.5 PPT 67% #5 2.613MSodium Chloride, 1.34% v/v PEG 400, 0.1M Rods Magnesium Chloride, 0.1MAcetate pH 5.5 PPT 67% #9 1.34% v/v PEG 400, 1.34M Potassium PhosphateRods Monobasic/Sodium Phosphate Dibasic pH 6.5 PPT 67% #31 20.1% v/vMPD, 5.36% w/v PEG 8000, 0.5M Sodium Rods Chloride, 0.1M Tris base pH8.5 PPT 67% #35 13.4% v/v Isopropanol, 10.05% w/v PEG 3350, 0.2M RodsAmmonium Citrate/Citric Acid pH 7.5 PPT 67% #39 13.4% v/v PEG 400,10.05% w/v PEG 1000, 0.15M Rods Potassium Phosphate Monobasic/SodiumPhosphate Dibasic pH 6.5

TABLE 6 Additional commercially available screen conditions producingAb-30 crystals at 4° C. Crystallization Crystal Screen Crystallizationconditions morphology INDX #17 pH 5.6, 1.26M Sodium dihydrogenPhosphate, 0.14M not recorded di-Potassium hydrogen Phosphate INDX #261.1M di-Ammonium Tartrate pH 7.0 small crystals INDX #28 35% v/vTacsimate pH 7.0 small crystals INDX #33 1.1M Sodium Malonate pH 7.0,0.1M HEPES pH 7.0, small crystals 0.50% v/v Jeffamine ED-2001 Reagent pH7.0 WIZ I #2 0.2M NaCl, 0.1M HEPES, 10% v/v 2-propanol small crystalsWIZ I #9 0.1M Acetate pH 4.5, 1M (NH₄)₂HPO₄ Rods WIZ I #13 0.1MCacodylate pH 6.5, 1.26M (NH₄)₂SO₄ not recorded WIZ I #18 0.2M NaCl,0.1M Imidazole pH 8, 1M K/Na Tartrate small crystals WIZ I #22 0.1M TrispH 8.5, 10% v/v 2-propanol Rods WIZ I #25 0.2M MgCl₂, 0.1M Tris pH 8.5,30% v/v PEG-400 small crystals WIZ I #34 0.1M Imidazole pH 8, 1M(NH₄)₂HPO₄ small crystals WIZ I #35 0.1M Acetate pH 4.5, 20% v/v1,4-butanediol not recorded WIZ I #37 0.1M Imidazole pH 8, 2.5M NaCl notrecorded WIZ I #40 0.2M Ca(OAc)₂, 0.1M MES pH 6.0, 10% v/v 2- smallcrystals propanol WIZ I #42 0.1M Tris pH 7.0, 15% v/v Ethanol needlesWIZ I #43 0.1M Na/K phosphate pH 6.2, 35% v/v 2-methyl-2,4- not recordedpentanediol WIZ I #44 0.2M Ca(OAc)₂, 0.1M Acetate pH 4.5, 30% v/v PEG-not recorded 400 WIZ I #46 0.2M Ca(OAc)₂, 0.1M Imidazole pH 7.0, 10% w/vsmall crystals PEG-8000 WIZ II #5 0.2M NaCl, 0.1M HEPES pH 7.5, 20% v/v1,4- not recorded butanediol WIZ II #6 0.2M Li₂SO₄, 0.1MPhosphate-citrate pH 4.2, 10% v/v not recorded 2-propanol WIZ II #100.1M Tris pH 8.5, 1M (NH₄)₂HPO₄ small crystals WIZ II #13 0.2M Li₂SO₄,0.1M Citrate pH 5.5, 15% v/v Ethanol small crystals WIZ II #14 0.2MNaCl, 0.1M Na/K phosphate pH 6.2, 20% w/v Rods PEG-1000 WIZ II #17 0.2MMgCl₂, 0.1M Tris pH 7.0, 2.5M NaCl small crystals WIZ II #20 0.2MZn(OAc)₂, 0.1M MES pH 6.0, 15% v/v Ethanol small crystals WIZ II #210.1M Acetate pH 4.5, 35% v/v 2-methyl-2,4- small crystals pentanediolWIZ II #22 0.1M Imidazole pH 8.0, 10% v/v 2-propanol needles WIZ II #230.2M MgCl₂, 0.1M HEPES pH 7.5, 15% v/v Ethanol small crystals WIZ II #270.2M MgCl₂, 0.1M Cacodylate pH 6.5, 10% w/v PEG- Rods 3000 WIZ II #290.2M NaCl, 0.1M CHES pH 9.5, 1.26M (NH₄)₂SO₄ small crystals WIZ II #330.2M NaCl, 0.1M Citrate pH 5.5, 1M (NH₄)₂SO₄ small crystals WIZ II #360.2M NaCl, 0.1M Phosphate-citrate pH 4.2, 10% w/v small crystalsPEG-3000 WIZ II #45 0.1M MES pH 6.0, 1.26M (NH₄)₂SO₄ Rods WIZ II #460.2M NaCl, 0.1M Imidazole pH 8.0, 1M (NH₄)₂HPO₄ small crystals WIZ II#48 0.1M MES pH 6.0, 1M K/Na Tartrate small crystals WIZ III #8 0.2MPotassium nitrate, 20% w/v PEG 3350 Rods WIZ III #22 0.1M Tris pH 8.5,20% v/v Ethanol needles WIZ III #23 2% v/v Dioxane, 0.1M Bicine pH9.0,10% w/v PEG 20,000 small crystals WIZ III #24 0.1M Sodium Acetate pH4.6, 2M Ammonium Sulfate small crystals WIZ III #27 0.2M MagnesiumChloride, 0.1M HEPES pH 7.5, 30% v/v small crystals PEG 400 WIZ III #320.04M Potassium Phosphate (monobasic), 16% w/v small crystals PEG 8000,20% v/v Glycerol WIZ III #33 0.1M MES pH 6.5, 1.6M Magnesium Sulfatesmall crystals WIZ III #40 0.1M Bicine pH 9.0, 10% v/v MPD Rods Peg-Ion#1 0.2M Sodium Fluoride 20% w/v PEG 3,350 pH 7.3 small crystals Peg-Ion#2 0.2M Potassium Fluoride 20% w/v PEG 3,350 pH 7.3 small crystalsPeg-Ion #10 0.2M Sodium Iodide 20% w/v PEG 3,350 pH 7.0 small crystalsPeg-Ion #11 0.2M Potassium Iodide 20% w/v PEG 3,350 pH 7.0 smallcrystals Peg-Ion #12 0.2M Ammonium Iodide 20% w/v PEG 3,350 pH 6.2 smallcrystals Peg-Ion #13 0.2M Sodium Thiocyanate 20% w/v PEG 3,350 pH smallcrystals 6.9 Peg-Ion #14 0.2M Potassium Thiocyanate 20% w/v PEG 3,350 pHsmall crystals 7.0 Peg-Ion #21 0.2M Sodium Formate 20% w/v PEG 3,350 pH7.2 small crystals Peg-Ion #22 0.2M Potassium Formate 20% w/v PEG 3,350pH 7.3 small crystals Peg-Ion #23 0.2M Ammonium Formate 20% w/v PEG3,350 pH small crystals 6.6 CS-CRYO #36 0.065 Tris Hydrochloride pH 8.5,5.2% w/v Rods Polyethylene Glycol 8,000, 35% Glycerol

TABLE 7 Additional crystallization conditions producing Ab-30 crystalsat room temperature. Crystallization Crystal Screen Crystallizationconditions morphology GRAS #1 19.90% Isopropanol, 0.02M Na—K phosphatepH7.5 Small GRAS #2 45.39% Isopropanol Small GRAS #50 0.40M Na citrate,0.06M Tris-HCl pH 7.5, 2.36% needles, Glycerol rods, blocks GRAS #5346.10% Ethanol, 0.03M Na Acetate pH 4.5, 4.94% Small Glycerol GRAS #5443.29% Ethanol, 0.01% Tween-80 Small GRAS #58 49.65% Isopropanol, 0.06MTris-HCl pH 6.5 Small GRAS #65 33.74% Isopropanol, 0.06M Glutamic acidpH 6.5 Small GRAS #67 39.35% Isopropanol, 0.03M Na Acetate pH 4.5, Small0.01M EDTA GRAS #68 38.05% Isopropanol, 0.02M Na—K phosphate pH 7.5Small GRAS #70 1.60M Na acetate, 3.41% Ethanol needles GRAS #74 0.29M Nacitrate, 0.08M Na—K phosphate pH 7.5 needles, blocks GRAS #78 1.82M Naacetate needles GRAS #81 13.29% Ethanol, 0.01% Tween-80 Small GRAS #820.71M Na citrate, 0.01M Histidine pH 5.5, 6.29% Small Glycerol GRAS #832.04M Na acetate, 0.07M Tris-HCl pH 8.5 small needles GRAS #85 20.18%Isopropanol, 0.01M Histidine pH 5.5, small 0.09M Na—K phosphate needlesGRAS #88 12.78% Ethanol, 0.05M Na—K phosphate pH 5.5, small 0.01%Tween-80 needles GRAS #96 0.38M Na citrate, 0.03M Na acetate pH 6.5,0.01% needles, Tween-20 blocks

TABLE 8 Additional crystallization conditions producing Ab-30 crystalsat 4° C. Crystallization Screen Crystallization conditions GRAS #4 0.79MNa citrate, 0.01M Histidine pH 6.5 GRAS #5 39.39% Isopropanol, 0.8MTris-HCl pH 7.5 GRAS #10 1.9M Na acetate, 0.05M Na—K phosphate pH 7.5,7.07% Isopropanol GRAS #11 0.96M Na—K phosphate, 0.01M EDTA, 1.86%Glycerol GRAS #12 0.96M Na—K phosphate, 0.01M EDTA, 1.86% Glycerol GRAS#15 18.90% Ethanol, 0.02M EDTA GRAS #16 0.41M Na citrate, 0.10M Na—Kphosphate pH 7.5, 4.12% Glycerol GRAS #17 1.77M Na acetate, 6.00%Sucrose, 0.01% Tween-80 GRAS #18 1.97M Na acetate GRAS #22 2.31M Naacetate, 0.05M Na—K phosphate pH 7.5 GRAS #24 1.43M Na—K phosphate,0.03M Na citrate pH 4.5, 4.63% Glycerol GRAS #50 0.40M Na citrate, 0.06MTris-HCl pH 7.5, 2.36% Glycerol GRAS #54 43.29% Ethanol, 0.01% Tween-80GRAS #57 0.76M Na citrate, 0.01M Na citrate pH 4.5, 0.02M EDTA GRAS #601.77M Na—K phosphate GRAS #64 0.51M NaCl, 0.06M Na citrate pH 7.5 GRAS#66 12.13% Isopropanol, 9.21% Ethanol, 9.24% Glycerol GRAS #70 1.60M Naacetate, 3.41% Ethanol

TABLE 8 Additional crystallization conditions producing Ab-30 crystalsunder Index #36 and additives (salts) at room temperature.Crystallization Crystal Screen Crystallization conditions morphologyINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v rodsPolyethylene Glycol 3350, 10 mM Ammonium Acetate INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v rods Polyethylene Glycol3350, 10 mM Lithium Acetate Dihydrate INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v rods Polyethylene Glycol 3350, 10 mM MagnesiumAcetate Tetrahydrate INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v rods Polyethylene Glycol 3350, 10 mM Zinc Acetate INDX #3615% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v rods PolyethyleneGlycol 3350, 10 mM Magnesium Chloride INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v rods Polyethylene Glycol 3350, 10 mM ZincChloride INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vrods Polyethylene Glycol 3350, 10 mM magnesium formate INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v rods Polyethylene Glycol3350, 10 mM Magnesium nitrate INDX #36 15% v/v Tacsimate pH 7.0, 0.1MHEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 10 mM Magnesiumsulfate INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vrods Polyethylene Glycol 3350, 10 mM Zinc sulfate INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v rods Polyethylene Glycol3350, 10 mM Calcium acetate, 10 mM Zinc acetate

TABLE 9 Additional crystallization conditions producing Ab-30 crystalsusing Index #36 and additives (amino acids) at room temperature.Crystallization Crystal Screen Crystallization conditions morphologyINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 10 mM Arginine INDX #36 15% v/v Tacsimate pH7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 20 mMArginine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vRods Polyethylene Glycol 3350, 40 mM Arginine INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 80 mMArginine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vRods Polyethylene Glycol 3350, 100 mM Arginine INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 10 mM Cysteine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v Rods Polyethylene Glycol 3350, 20 mM Cysteine INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 40 mM Cysteine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v Rods Polyethylene Glycol 3350, 80 mM Cysteine INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 100 mM Cysteine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v Rods Polyethylene Glycol 3350, 10 mM Methionine INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 20 mM Methionine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v Rods Polyethylene Glycol 3350, 40 mM Methionine INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 80 mM Methionine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v Rods Polyethylene Glycol 3350, 100 mM Methionine INDX #3615% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods PolyethyleneGlycol 3350, 10 mM Proline INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 20 mM Proline INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 40 mM Proline INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v Rods Polyethylene Glycol 3350, 80 mM Proline INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 100 mM Proline

TABLE 10 Additional crystallization conditions producing AB-30 crystalsusing Index #36 and additives (cryoprotectants) at room temperature.Crystallization Crystal Screen Crystallization conditions morphologyINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 1% Ethylene Glycol INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 2%Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2%w/v Rods Polyethylene Glycol 3350, 3% Ethylene Glycol INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 4% Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 5% Ethylene Glycol INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 6% Ethylene Glycol INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 7%Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2%w/v Rods Polyethylene Glycol 3350, 8% Ethylene Glycol INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 9% Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 10% Ethylene Glycol INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 15% Ethylene Glycol INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 20%Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2%w/v Rods Polyethylene Glycol 3350, 25% Ethylene Glycol INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 30% Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 40% Ethylene Glycol INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 1% Glycerol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 2% GlycerolINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 3% Glycerol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 4% GlycerolINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 5% Glycerol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 6% GlycerolINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 7% Glycerol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 8% GlycerolINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 9% Glycerol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 10% GlycerolINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 1% Sucrose INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 2% Sucrose INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 3% Sucrose INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 4% Sucrose INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 5% Sucrose INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 6% Sucrose INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 7% Sucrose INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 8% Sucrose INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 9% Sucrose INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 10% SucroseINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 1% Trehalose INDX #36 15% v/v Tacsimate pH7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 2%Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vRods Polyethylene Glycol 3350, 3% Trehalose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 4%Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vRods Polyethylene Glycol 3350, 5% Trehalose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 6%Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vRods Polyethylene Glycol 3350, 7% Trehalose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 8%Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vRods Polyethylene Glycol 3350, 9% Trehalose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 10%Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vRods Polyethylene Glycol 3350, 15% Trehalose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 20%Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/vRods Polyethylene Glycol 3350, 1% Xylitol INDX #36 15% v/v Tacsimate pH7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 2% XylitolINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 3% Xylitol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 4% Xylitol INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 5% Xylitol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 6% Xylitol INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 7% Xylitol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 8% Xylitol INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 9% Xylitol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 10% XylitolINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 15% Xylitol INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 20% Xylitol

TABLE 11 Additional crystallization conditiond producing Ab-30 crystalsusing Index #36 and additives (varying percentages of Polysorbate 20) atroom temperature. Crystallization Crystal screen Crystallizationconditions morphology INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v Rods Polyethylene Glycol 3350, 0.05% Polysorbate 20 INDX #3615% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods PolyethyleneGlycol 3350, 0.10% Polysorbate 20 INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 0.15%Polysorbate 20 INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2%w/v Rods Polyethylene Glycol 3350, 0.20% Polysorbate 20 INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 0.25% Polysorbate 20 INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 0.30% Polysorbate 20 INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 0.35% Polysorbate 20 INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Rods Polyethylene Glycol3350, 0.40% Polysorbate 20 INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v Rods Polyethylene Glycol 3350, 0.45% Polysorbate 20 INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v RodsPolyethylene Glycol 3350, 0.50% Polysorbate 20

Various morphologies of Ab-30 crystals can be grown under scale-upconditions whereby the antibody in a liquid formulation is added to avolume of known crystallization reagent and stored in a sealedcontainer. Ab-30 crystals can be grown under these conditions in lessthan 24 hours, at room temperature or refrigerated temperatures (4° C.)and have been shown to produce slow release and high yield.

Ab-30 crystals produced under some of the conditions provided in Tables1-11 have been shown to withstand storage at 4° C. for a period ofgreater than 6 months and at room temperature (RT) for a period of 21months (Index#36 and different concentration of cryoprotectants), 22months (Index#36 and amino acids), 32 months (Index#36 and salts), and25 months (Index#36 with different percentages of Polysorbate 20).Exemplary crystallization conditions producing such Ab-30 crystals andthe length of storage time at 4° C. and room temperature are providedbelow in Tables 12 and 13, respectively.

TABLE 12 Length of storage Crystallization screen Crystallizationconditions time at 4° C. WIZ I #22 0.1M Tris pH 8.5, 10% v/v  9 months2-propanol WIZ I #9 0.1M Acetate pH 4.5, 1M  9 months (NH₄)₂HPO₄ WIZ I#42 0.1M Tris pH 7.0, 15% v/v 10 months Ethanol WIZ III #40 0.1M BicinepH 9.0, 10% v/v 10 months MPD

TABLE 13 Length of storage time at Crystallization room ScreenCrystallization conditions at room temperature temperature INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350 INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v21 months Polyethylene Glycol 3350, 3% Ethylene Glycol INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 4% Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1MHEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 5% EthyleneGlycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 9% Ethylene Glycol INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 15% Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1MHEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 25% EthyleneGlycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 30% Ethylene Glycol INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 35% Ethylene Glycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1MHEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 40% EthyleneGlycol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 1% Glycerol INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 2%Glycerol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 3% Glycerol INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 4%Glycerol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 5% Glycerol INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 6%Glycerol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 8% Glycerol INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 9%Glycerol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 10% Glycerol INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 1%Sucrose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 2% Sucrose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 3%Sucrose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 4% Sucrose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 5%Sucrose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 6% Sucrose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 7%Sucrose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21months Polyethylene Glycol 3350, 8% Sucrose INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350,10% Sucrose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v21 months Polyethylene Glycol 3350, 1% Trehalose INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 2% Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 3% Trehalose INDX #3615% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 monthsPolyethylene Glycol 3350, 4% Trehalose INDX #36 15% v/v Tacsimate pH7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 5%Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v21 months Polyethylene Glycol 3350, 6% Trehalose INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 7% Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 8% Trehalose INDX #3615% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 monthsPolyethylene Glycol 3350, 10% Trehalose INDX #36 15% v/v Tacsimate pH7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months Polyethylene Glycol 3350, 15%Trehalose INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v21 months Polyethylene Glycol 3350, 20% Trehalose INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 1% Xylitol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v 21 months Polyethylene Glycol 3350, 2% Xylitol INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 3% Xylitol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v 21 months Polyethylene Glycol 3350, 4% Xylitol INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 5% Xylitol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v 21 months Polyethylene Glycol 3350, 7% Xylitol INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 21 months PolyethyleneGlycol 3350, 9% Xylitol INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH7.0, 2% w/v 21 months Polyethylene Glycol 3350, 15% Xylitol INDX #36 15%v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 22 months PolyethyleneGlycol 3350, 20 mM Arginine INDX #36 15% v/v Tacsimate pH 7.0, 0.1MHEPES pH 7.0, 2% w/v 22 months Polyethylene Glycol 3350, 80 mM ArginineINDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 22 monthsPolyethylene Glycol 3350, 80 mM Cysteine INDX #36 15% v/v Tacsimate pH7.0, 0.1M HEPES pH 7.0, 2% w/v 22 months Polyethylene Glycol 3350, 100mM Cysteine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v22 months Polyethylene Glycol 3350, 10 mM Methionine INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 22 months PolyethyleneGlycol 3350, 40 mM Methionine INDX #36 15% v/v Tacsimate pH 7.0, 0.1MHEPES pH 7.0, 2% w/v 22 months Polyethylene Glycol 3350, 80 mMMethionine INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v22 months Polyethylene Glycol 3350, 100 mM Methionine INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 22 months PolyethyleneGlycol 3350, 10 mM Proline INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPESpH 7.0, 2% w/v 22 months Polyethylene Glycol 3350, 20 mM Proline INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 22 monthsPolyethylene Glycol 3350, 40 mM Proline INDX #36 15% v/v Tacsimate pH7.0, 0.1M HEPES pH 7.0, 2% w/v 22 months Polyethylene Glycol 3350, 80 mMProline INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 25months Polyethylene Glycol 3350, 0.05% Polysorbate 20 INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 25 months PolyethyleneGlycol 3350, 0.10% Polysorbate 20 INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v 25 months Polyethylene Glycol 3350, 0.15%Polysorbate 20 INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2%w/v 25 months Polyethylene Glycol 3350, 0.20% Polysorbate 20 INDX #3615% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 25 monthsPolyethylene Glycol 3350, 0.25% Polysorbate 20 INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 25 months PolyethyleneGlycol 3350, 0.30% Polysorbate 20 INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v 25 months Polyethylene Glycol 3350, 0.35%Polysorbate 20 INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2%w/v 25 months Polyethylene Glycol 3350, 0.40% Polysorbate 20 INDX #3615% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 25 monthsPolyethylene Glycol 3350, 0.45% Polysorbate 20 INDX #36 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 25 months PolyethyleneGlycol 3350, 0.50% Polysorbate 20 INDX # 36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v 26 months Polyethylene Glycol 3350 INDX #3615% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 31 monthsPolyethylene Glycol 3350, 10 mM Zinc acetate INDX #36 15% v/v TacsimatepH 7.0, 0.1M HEPES pH 7.0, 2% w/v 32 months Polyethylene Glycol 3350, 10mM Magnesium Acetate Tetrahydrate INDX #36 15% v/v Tacsimate pH 7.0,0.1M HEPES pH 7.0, 2% w/v 32 months Polyethylene Glycol 3350, 10 mMMagnesium nitrate INDX #36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0,2% w/v 32 months Polyethylene Glycol 3350, 10 mM Magnesium sulfate INDX#36 15% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 32 monthsPolyethylene Glycol 3350, 10 mM Zinc sulfate PEG Screen 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v 4 years and 3 Index #36Polyethylene Glycol 3350 months - The tray was set up at 4° C.originally and was stored at RT the last 6 months

The foregoing Example demonstrates that Ab-30 was crystallizable under avariety of crystallization conditions, but crystals did not form underevery condition tested. Approximately 2000 crystallization conditionswere tested in a number of different commercially-available (i.e.,Hampton Research, Emerald Bioscience) and proprietary screens, but onlyapproximately 775 conditions produced Ab-30 crystals.

Example 2 Batch Crystallization of Ab-30

50 μL of Ab-30 at 75.7 mg/mL was mixed with 50 μL of crystallizationconditions (GRAS Screen, Index Screen, Wizard I Screen, Wizard II Screenand Wizard III Screen) to make a total of 100 μL batch volume in a 1.5mL micro-centrifuge tube. 40 μL of Ab-30 (75.7 mg/mL) was mixed with 20μL of Low Iconic Strength Screen buffers and with 50 μL of 4% PEG-3350to make a total 110 μL batch volume. The crystallization conditions usedwere as described below in Table 14.

TABLE 14 Crystallization screen Crystallization conditions % EfficiencyMorphology GRAS 1 Isopropanol, 19.9%, Na—K-Phosphate, 0.02M, 85.783Ellipsoids pH 7.5 GRAS 2 Isopropanol, 45.39% N/A N/A GRAS 50 Na-Citrate,0.40M, TRIS-HCL, 0.06M, pH 70.012 Ellipsoids 7.5, Glycerol, 2.36% GRAS53 Ethanol, 46.10%, Glutamic acid, 0.03M, N/A N/A pH 4.5, Glycerol 4.94%GRAS 54 Ethanol, 43.29%, Tween-80, 0.01% N/A N/A GRAS 58 Isopropanol,49.65%, TRIS-HCL, 0.06M, pH N/A N/A 6.5 GRAS 65 Isopropanol, 33.74%,Glutamic acid, 0.06M, N/A N/A pH 6.5 GRAS 67 Isopropanol, 39.35%,Glutamic acid, 0.03M, N/A N/A pH 4.5, EDTA, 0.01M GRAS 68 Isopropanol,38.05%, Na—K-Phosphoate, 77.647 Ellipsoids 0.02M, pH 7.5 GRAS 70Na-Acetate, 1.60M, Ethanol, 3.41% 69.462 Ellipsoids GRAS 74 Na-Citrate,0.29M, Na—K-Phosphate, 0.08M, 73.229 Ellipsoids pH 7.5 GRAS 78Na-Acetate, 1.82M 73.561 Ellipsoids GRAS 81 Ethanol, 13.29%, Tween-80,0.01% N/A N/A GRAS 82 Na-Citrate, 0.71M, Histidine, 0.01M, pH 5.5,82.633 Ellipsoids Glycerol, 6.29% GRAS 83 Na-Acetate, 2.04M, TRIS-HCL,0.07M, pH 67.999 Ellipsoids 8.5 GRAS 85 Isopropanol, 20.18%, Histidine,0.01M, pH N/A N/A 5.5, Ka-K-Phosphate, 0.09M GRAS 88 Ethanol, 12.78%,Na—K-Phosphate, 0.05M, 72.536 Ellipsoids Tween-80, 0.01% GRAS 96Na-Ctrate, 0.38M, Na-Acetate, 0.03M, pH 75.029 Ellipsoids 6.5, Tween-20,0.01% INDX #17 1.4 Sodium phosphate monobasic 53.209 Rodsmonohydrate/potassium phosphate dibasic, pH 5.6 INDX#18 1.4 Sodiumphosphate monobasic 79.667 Rods monohydrate/potassium phosphate dibasic,pH 6.9 INDX#22 0.8M Succinic Acid, pH 7.0 82.371 Rods INDX#24 2.8 Sodiumacetate trihydrate, pH 7.0 76.762 Rods INDX#26 1.1M Ammonium tartratedibasic, pH 7.0 N/A N/A INDX#28 35% v/v Tacsimate, pH 7.0 83.178 RodsINDX#30 0.1M Sodium chloride, 0.1M BIS-TRIS, pH 70.106 Rods 6.5, 1.5MAmmonium sulfate INDX#31 0.8M Potassium sodium tartrate tetrahydrate,79.394 Rods 0.1M Tris, pH 8.5, 0.5% w/v polyethylene glycol monomethylether 5,000 INDX#33 1.1M Sodium malonare, pH 7.0, 0.1M 85.613 RodsHEPES, pH 7.0, 0.5% v/v Jeffamine ED- 2001, pH 7.0 INDX#34 1.0 Succinicacid, pH 7.0, 0.1M HEPES, pH 87.384 Rods 7.0, 1% w/v polyethylene glycolmonomethyl ether 2,000 INDX#35 1.0M Ammonium sulfate, 0.1M HEPES, pH51.844 Rods 7.0, 0.5% w/v/PEG-8000 INDX#36 15% v/v Tacsimate pH 7.0,0.1M HEPES, pH 76.235 Rods 7.0, 2% w/v PEG-3350 INDX#36-1 15% v/vTacsimate pH 7.0, 0.1M HEPES, pH 52.485 Ellipsoids 7.0, 2% w/v PEG-3350INDX#36-2 15% v/v Tacsimate pH 7.0, 0.1M HEPES, pH 70.246 Tiny 7.0, 2%w/v PEG-3350, 10 mM ammonium crystals acetate INDX#36-3 15% v/vTacsimate pH 7.0, 0.1M HEPES, pH 66.129 Ellipsoids 7.0, 2% w/v PEG-3350,10 mM lithium (small) acetate dehydrate INDX#36-4 15% v/v Tacsimate pH7.0, 0.1M HEPES, pH 57.306 Ellipsoids 7.0, 2% w/v PEG-3350, 10 mMmagnesium acetate tetrahydrate INDX#36-5 15% v/v Tacsimate pH 7.0, 0.1MHEPES, pH 50.297 Ellipsoids 7.0, 2% w/v PEG-3350, 10 mM zince acetateINDX#36-6 15% v/v Tacsimate pH 7.0, 0.1M HEPES, pH 51.951 Ellipsoids7.0, 2% w/v PEG-3350, 10 mM magnesium chloride INDX#36-7 15% v/vTacsimate pH 7.0, 0.1M HEPES, pH 48.838 Ellipsoids 7.0, 2% w/v PEG-3350,10 mM zinc chloride INDX#36-8 15% v/v Tacsimate pH 7.0, 0.1M HEPES, pH62.074 Ellipsoids 7.0, 2% w/v PEG-3350, 10 mM magnesium (small) formateINDX#36-9 15% v/v Tacsimate pH 7.0, 0.1M HEPES, pH 49.246 Ellipsoids7.0, 2% w/v PEG-3350, 10 mM magnesium nitrate INDX#36-10 15% v/vTacsimate pH 7.0, 0.1M HEPES, pH 70.490 Tiny 7.0, 2% w/v PEG-3350, 10 mMmagnesium crystals sulfate INDX#36-11 15% v/v Tacsimate pH 7.0, 0.1MHEPES, pH 54.408 Ellipsoids 7.0, 2% w/v PEG-3350, 10 mM zinc sulfateINDX#36-12 15% v/v Tacsimate pH 7.0, 0.1M HEPES, pH 64.613 Ellisoid 7.0,2% w/v PEG-3350, 10 mM calcium acetate and zinc acetate WIZ I #2 10% v/v2-propanol, 0.1M HEPES, pH 7.5, N/A N/A 0.2M NaCl WIZ I #9 1.0M ammoniumphosphate dibasic, 0.1M 48.48  Ellipsoids acetate, pH 4.5 WIZ I #12 20%w/v PEG-1000, 0.1M imidazole, pH 8.0, 47.87  Ellipsoids 0.2M calciumacetate WIZ I #13 1.26M ammonium sulfate, 0.1M cacodylate, N/A N/A pH6.5 WIZ I #18 1.0M K—Na tartrate, 0.1M imidazole, pH 8.0, 62.14 Ellipsoids 0.2M NaCl WIZ I #22 10% v/v 2-propanol, 0.1M Tris, pH 8.5 N/ARods WIZ I #26 10% w/v PEG-3000, 0.1M CHES, pH 9.5 48.04  Rods WIZ I #2910% w/v PEG-8000, 0.1M CHES, pH 9.5, 87.73  Ellipsoids 0.2M NaCl WIZ I#30 1.26M Ammonium sulfate, 0.1M acetate, pH N/A N/A 4.5, 0.2M NaCl WIZI #35 20% v/v 1,4-butanediol, 0.1M acetate, pH 4.5 N/A N/A WIZ I #372.5M NaCl, 0.1M imidazole, pH 8.0 N/A N/A WIZ I #39 20% w/v PEG-1000,0.1M phosphate-citrate, N/A N/A pH 4.2, 0.2M lithium sulfate WIZ I #4215% v/v ethanol, 0.1M Tris, pH 7.0 N/A N/A WIZ I #46 10% w/v PEG-8000,0.1M imidazole, pH 8.0, 91.46  Ellipsoids 0.2M calcium acetate WIZ II#10 1.0M ammonium phosphate dibasic, 0.1M 49.026 Ellipsoids Tris, pH 8.5WIZ II #12 30% v/v PEG-400, cacodylate, pH 6.5, 0.2M 59.491 Ellipsoidslithium sulfate WIZ II #13 15% v/v ethanol, 0.1M citrate, pH 5.5, 0.2MN/A N/A lithium sulfate WIZ II #14 20% w/v PEG-1000, 0.1M Na/Kphosphate, 90.258 Ellipsoids pH 6.2, 0.2M NaCl WIZ II #15 1.26M ammosiumsulfate, 0.1M HEPES, pH 7.5 64.775 Ellipsoids WIZ II #21 35% v/v2-methyl-2,4-pentanediol, 0.1M N/A N/A acetate, pH 4.5 WIZ II #22 10%v/v 2-proponol, 0.1M imidazole, pH 8.0 80.572 Ellipsoids WIZ II #25 35%v/v 2-methyl-2,4-pentanediol, 0.1M N/A N/A HEPES, pH 7.5, 0.2M NaCl WIZII #26 30% v/v PEG-400, 0.1M CHES, pH 9.5 N/A N/A WIZ II #27 10% w/vPEG-3000, 0.1M cacodylate, pH 54.811 Ellipsoids 6.5, 0.2M magnesiumchloride WIZ II #30 20% v/v 1,4-butanediol, 0.1M imidazole, pH N/A N/A8.0, 0.2M zinc acetate WIZ II #32 20% w/v PEG-1000, 0.1M Tris, pH 8.5N/A N/A WIZ II #37 1.0M K/Na tartrate, 0.1M Tris, pH 7.0, 0.2M 74.353Ellipsoids lithium sulfate WIZ II #38 2.5M NaCl, 0.1M acetate, pH 4.5,0.2M N/A N/A lithium sulfate WIZ II #42 30% v/v PEG-400, 0.1M HEPES, pH7.5, 82.982 Ellipsoids 0.2M NaCl WIZ II #43 10% w/v PEG-8000, 0.1M Tris.pH 7.0, 0.2M 91.443 Ellipsoids magnesium chloride WIZ III #13 8% w/vPEG-4000, 0.1M sodium acetate, pH N/A N/A 4.65 WIZ III #22 20% v/vethanol, 0.1M Tris, pH 8.5 51.597 Rods WIZ III #25 10% w/v PEG-100, 10%w/v PEG-8000 N/A N/A WIZ III #28 70% v/v MPD, 0.1M HEPES, pH 7.5 N/A N/AWIZ III #29 40% v/v MPD, 0.1M Tris, pH 8.0 N/A N/A WIZ III #35 14.4% w/vPEG-8000, 0.8M cacodylate, pH 92.195 Ellipsoids 6.5, 0.16M calciumacetate, 20% v/v glycerol WIZ III #36 30% v/v Jeffamine M-600*, pH 7.0,0.1M N/A N/A MES, pH 6.5, 0.05 cesium chloride WIZ III #38 15% w/vPEG-10,000, 0.1M citrate, pH 5.5, N/A N/A 2% v/v dioxane WIZ III #39 20%v/v Jeffamine M600* pH 7.0, 0.1M N/A N/A HEPES, pH 7.5 WIZ III #40 10%v/v MPD, 0.1M Bicine, pH 9.0 N/A N/A WIZ III #41 28% w/v PEG-400, 0.1MHEPES, pH 7.5, N/A N/A 0.2M Calcium chloride WIZ III #42 30% w/vPEG-4000, 0.1M Tris, pH 8.5, 0.2M N/A N/A lithium sulfate WIZ III #4650% v/v MPD, 0.1M Tris, pH 8.5, 0.2M N/A N/A ammonium chloride WIZ III#48 20% w/v PEG-10,000, 0.1M HEPES, pH 7.5 N/A N/A LISS #1 0.5MPotassium Chloride, 4% PEG-3350, pH 2 N/A N/A LISS #2 0.05M citric acid,4% PEG-3350, pH 3 N/A N/A LISS #3 0.05M citric acid, 4% PEG-3350, pH 3.5N/A N/A LISS #4 0.05M citric acid, 4% PEG-3350, pH 4 N/A N/A LISS #50.05M citric acid, 4% PEG-3350, pH 4.5 N/A N/A LISS #6 0.05M citricacid, 4% PEG-3350, pH 5 87.632 Ellipsoids LISS #7 0.05M citric acid, 4%PEG-3350, pH 5.5 88.526 Rods LISS #8 0.05M MES, 4% PEG-3350, pH 6 N/AN/A LISS #9 0.05M Bis Tris, 4% PEG-3350, pH 6.5 N/A N/A LISS #10 0.05MImidazole, 4% PEG-3350, pH 7 78.786 Ellipsoids LISS #11 0.05M HEPES, 4%PEG-3350, pH 7.5 N/A Heavy precipitation LISS #12 0.05M Tris, 4%PEG-3350, pH 8 N/A Heavy precipitation LISS #13 0.05M Tris, 4% PEG-3350,pH 8.5 N/A Heavy precipitation LISS #14 0.05M Glycine, 4% PEG-3350, pH 9N/A N/A LISS #15 0.05M Glycine, 4% PEG-3350, pH 9.5 N/A Mediumprecipitation LISS #16 0.05M Glycine, 4% PEG-3350, pH 10 N/A Heavyprecipitation LISS #17 0.05M sodium phosphate dibasic, 4% PEG- N/A Heavy3350, pH 11 precipitation LISS #18 0.05M sodium phosphate dibasic, 4%PEG- N/A Rods 3350, pH 11

Ab-30 was batch crystallized in a total of 104 conditions representing apercentage yield range of 40%-92% at room temperature (see Table 14).All of these conditions had crystal hits at room temperature by hangingdrop vapor diffusion but not all of them crystallized in the batch form.Out of the 104 batch crystallized conditions there were only 8conditions with percentage yield greater than 85% on day one at roomtemperature (i.e., INDX #34, WIZ I #46, WIZ II #43, WIZ II #14, WIZ III#35 and GRAS 1). The highest yield achieved for Ab-30 crystals was92.195% for WIZ #35 on day one. Crystal yield changed based on crystalgrowth conditions. Ab-30 crystallized both at room temperature and at 4°C. but only the room temperature crystal hits were considered based onefficiency of crystallization at room temperature.

Example 3 Batch Crystallization of Ab-30, Suspension and DissolutionStudies

200 μl of Ab-30 (75.7 mg/ml) was mixed with 200 μl of crystallizationcondition (as described below in Table 15) in a 1.5 ml microcentrifugetube at room temperature. The tube was vortexed after addition of thecrystallization condition and was visually checked for clarity,opalescence or precipitate formation. A picture was taken of eachmicrocentrifuge tube for each crystallization condition tested at day 0and day 1 with Zeiss microscope equipped with Axiocam software. Themorphology of the crystals produced under each crystallization conditionwas recorded. Crystals were harvested at day 3 for all three dissolutionrate studies irrespective of time it took to reach highest percent yieldfor individual condition except for study 4 (crystal dissolution basedon crystal packing where the crystals were harvested on day 8).

Crystals were spun down at 10,000 rpm for 15 minutes and supernatant wasremoved and the crystals were resuspended in different vehicles (asdescribed below in Table 15). The microcentrifuge tubes were stored atroom temperature during the course of the experiment. Percentage yieldwas measured using UV spec as A280 nm. The microcentrifuge tubes werespun down on a bench top centrifuge at 10,000 rpm for 15 minutes. A1:100 dilution was performed in water and the A280 was read on a UVspec.

TABLE 15 Study Crystallization No. conditions Suspension VehicleMorphology 1 INDX #36 Water Ellipsoids INDX # 36 10 mM Acetate, 9%Ellipsoids sucrose and 0.004% PS20, pH 5.2 INDX #36 Saline EllipsoidsINDX #36 Dextrose Ellipsoids INDX #36 PBS Ellipsoids 2 INDX #36 0.05MHEPES, pH Ellipsoids 7.5, 20% PEG-350 INDX #36 0.05M HEPES, pHEllipsoids 8.0, 20% PEG-350 INDX #36 0.05M HEPES, pH Ellipsoids 8.5, 20%PEG-350 INDX #36 10 mM Glutamate, 5% Ellipsoids sorbitol, pH 4.8 INDX#36 10 mM Glutamate, 5% Ellipsoids sorbitol, pH 5.0 3 WIZ III #35 PBSEllipsoids GRAS #88 PBS Rods WIZ I #26 PBS Rods Peg Ion #1 PBSPrecipitation GRAS #1 PBS Ellipsoids (tiny) GRAS #82 PBS Ellipsoids(tiny) GRAS #83 PBS Ellipsoids (tiny) 4 INDX #36-1 PBS Ellipsoids INDX#36-2 PBS Ellipsoids INDX #36 + 10 mM PBS Ellipsoids calcium acetateINDX #36-3 PBS Ellipsoids INDX #36-4 PBS Ellipsoids INDX #36-5 PBSEllipsoids INDX #36-12 PBS Ellipsoids INDX #36-6 PBS Ellipsoids INDX#36-7 PBS Ellipsoids INDX #36-8 PBS Ellipsoids INDX #36-9 PBS EllipsoidsINDX #36-10 PBS Ellipsoids INDX #36-11 PBS Ellipsoids 5 WIZ III #35*Dextrose Ellipsoids GRAS #88* Dextrose Rods WIZ I #26* Dextrose RodsGRAS #1* Dextrose Ellipsoids (tiny) GRAS #82* Dextrose Ellipsoids (tiny)GRAS #83* Dextrose Ellipsoids (tiny) WIZ III #35** Dextrose EllipsoidsGRAS #88** Dextrose Rods WIZ I #26** Dextrose Rods GRAS #1** DextroseEllipsoids (tiny) GRAS #82** Dextrose Ellipsoids (tiny) GRAS #83**Dextrose Ellipsoids (tiny)

Crystal Dissolution and Suspension Vehicles:

Dissolution rate experiments for Studies 1-4 were performed at roomtemperature. Dissolution rate experiments for Study 5 samples markedwith an asterisk (*) were stored at 4° C. and Study 5 samples markedwith a double asterisk (**) were stored at 37° C. In study #1 and #2 thecrystal growth condition was kept constant, which was Hampton ResearchIndex Screen #36, and the crystals were resuspended in differentvehicles to monitor crystal dissolution rates. Index #36 was chosen as agrowth condition since it forms crystals very readily. In study #3 thecrystal growth conditions and morphology were variable but the crystalsuspension vehicle, PBS, was consistent for all conditions.

A52SuT (10 mM Acetate, 9% Sucrose, 0.004% Polysorbate20, pH5.2), salineand PBS showed the most difference in dissolution rates. Water andDextrose did not show much dissolution activity after 42 days whencompared to T=0. Hence, water and dextrose are ideal vehicles to washthe Ab-30 crystals without losing much of the crystals during the washstep. The Low Ionic Strength Screen buffers 0.05M HEPES pH7.5 20%PEG-3350, 0.05M Tris pH8.0 20% PEG-3350, 0.05M Tris pH8.5 20% PEG-3350showed extremely slow dissolution rates practically close to baselineover the course of a month. One possibility for the slow dissolution ofthe crystals in these buffers might be due to crystal coating by 20%PEG-3350. 10 mM Glutamate, 5% Sorbitol at pH4.8 and 10 mM Glutamate, 5%Sorbitol at pH 5.0 showed dissolution rates at about 1 mg/ml similar towater and dextrose dissolution rates in study #1. A52SuT, saline,dextrose, PBS and 10 mM Glutamate buffers are isotonic and injectable(See FIGS. 3 and 4).

Crystal Dissolution and Crystal Morphology:

In study #3 the crystal growth conditions and the morphology weredifferent while the suspension vehicle PBS was same for all conditions.A total of four different morphologies were considered: ellipsoids,rods, precipitation and tiny ellipsoids. The mg/ml crystal dissolutionwas different based on the crystal morphology but overall all themorphologies followed a similar dissolution pattern with peakdissolution at Day 12. Based on the dissolution profiles obtained it canbe concluded the crystal dissolution depends on the crystal morphology,crystal size, crystal growth condition and even crystal packing.

Crystal Dissolution and Crystal Packing:

In study #4 the crystal growth conditions were different while thecrystal morphology and suspension vehicle (PBS) were consistent in allthe conditions. Ab-30 was grown in Index36 along with differentadditives (10 mM salts). The data for this study suggests that thedifferent cations and anions in the additives have an impact on thecrystal packing (FIGS. 5A-5F). Out of all the additives, Zinc saltsshowed the least dissolution suggesting that Zinc can be added for asustained release effect. Zinc chloride showed the least dissolutioncompared to other Zinc salts while Magnesium nitrate showed the leastdissolution among Magnesium salts.

Crystal Dissolution Based on Temperature and Crystal Morphology:

In study #5 the crystal growth conditions, crystal morphology, crystalstorage temperature were different but the suspension vehicle dextrosewas kept the same for all the conditions. The crystals were resuspendedin dextrose, stored at 4° C. and 37° C. and dissolution rates weremonitored for 9 days. The crystal dissolution rates were mostly notdependent on temperature (except WIZ III #35) wherein the dissolutionrate was higher at 37° C. vs. 4° C.) or morphology as expected. Insteadthe dissolution rates were related to crystal growth conditions. Thetrend for dissolution rates was similar irrespective of the temperaturefor a particular crystal growth condition (FIGS. 6A and 6B). This maynot be the case for all the Ab-30 crystals grown in different conditionsand resuspended in the same or different suspension vehicles atdifferent temperatures.

In summary, crystal dissolution depends upon more than one factor namelythe crystal growth solution and its components, crystal shape, size,length, crystal morphology, crystal suspension vehicle, temperatureand/or crystal packing. One or more of the above mentioned factors canbe changed in various combinations for formulating different kinds(liquid, solid or slurries) of formulation.

Example 4 Assaying Protein Content of Ab-30 Crystals

Salts are often present in the sample or countersolvent, and these saltsmay form crystals during crystallization attempts. One popular method ofdistinguishing the growth of salt crystals from the target crystals ofinterest is through exposure to a staining dye such as IZITT™,manufactured by Hampton Research of Laguna Niguel, Calif. The IZITT™ dyestains protein crystals blue, but does not stain salt crystals.

Ab-30 crystals produced under crystallization conditions of 15% v/vTacsimate pH 7.0, 0.1M HEPES pH 7.0, 2% w/v Polyethylene Glycol 8000were confirmed to be protein crystals by staining (IZITT™ dye; HamptonResearch) and were recorded as crystallization hits.

Example 5 Crystalline Anti-Sclerostin Antibody Formulation

This Example illustrates a formulation of anti-sclerostin antibodycrystals comprising a high concentration of protein with a potential forslow release, using an anti-sclerostin antibody comprising the Ab-30Rmheavy and light chains set forth in SEQ ID NOS: 19 and 21, respectively.

Briefly, a total of 108 crystallization conditions were screened forAb-30Rm using the Low Ionic Strength Screen (Harris et al, (1995)Crystallization of intact monoclonal antibodies, Proteins: Structure,Function and Genetics 23, 285-289; Hampton Research, Aliso Viejo,Calif.). Two conditions were narrowed down for a formulation based onpH, osmolality, injectable ingredients and percent crystallizationefficiency. A formulation for Ab-30Rm crystals suitable for subcutaneousinjection in animal study was successfully produced.

Materials and Methods

Hanging Drop Vapor Diffusion and Visual Examination of Protein CrystalHits:

Ab-30Rm crystals were grown using the hanging drop vapor diffusionmethod using VDX 24 well plates with sealant (Hampton Research, AlisoViejo, Calif. (HR3-170)). 1 ml of dehydrant 24% PEG-3350 was pipetted inthe well solution. 4 μl of 4 mg/ml Ab-30Rm in A5SuT (10 mM SodiumAcetate (from acetic acid), 9% Sucrose, 0.004% Polysorbate 20 pH5.0)+2μl of Low Ionic Strength Buffer+5 ul of x % PEG-3350 was added on to acover slip (HR3-233, 22 mm diameter by 0.22 mm thick siliconized glasscover slips: Hampton Research, Aliso Viejo, Calif.) for a final volumeof 11 μl. The cover slip was inverted without mixing the drop and placedon an already gapped sealant to form an air tight seal. In the hangingdrop vapor diffusion experiment, crystals are formed the whenequilibrium is reached between the drop and the well solution.

A total of 108 conditions were set up using the Low Ionic StrengthScreen (LISS) (HR2-120, Hampton Research). LISS is a three partcrystallization screen with 18 buffers in a pH range of 2-12, 6different percentages of precipitant PEG-3350 and 24% PEG-3350 as thedehydrant. See Table 16 below.

TABLE 16 PEG Concentration LISS Screen 4% 8% 12% 16% 20% 24% 0.05M.Potassium chloride, pH 2 C 0.05M citric acid, pH 3 0.05M citric acid, pH3.5 0.05M citric acid, pH 4 0.05M citric acid, pH 4.5 0.05M citric acid,pH 5 0.05M citric acid, pH 5.5 0.05M MES, pH 6 0.05M Bis Tris, pH 6.5 C0.05M Imidazole, pH 7 C C C 0.05M HEPES, pH 7.5 C C C 0.05M Tris, pH 8 CC C C C 0.05M Tris, pH 8.5 C C C C 0.05M Glycine, pH 9 C C C 0.05MGlycine, pH 9.5 0.05M Glycine, pH 10 0.05M Sodium phosphate dibasic, pH11 0.05M Sodium phosphate dibasic, pH 12 C = crystals obtained

Crystal trays were scanned everyday for a week and then once a weekusing Carl Zeiss Stemi SV11 Microscope equipped with software Axiovison4.0. Crystal hits were recorded and characterized using an in housecrystal scoring system and morphology description.

The following two sets of conditions are exemplary conditions for anantibody crystal formulation: (a) A5SuT+0.05M Tris pH 8.0+22% PEG-3350(final pH about 7.2, osmolality was 340 mOsm/kg and % efficiency 95%);(b) A5SuT+0.05M Tris pH 8.0+24% PEG-3350 (final pH about 7.2, osmolalitywas 412 mOsm/kg and % efficiency 99%).

pH Measurement:

pH was measured using an Mettler Toledo MP230 pH meter and wascalibrated against pH 4.0 and pH 7.0 buffers standards. For pHmeasurement sample was prepared by adding 40 μl of protein, 20 μl of theLISS buffer and 50 μl of the respective percentage of PEG-3350 in aneppendorf tube and vortexed.

Osmolality:

Osmolality was measured using Advanced Instruments 2020 Multi sampleOsmometer, Norwood, Mass. The instrument measures Osmolality by usingthe Freezing Point Depression method. For Osmolality measurements ofAb-30Rm in the Low Ionic Screen 8 μl of protein, 2 μl of LISS buffer and5 μl of x % PEG-3350 was mixed. Exactly 20 μl of this mixture was placedin the disposable micro-sample tubes (Advanced Instruments, Norwood,Mass. Catalog #202825) and were placed into the instrument carousel.

Efficiency:

% Efficiency was calculated by spinning down the 1.5 ml eppedorf tubesat 10,000 rpm for 15 minutes, making a 1:100 dilution of the supernatantwith mili-Q water and reading it on a UV-VIS spec at A280.

Batch Crystallization and Details for Animal Study Experiment:

Ab-30Rm at a concentration of 24.39 mg/ml in A5SuT was used for initialAb-30Rm crystal screening and batch crystallization. For final batchcrystallization studies for animal study Ab-30Rm at a concentration of31.148 mg/ml in A5SuT was used. The liquid formulation for Ab-30Rm foranimal studies was 100 mg/ml in A5SuT while the crystal slurry for theformulation was in 0.05M Tris pH 8.0 and 22% PEG-3350 at 100 mg/ml, pH7.2.

The formulation for Ab-30Rm was prepared by adding 400 μl of Ab-30Rm inA5SuT+200 μl of 0.05M Tris pH8.0 buffer+500 μl of 22% PEG-3350precipitant to a final volume of 1.1 ml in a 1.5 ml eppendorf tube whichturned cloudy on mixing. The solution eventually turned clear on day twowith the formation of distinguishable crystals. The crystals wereharvested after six days and spun down at 3000 rpm for 15 minutes andthe supernatant was removed so that there was no soluble protein left inthe tube. The supernatant was replaced with mother liquor. The motherliquor was prepared as follows: 200 μl 0.05M Tris pH8.0 buffer+500 μl22% PEG-3350 precipitant in an eppendorf tube. Note that there was noA5SuT added to this. There was 12.46 mg of protein in 1.1 ml batch andhence 124.9 μl of mother liquor was added to reach a 100 mg/ml finalconcentration. 100 mg/ml slurries from two additional eppendorf tubeswere mixed in one 3 cc vial to prepare a separate vial for each rat. Theformulation buffer was prepared as follows: 4000 of A5SuT buffer+200 μl0.05M Tris pH8.0 buffer+500 μl of 22% PEG-3350 precipitant to make afinal volume of 1.1 ml. At 100 mg/ml the final injection volume was inbetween 200 μl-250 μl depending on the weight of an individual rat and a27 G1/2 needle was used for the subcutaneous injection.

A single dose study lasting 8 weeks was performed with 28 6-month oldfemale SD rats weighing between 400-500 grams. The final dose was 50mg/kg (20-25 mg protein was required for each rat) 10 individual ratswere used for each liquid and powder formulation while 8 rats were usedfor the placebo (A52SuT+0.05M Tris pH8.0+22% PEG-3350).

Results and Discussion:

Ab-30Rm was screened using Hampton Low Ionic Screen Strength Screen(LISS) and a total of 20 crystal hits were obtained at pH 2 and inbetween pH 6.5-9.0.8% and 12% PEG-3350 had the most crystal hits of allthe different percentages of PEG-3350 screened. 0.05M Tris at pH 8.0 wasthe only condition that had crystals from 8%-24% PEG-3350 except at 4%PEG-3350. Most crystal hits obtained for Ab-30Rm fall within the pHrange of pH 7.0-7.5 which is important in animal studies to avoid tissuenecrosis after a subcutaneous injection.

Based on the Osmolality data, some of 16% and 24% PEG-3350 and all of20% PEG-3350 conditions fell within the Osmolality range. AcceptableOsmolality range for subcutaneous injection is about 250-350 mOsm/Kg(see FIG. 1A). When the Osmolality and the crystals hits were overlaid,there were only three conditions that fell within the Osmolality rangethat also had crystal hits (FIG. 1B).

PEG-3350 falls under the chemical factors effecting crystallization andcan be characterized as a long chain polymer precipitant which works byvolume exclusion effect. The morphology of Ab-30Rm crystals degradedwith the increase in PEG-3350 concentrations as seen in the screeningwith LISS (FIG. 2). Higher percentage PEG-3350 crystal hits had biphasicseparation and/or precipitation. Ab-30Rm crystals took about a week togrow which is slow if the same conditions were to be used for batchcrystallization.

The rate of crystallization is not necessarily the same in the hangingdrop vapor diffusion and batch crystallization. To increase the rate ofcrystallization the pH range was manipulated, another of the chemicalfactors effecting crystallization and concentration of Ab-30Rm focusingon HEPES and Tris conditions with 12% PEG-3350 only. Ab-30Rm was putthrough HEPES Grid Screen pH 6.8-8.2 and Tris Grid Screen pH 7.0-9.0. Nochange in rate of crystallization was observed in either of the gridscreen but there was an increased abundance in crystals at pH higherthan 7.5 seen in both the grid screens. Hence, to change the rate ofcrystallization another attempt was made by exploring the concentrationof the precipitant PEG-3350.

LISS conditions #10-14 with a pH range of 7-9.0 were used and PEG-3350from 4% to 24% in increments of 2% was explored. 0.05M Tris pH8.0 at 22%and 24% PEG-3350 gave the first crystal hits at day 2. These conditionswere batch crystallized at 55 μl, 110 μl and 1 ml total volume allgiving crystal hits at day 2. The rate of crystallization for 22% and24% PEG-3350 is the same in an 11 μl hanging drop vapor diffusion andbatch crystallization. Final pH measured for both the conditions lieswithin the pH range of 7-7.5 with pH=7.203 for 22% PEG-3350 and pH=7.354for 24% PEG-3350. Osmolality for 0.05M Tris 22% PEG-3350 is 340 mOsm/kgwhile that for 0.05M Tris pH8.0 is 412 mOsm/kg which is over theOsmolality range. % Efficiency was measured by spinning the crystals at10,000 rpm for 15 minutes, A280 nm measured for the supernatant.Dissolution rates for Ab-30Rm crystals in water is 11 minutes, in salineis 6 minutes and in PBS is 15 minutes.

Isotonic and injectable conditions were achieved for an Ab-30Rmformulation for animal study with a final pH of 7.203, osmolality of 340mOsmo/kg and 95% crystallization efficiency. Liquid vs resuspendingantibody crystal formulations were tested in the animal study.

The foregoing Example demonstrates that Ab-30Rm was crystallizable undera variety of crystallization conditions, but crystals did not form underevery condition tested. Approximately 240 crystallization conditionswere tested in a number of different commercially-available (i.e.,Hampton Research) screens, but only approximately 50 conditions producedAb-30Rm crystals. Interestingly, Ab-30R (which has one amino aciddifference compared to Ab-30Rm) only produced crystals in 5 of theapproximately 1120 conditions tested in a number of differentcommercially-available (i.e., Hampton Research, Emerald Bioscience) andproprietary screens.

The foregoing Example also demonstrates that formulations comprisingAb-30Rm crystals of sufficient pH and osmolality for administration to amammal were obtained.

Example 6 In Vivo Testing of Anti-Sclerostin Antibody “Liquid” and“Crystal/Crystallized” Formulations in Rats

Female Sprague Dawley (SD) rats were obtained from Charles RiverLaboratories and housed in clean caging, two animals per cage. Roomtemperature was maintained between 68 and 72° F., and relative humiditywas maintained between 34 and 73%. The laboratory housing the cages hada 12-hour light/dark cycle and met all AAALAC specifications.

Subcutaneous injection of test article (liquid Ab-30Rm andcrystal/crystallized Ab-30Rm) and buffer (vehicle control) was done whenthe rats were about 6.5 months old. At the start of the study (day 0) 9rats were injected with buffer made with the following ratios ofingredients: take 400 microliters of A5SuT (10 mM Sodium Acetate pH 5,9% sucrose, 0.004% polysorbate 20 [Tween]), then add 200 microliters of0.05 M Tris pH 8 and then add 500 microliters of 22% PEG-3350. This isthe buffer/vehicle group. At the start of the study (day 0) 10 rats wereinjected at 50 mg/kg with a 100 mg/ml solution of “crystal/crystallized”Ab-30Rm in a suspension made of the following ratios of ingredients: 200microliters of 0.05 M Tris pH 8 and 500 microliters of 22% PEG-3350.This is the “crystal/crystallized” group. At the start of the study (day0) 10 rats were injected at 50 mg/kg with a 100 mg/ml solution of“liquid” Ab-30Rm (non-crystallized) in A5SuT. This is the “liquid”group.

Areal bone mineral density (BMD) was determined from anesthetized rats(isoflurane) by dual-energy X-ray absorptiometry (DXA, Hologic QDR4500a,Hologic Inc., Bedford, Mass.). Baseline BMD was determined 4 days beforetreatment was initiated. BMD was also determined at weeks 2, 3, 4, 6 and8 after treatment (day 0). The region of interest (ROI) included thelumbar vertebrae (LV1-5) and the “leg” (femur-tibia [entire femur inaddition to the part of tibia above tibia/fibular junction]).

Statistical analysis was performed using GraphPad Prism. A one-wayanalysis of variance (ANOVA) followed by Dunnett's test was used todetermine statistical differences. Group means for each data set wereconsidered significantly different when the P value was less than 0.05(P<0.05). Data were analyzed as absolute BMD (g/cm²) and also separatelyas percent change in BMD from baseline (calculated for each individualanimal).

The BMD data (absolute BMD and percent change in BMD from base line) forthe 3 animal groups indicated that a single administration of the“liquid” formulation of Ab-30Rm and a single administration of the“crystal/crystallized” formulation of Ab-30Rm resulted in similarincreases in BMD in this rat study. Statistically significant increasesversus the buffer/vehicle group were found for both the “liquid” Ab-30Rmgroup (FIGS. 7A and 7B) and the “crystal/crystallized” Ab-30Rm group(FIG. 7B) at the lumbar vertebrae skeletal site and the “leg”(femur-tibia) skeletal site (FIG. 8B). These data demonstrate positivebone effects for both the “liquid” and the “crystal/crystallized”Ab-30Rm formulations.

Example 7 Crystalline Ab-30 Formulations

This Example illustrates formulations of anti-sclerostin antibodycrystals comprising a high concentration of protein with a potential forslow release, comprising anti-sclerostin antibody Ab-30 consisting oftwo mature heavy chains (SEQ ID NO: 15) and two mature light chains (SEQID NO: 13) recombinantly produced by DNA encoding each of these chains.

Briefly, a total of 104 crystallization conditions were screened forAb-30 using the GRAS Screen, Index Screen Wizard I Screen, Wizard IIScreen and Wizard III Screen. Four conditions were narrowed down for aformulation based on percent crystallization efficiency (i.e., WIZ III#35, GRAS #1, INDX #34, INDX #36 and WIZ I #46). Formulations for Ab-30resuspended in 5% dextrose suitable for subcutaneous injection in animalstudy were successfully produced.

Example 8 In Vivo Testing of Anti-Sclerostin Antibody Ab-30 “Liquid” and“Crystal/Crystallized” Formulations in Rats

Female Sprague Dawley (SD) rats were obtained from Charles RiverLaboratories and housed in clean caging, two animals per cage. Roomtemperature was maintained between 68 and 72° F., and relative humiditywas maintained between 34 and 73%. The laboratory housing the cages hada 12-hour light/dark cycle and met all AAALAC specifications.

Subcutaneous injection of test article (liquid Ab-30 and variouscrystal/crystallized forms of Ab-30) and buffer (vehicle control) wasadministered when the rats were about 6.5 months old. At the start ofthe study (day 0) 8 rats were injected with 5% Dextrose (source: BaxterIV bag). This is the buffer/vehicle group. At the start of the study(day 0) 8 rats were injected at 100 mg/kg with a 100 mg/ml solution ofone of the following

-   -   “crystal/crystallized” Ab-30 formulation WIZ III #35, said        crystals having been resuspended in 5% Dextrose (source: Baxter        IV bag) (“Group W35);    -   “crystal/crystallized” Ab-30 formulation INDX #34, said crystals        having been resuspended in 5% Dextrose (source: Baxter IV bag)        (“Group I34”);    -   “crystal/crystallized” Ab-30 formulation INDX #36, said crystals        having been resuspended in 5% Dextrose (source: Baxter IV bag)        (“Group I36”);    -   “crystal/crystallized” Ab-30 formulation WIZ I #46, said        crystals having been resuspended in 5% Dextrose (source: Baxter        IV bag) (“Group W46”); or    -   “liquid” Ab-30 (non-crystallized) in A5Su (10 mM Sodium Acetate        pH 5, 9% sucrose) (“liquid group”).

Areal bone mineral density (BMD) was determined from anesthetized rats(isoflurane) by dual-energy X-ray absorptiometry (DXA, Hologic QDR4500a,Hologic Inc., Bedford, Mass.). Baseline BMD was determined 7 days beforetreatment was initiated. BMD was also determined at weeks 2 and 4 aftertreatment (day 0). The region of interest (ROI) included the lumbarvertebrae (LV1-5) and the “leg” (femur-tibia [entire femur in additionto the part of tibia above tibia/fibular junction]).

Statistical analysis was performed using GraphPad Prism. A one-wayanalysis of variance (ANOVA) followed by Dunnett's test was used todetermine statistical differences. Group means for each data set wereconsidered significantly different when the P value was less than 0.05(P<0.05). Data were analyzed as absolute BMD (g/cm²) and also separatelyas percent change in BMD from baseline (calculated for each individualanimal).

Statistically significant increases in BMD versus the buffer/vehiclegroup were found at lumbar vertebrae for both the “liquid” Ab-30 group(FIGS. 9A and 9B) and some (e.g., W35, I36) of the“crystal/crystallized” Ab-30 formulation groups (FIG. 9B). Statisticallysignificant increases in BMD versus the buffer/vehicle group were alsofound at the “leg” (femur-tibia) skeletal site for both the “liquid”Ab-30 group (FIG. 10B) and some (e.g., W35, I36) of the“crystal/crystallized” Ab-30 formulation groups (FIG. 10B). These datademonstrate positive bone effects for both “liquid” and“crystal/crystallized” Ab-30 formulations.

Example 9 Crystallization of Anti-Sclerostin Antibody Ab-31

Antibody Ab-31, consisting of two mature heavy chains (SEQ ID NO: 35)and two mature light chains (SEQ ID NO: 33) was recombinantly producedby DNA encoding each of these chains, was crystallized under a varietyof conditions.

Crystallization of Ab-31 was achieved using a crystallization screen(PEG/LiCl Grid Screen; Hampton Research, Aliso Viejo, Calif.), whichemploys a method for crystallization of macromolecules known as ‘hangingdrop’ vapor diffusion. A drop composed of a mixture of the polypeptidesample and the crystallization reagent (the “crystallization buffer” orthe “mother liquor”) is deposited on the underside of a sialanizedcoverslip, and then the drop on the coverslip is sealed with grease andplaced over typically a 24 well VDX tray causing a vapor equilibriumwith a liquid reservoir of reagent. To achieve equilibrium, water vaporexchanges between the drop and a 1 ml reservoir solution in the well ofthe tray. As water leaves the drop, the polypeptide sample undergoes anincrease in relative concentration which may eventually lead tosupersaturation. It is the increased concentration of the polypeptidesample that is required for crystallization to take place. Typically thedrop contains a lower concentration of reagent than the reservoir, andtypically, the drop contained half the concentration of reagent in thereservoir, because equal volumes of sample and reagent were mixed toform the drop.

In these experiments, the initial protein concentration of Ab-31 in thedrop was 30 mg/ml. The crystallization screen was set up in 24-well VDXpolypropylene tissue culture trays. Each position in the VDX traycontained 1 mL of reagent reservoir, with the reagent reservoir in eachwell differing in composition from that in the other wells, to establishan array of differing crystallization buffer conditions. 1 mL ofpolypeptide solution at each polypeptide concentration was added to 1 μlof reservoir solution to form the drops. Trays were incubated either at4° C. or at ambient room temperature.

Ab-31 crystallization was observed at both 4° C. and room temperatureunder the following crystallization conditions: 10 mM Histidine, pH 7.15to pH 7.47 as well as 10 mM Potassium Phosphate, pH 7.2. The resultingcrystals varied in length from about 100 μm to about 1000 μm anddemonstrated an ellipsoidal shape as determined by Zeiss Stemi SV11stereomicroscope with polarization, which was interfaced with a ZeissAxioCam MRc digital camera which operated with AxioVision 4.0 software.

The foregoing Example demonstrates that Ab-31 was crystallizable under avariety of crystallization conditions, but crystals did not form underevery condition tested. Approximately 250 different crystallizationconditions were tested, but only approximately 36 conditions producedAb-31 crystals.

Numerous modifications and variations in the practice of the inventionare expected to occur to those of skill in the art upon consideration ofthe presently preferred embodiments thereof. Consequently, the onlylimitations which should be placed upon the scope of the invention arethose which appear in the appended claims.

All of the U.S. patents, U.S. patent application publications, U.S.patent applications, foreign patents, foreign patent applications andnon-patent publications referred to in this specification and/or listedin the Application Data Sheet, are incorporated herein by reference, intheir entireties.

From the foregoing it will be appreciated that, although specificembodiments of the invention have been described herein for purposes ofillustration, various modifications may be made without deviating fromthe spirit and scope of the invention.

1. A crystal of an anti-sclerostin IgG antibody comprising light andheavy chain variable regions of SEQ ID NOS: 3 and 5, preferably havingthe amino acid sequences of SEQ ID NOS: 13 and
 15. 2. A sterileformulation comprising a crystal of an anti-sclerostin IgG antibody,wherein at least 70% of the antibody is in a crystalline form. 3.(canceled)
 4. The formulation of claim 2, wherein the IgG antibodycomprises light and heavy chain variable regions of SEQ ID NOS: 3 and 5,preferably having the amino acid sequences of SEQ ID NOS: 13 and
 15. 5.The crystal of claim 1, wherein the crystal has a length of up to about500 μm.
 6. The crystal of claim 1, wherein the crystal has a shapeselected from the group consisting of ellipsoids, rods and needles. 7.The formulation of claim 2, comprising crystals having a length of up to500 μm and a shape selected from the group consisting of ellipsoids,rods and needles or mixtures thereof.
 8. The formulation of claim 2,wherein the crystal comprises a salt selected from the group consistingof sodium dihydrogen phosphate, di-potassium hydrogen phosphate, sodiumchloride, ammonium sulfate, potassium sodium tartrate tetrahydrate,tacsimate, sodium citrate dihydrate, sodium acetate trihydrate,di-ammonium tartrate, sodium malonate, acetate, calcium acetate,cacodylate, CHES, lithium sulfate, magnesium chloride, zinc acetate,cesium chloride, ammonium phosphate, sodium phosphase, potassiumphosphate, sodium fluoride, potassium iodide, sodium idodide, ammoniumiodide, sodium thiocyanate, potassium thiocyanate, sodium formate,potassium formate and ammonium formate.
 9. The formulation of claim 2,that is a lyophilized formulation.
 10. The formulation of claim 2, thatis a liquid formulation.
 11. The formulation of claim 10, comprising aconcentration of at least about 100 mg of said antibody per ml offormulation.
 12. The formulation of claim 10, comprising at least about140 mg of antibody dispersed in 1.5 ml or less of liquid.
 13. Theformulation of claim 12 that is injectable through a syringe having a 20Gauge needle or finer using a clinically acceptable amount of force. 14.The formulation of claim 2, that retains at least 50% of the in vivoactivity, when given at the same dose and in the same manner, of aliquid formulation of said antibody that has not been crystallized. 15.The formulation of claim 12, that, when administered to a mammaliansubject, mediates an increase in bone mineral density that is at leastabout 70% of the level of bone mineral density increase mediated by aliquid formulation of said antibody that has not been crystallized,wherein the formulation and the liquid formulation of the antibody thathas not been crystallized is administered to the subject at the samedose and in the same manner. 16-17. (canceled)
 18. A containercomprising at least 50 mg of the antibody crystal of claim 1 forsuspension in a volume of 0.5-2 mL.
 19. A container comprising theformulation of claim
 2. 20-21. (canceled)
 22. A method of resuspendingthe formulation of claim 9, comprising contacting the formulation withabout 0.5-2 mL of a sterile suspension vehicle.
 23. (canceled)
 24. Amethod of making a crystal of an anti-sclerostin IgG antibody comprisinglight and heavy chain variable regions of SEQ ID NOS: 3 and 5,preferably having the amino acid sequences of SEQ ID NOS: 13 and 15, themethod comprising combining a solution of the antibody with acrystallization reagent comprising a salt selected from the groupconsisting of sodium dihydrogen phosphate, di-potassium hydrogenphosphate, sodium chloride, ammonium sulfate, ammonium acetate,potassium sodium tartrate tetrahydrate, tacsimate, sodium citratedihydrate, sodium acetate trihydrate, di-ammonium tartrate, sodiummalonate, acetate, calcium acetate, cacodylate, CHES, lithium sulfate,lithium acetate dihydrate, magnesium chloride, magnesium acetatetetrahydrate, magnesium formate, magnesium nitrate, magnesium sulfate,zinc acetate, zinc chloride, zinc sulfate, cesium chloride, ammoniumphosphate, sodium phosphase, potassium phosphate, sodium fluoride,potassium iodide, sodium idodide, ammonium iodide, sodium thiocyanate,potassium thiocyanate, sodium formate, potassium formate and ammoniumformate, optionally at pH of about 6 to about 8, such that a crystal isformed.
 25. The method of claim 24, wherein the concentration of thesalt is from about 0.1 M to about 10 M.
 26. A method of making a crystalof an anti-sclerostin IgG antibody comprising light and heavy chainvariable regions of SEQ ID NOS: 3 and 5, preferably having the aminoacid sequences of SEQ ID NOS: 13 and 15, the method comprising combininga solution of the antibody with a crystallization reagent comprisingsuccinic acid, PEG-1000, PEG-8000 or isopropanol such that a crystal isformed. 27-28. (canceled)
 29. The method of claim 26, wherein thecrystallization reagent comprises (a) from about 0.1 M to about 5 Msuccinic acid, from about 0.1 M to about 5 M HEPES and from about 0.1%(w/v) to about 60% (w/v) polyethylene glycol monomethyl ether 2000; (b)from about 1% (w/v) to about 50% (w/v) PEG-8000, from about 0.05 M toabout 5 M imidazole and from about 0.1 M to about 5 M calcium acetate;(c) from about 10% to about 80% (w/v) PEG-1000, from about 0.05 M toabout 5 M sodium/potassium phosphate and from about 0.05 M to about 5 Msodium chloride; (d) from about 1% (w/v) to about 20% (w/v) PEG-8000,from about 0.05 M to about 5 M cacodylate, from about 0.1 M to about 2 Mcalcium acetate, and from about 10% to about 30% (w/v) glycerol; or (e)from about 10% to about 30% isopropanol and from about 0.1 M to about 2M sodium/potassium phosphate.
 30. An antibody crystal produced by themethod of claim
 24. 31. A method of increasing bone mineral density,treating a disorder associated with decreased bone density, treating abone-related disorder, or improving outcomes in a procedure,replacement, graft, surgery or repair in a mammalian subject comprisingadministering the formulation of claim 2 in an amount effective toincrease bone mineral density in the subject.
 32. An antibody crystalproduced by the method of claim 26.